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For over 50 years researchers have been trying to understand the peculiarities of 
translation mechanism. For the present moment we have enormous information 
about ribosome structure, formation and translation regulation. But continuing 
discoveries of new and suprising mechanisms of translation regulation suggest 
that our understanding of this complex biological process remains incomplete.  
The main step of translation regulation in bacteria occurs during initiation. 
The rate-limiting step in this process is binding of the small ribosomal subunit 
to the translation initiation region on mRNA. The mRNA translation initiation 
region comprises the initiator codon, Shine-Dalgarno sequence and translational 
enhancers. We have tested the influence of Shine-Dalgarno sequence length and 
the presence of enhancers on the efficiency of translation initiation.  
The ribosome is one of the main antibiotic targets in the cell. Studies on the 
ribosome targeted antibiotics are interesting from two viewpoints: characte-
rization of the antibiotic mechanisms of action and resistance mechanisms can 
help in designing better drugs; as the antibiotics bind to functionally essential 
parts of the ribosome, studies on ribosome targeted antibiotics have often 
provided information essential for understanding the basic mechanisms of 
protein synthesis. 
Macrolides are a group of clinically useful antibiotics containing a 14-, 15- 
or 16- member lactone ring. The macrolides bind to the large ribosomal subunit 
in the vicinity of the peptidyl trasferase centre, where tight contacts with 23S 
rRNA are formed. The primary mode of action of the macrolides is inhibition of 
protein synthesis, although they can also interfere with ribosome assembly. 
The therapeutical utility of macrolides has been compromised by the 
emergence of drug resistance in many pathogenic bacteria. The known 
mechanisms of macrolide resistance include modification of 23S ribosomal 
RNA (methylation or mutation of 23S rRNA bases) and ribosomal protein 
mutations, active efflux of the drug from the cell, structural modification of 
macrolides. 
In the present work we determine the mechanism of macrolide resistance 
conferred by expression of specific short peptides. We argue that broad-specific 
multi-drug pumps located in the inner membrane may account for the required 
rapid outflow rate of the antibiotic to confer peptide-mediated resistance. 
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1. REVIEW OF LITERATURE 
 
1.1. Protein Biosynthesis in Bacteria 
 
Protein synthesis is a final step in gene expression. During this process genetic 
information, encoded within mRNA, is translated into protein. Pivotal for 
protein biosynthesis is a multifunctional ribonucleoprotein complex, termed 
ribosome.  
Ribosomes of bacteria consist of two unequal subunits containing 3 RNA 
molecules and a number of different ribosomal proteins. In prokaryotes, the 
larger subunit sediments at 50S, is ~1.5MDa in molecular weight and contains 
~3000 nucleotides of ribosomal RNA (termed 23S rRNA) and 34 proteins. The 
smaller subunit sediments at 30S, has a molecular weight of 0.8MDa and 
comprises 1500 nucleotides of ribosomal RNA (termed 16S rRNA) and 21 
proteins (Schuwirth et al., 2005; Selmer et al., 2006). The small ribosomal 
subunit is engaged in decoding of genetic information, while the large subunit 
assembles amino acids into a polypeptide chain. Catalysis of peptide bond 
formation and amino acid polymerization occurs in the peptidyl transferase 
centre located on the large subunit (reviewed in Steitz, 2008). The ribosome has 
three separate tRNA binding sites, each spanning the two subunits (Yusupov et 
al., 2001; Marquez et al., 2002). The A site binds aminoacyl-tRNA, the P site 
binds peptidyl-tRNA or deacylated tRNA, and the E site binds deacylated tRNA 
(Rheinberger, 1991).  
Translation is viewed conceptually as a three-step process: initiation, in 
which the translation machinery is assembled; elongation, in which amino acids 
are added to the growing peptide; and termination, in which the nascent peptide 
synthesis is terminated and the translation machinery is disassembled (reviewed 
in Ramakrishnan, 2002).  
The efficiency of initiation is the most important determinant of mRNA 
translation efficiency (Boelens and Gualerzi, 2002). In bacteria the 30S small 
ribosomal subunit, assisted by initiation factors 1, 2 and 3 and fMet-tRNAfMet 
recognizes the translation initiation region (TIR) of the mRNA. This event is 
followed by binding of the 50S large ribosomal subunit and release of the 
initiation factors. The rate-limiting step of this process is 30S subunit binding to 
the TIR (Gualerzi and Pon, 1990). 
TIR consists of several sequence elements (Figure 1) that contribute to its 
efficiency: (1) the initiation codon, that is most commonly AUG but sometimes 
also GUG and very rarely UUG or AUU (Gren 1984; Schneider et al., 1986); 
(2) Shine-Dalgarno (SD) sequence (Shine and Dalgarno, 1974; Shultzaberger et 
al., 2001); (3) regions upstream of the SD sequence and downstream of the 
initiation codon that are often described as enhancers of translation (Stormo et 
al., 1982; Stenstrom and Isaksson, 2002 ). In addition, spacing between these 
sequence elements is often critical. For example, the distance between the SD 
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sequence and the initiation triplet has large effect on the efficiency of translation 




















Figure 1. Elements of mRNA translation initiation region, that contribute to the 
efficiency of translation initiation. Secondary structure of TIR, indicated by green 
arrow, is an important determinant of TIR effectiveness. 
 
 
The SD sequence base pairs directly with the anti Shine-Dalgarno (aSD) 
sequence on the 16S rRNA 3’ terminal end (Shine and Dalgarno, 1974). The 
maximal length of the SD:aSD duplex is 12 or 13 nucleotides (Yusupova et al., 
2006). In most E. coli genes the SD sequence is shorter. The calculation of the 
free energies for all possible duplexes between the 16S rRNA 3’ end and a 
region of 21 nucleotides upstream from the start codon in 1159 E. coli genes has 
revealed that the average number of paired mRNA:rRNA nucleotides is 6.3 
(Schurr et al., 1993). A similar calculation has been made for the ribosomal 
protein genes. This study suggests that the average SD length is 4.4 nucleotides 
(Komarova et al., 2002). It was also observed that long SD sequences are not 
very efficient, probably because of increased time for clearance of the TIR. On 
the other hand, there are studies where the importance of the SD for the 
initiation of translation has been argued: Lee et al. (1996) reported that 
translational efficiency correlates very poorly with the strength SD:aSD inter-
action. Unfortunately, we are currently lacking a systematic study that could 
reveal the correlation between the strength of SD:aSD interaction and the 
efficiency of translation. 
It has been recently described that before the SD:aSD interaction occurs, the 
30S ribosomal subunit can bind to a standby site in the vicinity of SD (de Smit 
and van Duin, 2003; Studer and Joseph, 2006). Binding to the standby site 
might increase the local concentration of 30S subunits at the TIR. In addition, 
the ribosome attached to the standby site might wait for the moment when the 
SD sequence will be in appropriate conformation able to bind the aSD. Through 
this mechanism the standby site could stimulate translation of mRNAs where 
the SD can be trapped in secondary structures. Attachment to the standby site 
could be mediated by ribosomal S1 protein, the largest protein of the small 
ribosomal subunit. S1 consists of two major domains with a freely rotatable 
region in between (Subramanian, 1983). One domain is attached to the 30S; the 
second domain is exposed outside the small subunit, scanning the space around 
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the ribosome and searching for A and U nucleotide (A/U) rich sequences that 
are recognized with the help of four RNA-binding motifs. It has been shown 
that S1 can act as a RNA chaperone, destabilizing RNA secondary structures 
(Thomas and Szer, 1982). Cross-linking studies have aligned the nucleic acid-
binding domain of S1 with a region of the mRNA upstream of the SD, 
suggesting that S1 may interact with 5’ parts of the TIR (Boni et al., 1991; 
Zhang and Deutscher, 1992). Consistent with this observation, A/U rich 
sequences in front of SD enhance protein synthesis (Komarova et al., 2002). 
Currently, there are nine sequences that have been shown experimentally to act 
as translational enhancers. They are all rich in A and U nucleotides and contain 
very few Gs (Komarova et al., 2002). The disruption of the E. coli gene coding 
for S1 protein has been previously reported to be lethal (Kitakawa and Isono, 
1982). The decrease in the level of S1 protein in the cells leads to the fast 
decrease in the whole protein synthesis (Sorensen et al., 1998). Thus it could be 
speculated that the SD sequence alone cannot mediate efficient initiation of 
translation but has to be complemented with an enhancer sequence. Un-
fortunately, there are no experimental reports describing the effects of 
combining the enhancers with different SD sequences. 
Once an initiation complex has been formed translation elongation starts. 
During this process the ribosome with the help of tRNAs, charged with specific 
amino acids, and elongation factors Tu, Ts and G (EF-Tu, EF-G, EF-TS), 
decodes mRNA and synthesizes protein. Elongation is activated when amino 
acid enters the ribosome acceptor site (A site) as aminoacyl-tRNA together with 
EF-Tu and GTP, ternary complex. When the correct base pairing between 
mRNA codon and the tRNA anticodon occurs GTP is hydrolysed and EF-Tu 
leaves the ribosome (Daviter et al., 2006; Steitz, 2008). Aminoacyl-tRNA, 
released from the EF-Tu moves through the ribosome into the peptidyl 
transferase centre (Beringer and Rodnina, 2007). In the peptidyl transferase 
centre the nascent peptide from the peptidyl-tRNA is transferred to the amino 
acid on the A-site tRNA, and thus the peptide grows by one amino acid 
(reviewed in Steitz, 2008). Completion of the elongation cycle involves EF-G 
dependent translocation event, resulting in the moving of the peptidyl-tRNA 
from the A to the P site, and EF-G is released upon GTP hydrolysis (Frank et 
al., 2007). 
The final step in protein synthesis is hydrolysis of the ester bond in peptidyl-
tRNA and release of the finished protein. The reaction is induced in prokaryotes 
by one of the two class I release factors, RF1 or RF2 (Scolnick et al., 1968). 
Termination of translation is triggered by the class I factors following a 
translocation step that places a stop codon in the ribosomal A site and peptidyl-
tRNA in the P-site. In prokaryotes, RF1 recognizes stop codons UAA and 
UAG, while RF2 recognizes UAA and UGA (Kisselev and Buckingham, 2000). 
After the protein has been released from the ribosome a class II factor, RF3, 
promotes rapid dissociation of RF1 or RF2 from the posttermination complex 
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(Zavialov et al., 2001). And finally, ribosome recycling factor with the help of 
EF-G and IF3 dissociates ribosome into two subunits (Karimi et al., 1999). 
 
 
1.2. Antibiotics and the Ribosome 
 
The ribosome is essential to all living cells and is one of the major targets for 
antibiotics (Spahn and Prescott, 1996; Tenson and Mankin, 2006). In the Tabel 
1 antibiotics, implicated in inhibition of the protein synthesis, are described.  
 
Table 1. Antibiotics that inhibit protein synthesis. 











Bind to 30S subunit. Affect 
ribosome accuracy at the initial step 
of aminoacyl-tRNA selection that 
leads to increased frequency of 
amino acid misincorporation into 
nascent protein. Increase the rate of 
GTP hydrolysis in case of the near 
cognate tRNA to be closer to the 
cognate value. 
Inhibit translocation. 
Reviewed in Spahn and 
Prescott, 1996;  
Recht et al., 1999;  
Ogle and Ramakrishnan, 
2005;  





Bind to 30S subunit. Affect 
ribosome accuracy at the initial step 
of aminoacyl-tRNA selection by 
reducing the conformational 
flexibility of the small ribosomal 
subunit, lowering the rate of 
GTPase activation for cognate 
tRNA but increasing it for near 
cognate tRNA. 








Bind to 30S subunit. 
Prevent aminoacyl-tRNA binding 
to A site. 
Inhibit fMet-tRNA binding to P 
site. 
Block tRNA selection after codon 




Moazed and Noller, 
1987; 
Blanchard et al., 2004. 
Chloramphenicol Binds 50S subunit.  
Blocks peptidyl transferase activity 
by interfering with the positioning 
of the amino acyl moiety of 
aminoacyl-tRNA in the A site. 
Causes translational inaccuracy. 
Kirillov et al., 1997; 
Thompson et al., 2002. 
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Table 1. Continuation 





Bind 50S subunit.  
Block peptidyl-transferase reaction.
Directly interfere with the 
positioning of the aminoacyl group 
at the A site and the peptidyl group 
at the P site while also sterically 
blocking the progression of the 
nascent peptide toward the tunnel. 
Douthwaite, 1992;  














Bind to 50S subunit. 









Bind to 50S subunit. 
Hamper mRNA and/or tRNA 
binding.  
Inhibit formation of the first 
peptide bond. 
Interfere translocation. 
Cause translational inaccuracy. 
Shinabarger et al., 1997; 
Xiong et al., 2000; 




Binds to 50S subunit. 
Blocks peptidyl-transferase 
reaction. 
Reviewed in Spahn and 
Prescott, 1996; 





Bind to 50S subunit.  
Do not block peptidyl-transferase 
reaction. 
Prevent the extension of nascent 
peptide, inducing peptidyl-tRNA 
drop off. 
Reviewed in Spahn and 
Prescott, 1996; 
Cocito et al., 1997 
Puromycin Binds to 50S subunit. 
Structural analogue of the 3’-end of 
aminoacyl-tRNA. Binds to A site 
and peptidyl transferase links the 





Table 1. Continuation 
Antibiotic Mode of action Reference 
Thiostrepton Binds to 50S subunit.  
Inhibits GTP hydrolysis during 
translocation. 
Reviewed in Spahn and 
Prescott, 1996 
Kirromycin Binds to EF-Tu-GTP-aminoacyl-
tRNA at 50S subunit, inhibiting the 
structural transition of EF-Tu to the 
GDP bound conformation. 
Parmeggiani and Swart, 
1985. 
Vogeley et al., 2001. 
Fusidic acid Binds to 50S subunit. 
Stalls the ribosome in the complex 
with EF-G and GDP. 
Rodnina et al., 2000 
 
 
1.3. Macrolide Antibiotics 
 
Macrolides 
Macrolides are important antibacterial antibiotics, commonly used in clinical 
practice to treat infections such as respiratory tract and soft tissue infections 
(Õmura, 2002). The structures of all macrolides are based on a lactone ring. The 
therapeutically most relevant macrolides comprise a 14-, 15- or 16- membered 
lactone ring (Figure 2).  
 
Erythromycin 
Erythromycin, derived in 1949 from Saccharopolyspora erythraea, was the first 
macrolide to be used clinically (Blondeau et al., 2002).  
 
Erythromycin structure 
Erythromycin consists of a 14-membered lactone ring with two attached sugar 
groups: L-cladinose at position 3 and desosamine at position 5 of the lactone 
ring (Figure 2). 
 
Erythromycin disadvantages 
Although erythromycin is an important antimicrobial agent, it has some 
negative features that impair it’s clinical use: 
• poor oral bioavailability 
• inactivation in acidic environment  
• gastrointestinal side effects – nausea, cramping, diarrhoea 
• short half-life – multiple daily dosing 
• poor activity against gram-negative bacteria 
Erythromycin properties were improved by chemical modifications of the 
lactone ring and/or sugar moiety. 
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Josamycin – macrolide with 16-membered lactone ring 
Josamycin is a macrolide with 16-membered lactone ring with mycaminose-
mycarose-isobutyrate side chain attached at carbon 5 of the lactone ring 
produced by Streptomyces narbonensis (Figure 2). It’s spectrum of activity is 
similar to that of erythromycin; at the same time, josamycin is better tolerated 
by patients than erythromycin (Strausbaugh et al., 1976; Periti et al., 1993; von 
Rosensteil and Adam, 1995). The main disadvantage of the josamycin is short 
half life in comparence with that of next generation of macrolides (Fraschini, 
1990; Aprim et al., 1990).  
 
Second generation of macrolides 
Semisynthetic derivatives of erythromycin, such as clarithromycin, roxi-
thromycin, azithromycin and oleandomycin represented the second generation 
of macrolides (Figure 2). 
Clarithromycin has been synthesized by methylation of the C6-OH group of 
erythromycin, whereas roxithromycin has been produced by the insertion of an 
etheroxime chain at the C9 position (Figure 2). 
Azithromycin is a derivative of erythromycin with a 15-membered lactone 
ring possessing an additional nitrogen (Figure 2). 
Oleandomycin differs from erythromycin by the presence of an 8-oxirane 
cycle, a methyl attached at carbon 13 of the lactone ring and the lack of a 12-
hydroxyl (Figure 2). 
These antibiotics have higher activity against gram-negative bacteria, as with 
that of erythromycin. Modifications increase drugs’ stability in acidic 
environment and reduce gastrointestinal side effects (Blondeau et al., 2002; 
Asaka et al., 2003). 
 
Third generation of macrolides 
Increasing macrolide resistance among respiratory tract pathogens, particularly 
Streptococcus pneumoniae, has led to a search for new agents that are more 
effective against macrolide resistant strains. Ketolides represent a new family of 
antibiotics that are derived chemically from the macrolides. Ketolides contain a 
keto group instead of the cladinose residue at position three of the lactone ring 
and carry alkyl-aryl or quinolylallyl side chains (Figure 2). These modifications 
increase macrolide stability in acidic environment and help to overcome 
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Figure 2. Chemical structures of the representative macrolide antibiotics (Adapted from 
Vimberg et. al., 2004). 
 
 
1.4. Macrolides’ Action 
 
Macrolides inhibit protein synthesis in prokaryotes (Pestka, 1977). 
 
Macrolides’ target 
Macrolides bind to either the vacant ribosome or a translating ribosome carrying 
a very short nascent peptide, the ribosomes that contain longer nascent peptide 
are resistant to the drug (Andersson and Kurland, 1987; Tenson et al., 2003). 
All macrolides bind to the large ribosomal subunit of the ribosome (Vazquez, 
1979). The macrolides’ binding site is located between the peptidyl transferase 
centre and the entrance of the nascent polypeptide exit tunnel (Nissen et al., 
2000; Schlünzen et al., 2001, 2003; Hansen et al., 2002, 2003; Berisio et al., 
2003a, b; Tu et al., 2005).  
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Macrolide’s interactions with the ribosome 
Different macrolide compounds bind to the ribosome with a similar orientation 
of the lactone ring. Binding of the macrolide is achieved through hydrogen 
bonding of the macrolide sugar residues to 23S rRNA as well as hydrophobic 
and van der Waals interactions of the lactone ring with the RNA-based surface 
of the ribosome (Figure 3) (Schlünzen et al., 2001; Hansen et al., 2002). 
 
 
Figure 3. Interaction of macrolides with the ribosome (Adapted from Schlünzen et al., 
2001). Chemical structure diagram of the macrolides (erythromycin, clarithromycin and 
roxithromycin) showing the interactions (coloured arrows) of the reactive groups of the 
macrolides with the nucleotides of the peptidyl transferase cavity (coloured). Coloured 
arrows between two chemical moieties indicate that the two groups are less than 4.4Ǻ 
apart. Distance of macrolide moieties to groups implicated previously in antibiotic 
interaction (L4, L22 and domain II of the 23S rRNA) are shown. Nucleotides of 23S 
rRNA of Deinococcus radiodurance (Dr) that correspond to the Escherichia coli (Ec) 
23S rRNA nucleotides and interact with the macrolides are marked. L4-Arg111 of 
Deinococcus radiodurance corresponds to Lys90 of Escherichia coli L4. L22-Gly63 of 




23S rRNA V domain 
The main component of the macrolide binding site on the ribosome is the 
central loop of domain V of the 23S rRNA, where adenosine 2058 (A2058) and 
adjacent nucleotides interact with desosamine sugar of the macrolide. The 2’OH 
group of the desosamine sugar forms hydrogen bonds with N6 and N1 of A2058 
and N6 of A2059 (Schlünzen et al., 2001).  
 
Macrolides’ universal interactions 
Various side chains attached to the lactone ring confer universal interactions of 
macrolides with the 23S rRNA (Poulsen et al., 2000; Schlünzen et al., 2001; 
Hansen et al., 2002; Tu et al., 2005). 
Alkyl-aryl side chains of ketolides protube in the direction of the peptide 
chain exit channel and form likely direct contacts with domain II of 23S rRNA 
(Xiong et al., 1999; Hansen et al., 1999; Douthwaite et al., 2000; Hansen et al., 
2002; Liu and Douthwaite 2002; Schlünzen et al., 2003). 
Josamycin mycaminose-mycarose-isobutyrate moiety attached to position 5 
of the lactone ring approaches the peptidyl transferase centre where it interacts 
with the A2451 and A2452 nucleotides of 23S rRNA (Hansen et al., 2002). 
 
Mechanism of macrolide action 
Macrolide bound in the vicinity of the narrowest point of the peptide exit 
channel perturbs nascent peptide penetration into the exit tunnel, leading to 
arrest of protein synthesis during early rounds of translation.  
Inhibition of translation elongation leads to the dissociation of peptidyl-
tRNA from the ribosome (Menninger and Otto, 1982; Tenson et al., 2003). This 
might cause the depletion of free tRNA pools, that might be important factor 
contributing to the inhibition of protein synthesis (Menninger 1979., Heurgue-
Hamard et al., 1996; 2000). 
There is a correlation between the space available for the nascent peptide 
within the drug-bound ribosome and the average length of peptides on the 
peptidyl-tRNAs that dissociate from ribosomes under the influence of various 
macrolides (Figure 4) (Tenson et al., 2003). Translation of the protein results in 
drop off of di- or tripeptidyl-tRNA in the case of josamycin, di- and 
tetrapeptidyl-tRNA in the case of clindamycin, di-, tri- or tetrapeptidyl-tRNA in 
the case of spiramycin and hexa-, hepta- or octapeptidyl-tRNAs for erythro-
mycin. The ketolides, due to the absence of the cladinose sugar residue, leave 
more space for the growing peptide than erythromycin. Thus telithromycin 
causes drop off of peptidyl-tRNAs with peptides ranging from 9 to 12 amino 







Figure 4. The Figure shows the crystal structure of 50S subunits in complex with a 
peptidyl-tRNA analogue and different MLS antibiotics as well as N3 of A2451, an atom 
located very close to the catalytic site of the peptidyl transferase. (Adapted from Tenson 
et al., 2003)  
A. Haloarcula marismortui 50S subunit with a dipeptidyl-tRNA analogue in the A 
site.For clarity, parts of the analogue (caproic acid and biotin residues) are not shown. 
The N-terminal phenylalanine residue is shown in red, the next, tyrosine residue in 
black and A76 of tRNA is shown in magenta. Nucleotides A2058, A2059, A2062 (E. 
coli numbering) of the 23 S ribosomal RNA,essential for macrolide binding, are shown 
in green, A2451, an important component of the peptidyl transferase centre, is shown in 
red and C2452 is shown in blue. N3 of A2451 of 23 S RNA is shown in yellow and the 
proteins L4 and L22 that form part of the tunnel wall are shown in blue and yellow, 
respectively. 
B. Josamycin (carbomycin) bound to the H. marismortui 50S ribosomal subunit. 
Carbomycin has been used as a guide for josamycin–ribosome interactions. These com-
pounds have very similar chemical structures and have the same groups (mycaminose, 
mycarose and isobutyrate residues) approaching the peptidyl transferase centre. The 
lactone ring is shown in red, the mycaminose and mycarose residues in black and the 
isobutyrate residue, which approaches the peptidyl transferase center, is shown in 
magenta.  
C. Erythromycin, bound to the D. radiodurance 50S ribosomal subunit. The desosamine 
residue of erythromycin is shown in black and the cladinose moiety (not present in 
ketolides) is shown in magenta.  
D. ABT 773 in the D. radiodurance 50S ribosomal subunit, as a guide to the binding of 
telithromycin to the ribosome. The desosamine residue of ABT 773 is shown in black 




Macrolides prevent ribosomal large subunit formation (Champney and Tober, 
1998; Usary and Champney, 2001). According to Champney and Tober, 1998., 
macrolides bind to the precursors of the large ribosomal subunit and stall 
ribosome assembly. These stalled assembly intermediates then become 
substrates for ribonucleases (Usary and Champney, 2001). However, the effect 
of erythromycin on ribosome assembly might be indirect. Observations made by 
Siibak et al. (unpublished results) suggest that ribosome can become fully 
assembled in the presence of the macrolide. 
 
 
1.5. Macrolide Resistance 
 
The therapeutical utility of macrolides has been severely compromised by the 
emergence of drug resistance in many pathogenic bacteria (Blondeau et al., 
2002; Katz and Klausner, 2008; Richter et al., 2008; Wang et al., 2008). 
The known mechanisms of macrolide resistance include modification of 23S 
ribosomal RNA (methylation or mutation of 23S rRNA bases) (Weisblum, 
1995; Vester and Douthwaite, 2001), ribosomal protein mutations (Wittmann et 
al., 1973; Chittum and Champney, 1994), active efflux of the drug from the cell 
(Borges-Walmsley et al., 2003), structural modification of macrolides (Ounissi 
and Courvalin, 1985; Jenkins and Cundliffe, 1991; Chesneau et al., 2007), 
peptide mediated macrolide resistance (Tenson et al., 1996; Tripathi et al., 
1998; Tenson and Mankin, 2001). 
 
 
1.5.1 Methylation of rRNA 
 
Erm ribosomal RNA methylases  
The synthesis of ribosomal RNA methyltransferases, encoded by erm genes, 
leads to the macrolide resistance (Weisblum et al., 1995a, b). 
Erm genes are found in a diverse range of pathogenic and drug-producing 
bacteria (Shivakumar and Dubnau, 1981; Rasmussen et al., 1986; Weisblum et 
al., 1995a; Douthwaite et al., 2005; Madsen et al., 2005).  
All erm genes encode methyltransferases that specifically target nucleotide 
A2058 in 23S rRNA but differ as to whether they monomethylate or 
dimethylate this nucleotide (Skinner et al., 1983; Weisblum, 1995a). Mono-
methylation of A2058 confers resistance to erythromycin, but cells remain 
sensitive to ketolides (telithromycin); dimethylation renders cell resistant to 
macrolides and ketolides (Douthwaite et al., 2005).  
Methylation of A2058 sterically hinders the binding of macrolides to the 
ribosome (Schlunzen et al., 2001; Tu et al., 2005). 
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Substrate for methylation 
It has been found that fully assembled 50S subunits cannot be methylated 
(Skinner et al., 1983; Weisblum, 1995a). In the presence of the methyltrans-
ferase, the 50S ribosomal subunit precursors serve as a substrate for methylation 
(Pokkunuri and Champney, 2007).  
 
Erm expression 
Expression of Erm methyltransferases can be either constitutive or inducible by 
low concentrations of macrolides (Weisblum, 1995a, b; Liu and Douthwaite, 
2002).  
The mechanism of inducible Erm resistance regulation came from the study 
of ErmC methyltransferase (Weisblum et al., 1971; Dubnau et al., 1984; 
Mayford and Weisblum, 1989; Weisblum, 1995a). ErmC expression is induced 
by the low concentration of erythromycin. Erythromycin binds to the ribosome 
and inhibits translation of 19 amino acid peptide encoded by the 141 nucleotide 
leader sequence of the ermC mRNA extending from the transcription initiation 
site to the methylase initiator methionine codon (Mayford and Weisblum, 1989; 
Weisblum, 1995b). 
The 141 nucleotide ermC mRNA leader can take three alternative 
conformations (Figure 5). When no erythromycin is present the ErmC protein 
synthesis occurs with a low efficiency because the first two codons of ErmC 
ORF, as well as ErmC ribosome binding site, are sequestered in the secondary 
structure, only the leader peptide being synthesized (Figure 5A). When the 
erythromycin binds to the ribosome, translating ribosome stalls on the ermC 
upstream ORF and induces conformational change in ermC mRNA secondary 
structure. This opens translation initiation reagion of the ErmC protein coding 
ORF, allowing the ribosome, free from the macrolide, to start methyltransferase 
synthesis (Figure 5B). After the concentration of erythromycin decreases and 
can no longer support induction, the leader region can refold into an inactive 
conformation, shown in figure 5C. The conformational transition 4B to 5A 
would also repress ermC, but the conformational transition 5B to 5C would be 
energetically more favored (Mayford and Weisblum, 1989, Weisblum, 1995b). 
This mechanism has been known as translational attenuation. Although the 
leader peptide is 19 amino acids long, only the first 9 amino acids 
(fMGIFSIFVI-) are necessary for induction. Whereas SIFVI amino acids are 
crucial for the ribosome stalling on the mRNA during leader peptide synthesis 








   
 






Spread of erm coded resistance 
In Europe and the Far East erm genes are responsible for most of the macrolide 
resistance (Farrell et al., 2004). The resistance caused by rRNA methylation is a 
more serious threat to human health than other resistance mechanisms. 
Methylation of the rRNA not only confers higher level erythromycin resistance 
but simultaneously confers cross-resistance to all other macrolide, lincosamide 
and streptogramin B classes of antibiotics (Weisblum, 1995b).  
 
Methylation of rRNA hairpin 35 in domain II 
Methylation of the nucleotide G745 in gram-negative bacteria 23S rRNA by 
methyltransferase enzyme RrmA (RlmI) and methylation of the nucleotide 
G748 in gram-positive bacteria by the methyltransferase enzyme TlrB (RlmII) 
has been described (Gustafsson and Persson, 1998; Liu et al., 2000; Liu and 
Douthwaite, 2002a, b). Both G745 and G748 nucleotides are integral compo-
nents of the narrowest region of the ribosome tunnel, which is the binding site 
for the macrolides (Schlünzen et al., 2001). Methylation of G745 or G748 
nucleotide alone confer very low resistance to the macrolides (Liu and 
Douthwaite, 2002b).  
However, acting together with methylation of A2058, G745 (gram-negative 
bacteria) or G748 (gram-positive bacteria) methylation confer high resistance to 
macrolides, especially tylosin and mycinamycin (Liu and Douthwaite, 2002b). 
 
 
1.5.2. Macrolide Resistance Conferred by Base Substitutions  
in 23S rRNA 
 
23S rRNA mutations confer macrolide resistance (Vester and Douthwaite, 
2001; and references therein). Mutations at A2058, or at A2059 confer the 
highest levels of resistance. Lower level drug resistance is provided by 
mutations at positions 2057, 2452, and 2611, which are close in the secondary 
structure although outside the focal point of macrolide interaction (Douthwaite 
and Aagaard, 1993). Low-level macrolide resistance is conferred in an E. coli 
laboratory strain by a mutation at position 754 (Xiong et al., 1999). 
 
Resistance in pathogenic strains 
This type of resistance is not widely spread in clinical pathogenic bacterial 
isolates (Farrell et al., 2003; Wierzbowski et al., 2007). Multiplicity of rRNA 
genes in most microorganisms slows development of this type of resistance 
(Cundliffe, 1990). rRNA mutations, conferring macrolide resistance, has been 
usually identified in clinical pathogens possessing only one or two rrn operons: 
Brachyspira hyodysenteriae, Mycoplasma pneumoniae, Mycobacterium absces-
sus, Helicobacter pylori, Treponema pallidum, Chlamydia trachomatis (Lucier 
et al., 1995; Versalovic et al., 1996; Vester and Douthwaite, 2001; Misyurina et 
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al., 2004). However, rRNA mutations, conferring macrolide resistance, have 
been also reported for clinical pathogenic bacteria isolates with 3 and 4 rrn 
operons: Streptococcus pneumoniae, Streptococcus pyogenes, Propiobacterium 
pneumoniae (Vester and Douthwaite, 2001; Farrell et al., 2003; Doktor et al., 
2004; Wierzbowski et al., 2007).  
In bacteria with several copies of the rrn operons mutations can be in one or 
more copies of the gene (Tait-Kramradt et al., 2000; Doktor et al., 2004). The 
resistance to macrolides when all copies of rRNA genes are mutated is higher 
(Doktor et al., 2004). 
 
 
1.5.3. Macrolide Resistance Mutations  
in Ribosomal Proteins L22 and L4 
 
Characteristics of L4 and L22 proteins 
L4 and L22 proteins are the early assembly proteins of the large subunit and 
their modifications perturb the assembly of the 50S subunit (Rohl and Nierhaus, 
1982; Herold and Nierhaus, 1987; Stelzl et al., 2000). L4 and L22 proteins have 
globular domains on the surface of the ribosome and long tentacles that extend 
into the core of the ribosome. L4 and L22 proteins reach the nascent 
polypeptide chain exit tunnel and form the narrowest cross-section of the exit 
tunnel entrance. 
 
Role of the exit tunnel gate formed by L4, L22 proteins 
The role of this narrowest cross-section of the exit tunnel (exit tunnel gate) is 
not understood. It might function as a sensor, recognizing special features of the 
nascent peptide chain and transmitting message to the peptidyl transferase 
centre (Nissen et al., 2000), it might provide alternative exits for the nascent 
peptides (Gabashvili et al., 2001), or it might regulate the protein elongation by 




The first isolated E. coli L22 mutation is a deletion of three amino acid residues, 
Met82, Lys83 and Arg84 (Chittum and Champney, 1994). The first isolated E. 
coli L4 mutation is a single amino acid substitution, Lys63Glu (Chittum and 
Champney, 1994). Mutated amino acid residues are located in the tunnel 
entrance (Gabashvili et al., 2001; Tu et al., 2005). 
Recently, new mutations in E. coli L4 and L22 ribosomal proteins, confer-
ring resistance to erythromycin, have been isolated (Zaman et al., 2007). In L4, 
all mutations mapped within the tentacle. Of the five new missense mutations, 
four were in the glycine at position 66 and one was in 62th amino acid. Three 
large insertion mutations after codons 56, 63 and 72 were also identified. Of the 
L22 mutations, one was in the extended loop of the tentacle (45 bp insertion 
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after codon 99), while one (6 bp insertion after codon 105) was in the globular 
domain (Zaman et al., 2007).  
 
Erythromycin sensitive mutation in L4 
It has been reported that heterologous overproduction of L4 protein from 
Thermus thermophilus with Gly55Ser mutation in E. coli make bacteria more 
sensitive to erythromycin (Tsagkalia et al., 2005). 
 
Mechanism of resistance 
Mutations in L4 and L22 confer macrolide resistance due to conformational 
changes in the structure of the ribosome rather than any direct interaction of the 
ribosomal proteins with the macrolide (Schlunzen et al., 2001). 
Biochemical studies have shown that ribosomes containing the mutant L4 
protein no longer bind erythromycin. In contrast, ribosomes carrying the altered 
L22 protein still bind the antibiotic (Wittmann et al., 1973; Zaman et al., 2007). 
Cryo-EM reconstructions indicated that the L4 mutant protein causes a 
narrowing of the entry of the exit tunnel that apparently prevented erythromycin 
binding while the altered L22 caused a widening of the tunnel that allowed drug 
binding without inhibiting entry of the nascent peptide into the enlarged tunnel. 
(Gabashvili et al., 2001; Tu et al., 2005). 
 
Resistance in pathogenic strains 
L4 and L22 mutations conferring resistance to the macrolides have been 
identified in clinical isolates of bacteria, including Haemophilus influenzae, 
Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus. 
Most of the mutations map to the nascent peptide exit tunnel entrance (Peric et 
al., 2003; Doktor et al., 2004; Franceschi et al., 2004; Berisio et al., 2006). 
 
 
1.5.4. Macrolide Resistance Conferred  
by Drug-Efflux Transporters 
 
One strategy in biological systems that provide resistance to cytotoxic drugs is 
efflux of these compounds from the cell via membrane proteins, decreasing the 
intracellular concentration of the drug to subtoxic levels (Piddock, 2006).  
The resistance pumps are categorized into families: MF (major facilitator) 
superfamily, SMR (small multidrug resistance) family, RND (resistance/ 
nodulation/cell division) family, MATE (multidrug and toxic compound efflux) 
family, ABC (ATP binding cassette) superfamily (Piddock, 2006). 
Macrolide resistance is conferred by pumps belonging to MF superfamily, 
RND family and ABC superfamily (Borges-Walmsley et al., 2003).  
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RND family macrolide efflux pumps  
RND family macrolide efflux pumps include AcrAB-TolC in Haemophilus 
influenzae and E. coli, MexAB-OprM in Pseudomonas aeruginosa, MtrCDE in 
Neisseria gonorrhoeae, and AmrAB-OprA in Burkholderia pseudomallei 
(Zhong and Shortridge, 2000). In addition to the macrolides these drug 
resistance pumps can transport a variety of structurally different drugs (Borges-
Walmsley et al., 2003). 
RND family pumps share a common three-component organization: a 
transporter located in the inner membrane functions with an outer membrane 
channel and a periplasmic accessory protein.  
 
AcrAB-TolC 
Knowledge about function and structure of RND family pumps comes from the 
studies on E. coli multidrug AcrAB-TolC pump. This pump can eliminate from 
the cell not only macrolides, but also acriflavin, bile salts, ethidium bromide, 
fusidic acid and other compounds (reviewed in Borges-Walmsley et al.,2003). 
AcrB is an inner membrane protein that interacts with the outer membrane 
protein TolC. This interaction is transiently coupled by the periplasmic protein 
AcrA, which anchores to the inner-membrane by a lipid moiety. 
All three components are required for efficient transport, because disruption 
of any of the three genes results in hypersusceptibility of E. coli to antibiotics 
(Okusu et al., 1996; Chollet et al., 2004). 
AcrAB-TolC complex is assembled in the absence of known substrates of 
this pump and no energy is required for the assembly, however, the substrates of 
the AcrAB-TolC stabilize interactions within the complex (Tikhonova and 
Zgurskaya, 2004). 
AcrB recognizes the substrate and transports drugs by a three-step binding 
mechanism involving substrate entry, binding and extrusion. This cycling 
peristaltic-like mechanism pumps drug into the central TolC exit duct 
(Murakami et al., 2006; Seeger et al., 2006; Sennhauser et al., 2007; Törnroth-
Horsefield et al., 2007).  
TolC can function as the protein channel for different efflux pumps and can 
interact with a variety of transporters, only some of which transport antibiotics 
(for example ErmAB and MacAB of E. coli) (Zgurskaya and Nikaido, 2000; 
Piddock et al., 2006). 
 
Macrolide resistance encoded by MF family efflux transporters 
Mef(A) and mef(E) coded proteins belong to the MF superfamily of efflux 
pumps (van Bambeke et al., 2000). The macrolide specific efflux system, coded 
by mef(A) and mef(E) gene was first described and firmly established in 1996 
(Clancy et al., 1996; Sutcliffe et al., 1996). No substrates other than 14- and 15-
membered macrolides were identified for efflux pumps coded by these genes 
(Tait-Kamradt et al., 1997). The coding sequences of these two genes appeared 
to share 90% identity at the DNA level. The encoded proteins are strongly 
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hydrophobic, apparent integral membrane proteins with 12 transmembrane 
segments (Klaassen and Mouton, 2005 and references therein).  
Because of the high degree of similarity between the mef(A) and the mef(E) 
genes, Roberts et al. (1999) suggested that both genes be referred to as just a 
single class, mef(A). 
The mef genes, originally described for gram-positive bacteria, have recently 
been identified in clinical isolates of gram-negative bacteria (Luna et al., 2000; 
Ojo et al., 2004; Klaassen and Mouton, 2005). Moreover, mef(A) gene was 
found to be the most frequent gene among macrolide resistance genes identified 
in gram-negative strains, isolated from healthy children in Portugal (Ojo et al., 
2004). 
 
ABC superfamily macrolide efflux pumps  
Msr(A) gene expression confers resistance to macrolides: azithromycin, 
clarithromycin, erythromycin, oleandomycin, as well as doxorubicin. Msr(A) 
gene codes for an ATP transporter that transports erythromycin from the cell 
using energy from ATP hydrolysis and has been identified in Staphylococcus, 
Streptococcus, Enterococcus, Corynobacterium and Pseudomonas isolates (Ojo 
et al., 2006). 
Msr(A homolog Mel that confers resistance to macrolides has been recently 
identified in Staphylococcus pneumoniae (Ambrose et al., 2005; Piddock, 
2006). 
MacB gene in E. coli codes for ABC superfamily drug efflux pump. MacB 
gene coexpression with peripheral membrane protein MacA and outer memb-
rane channel forming protein TolC confers E. coli resistance to macrolides 
composed of 14- and 15-membered lactones but no or weak resistance against 
16-membered ones (Kobayashi et al., 2001).  
 
 
1.6. Resistance Conferred by Structural  
Modification of Macrolide 
 
Macrolide phosphorylation 
Resistance by macrolide phosphorylation has been found in Stenotrophomonas 
maltophila, Aeromonas hydrophila, Pseudomonas aeroginosa (Alonso et al., 
2000; Nakamura et al., 2000; Poole et al., 2006) and in Staphylococcus aureus 
(Matsuoka et al., 1998). Phosphorylation, catalyzed by macrolide 2’-phospho-
transferases, is coded by mph genes, which phosphorylate 2’OH group of the 
desosamine sugar of the macrolides (O’Hara et al., 1989). 
 
Macrolide glycosylation 
Macrolides can be modified by glycosylation. Mgt gene coding for glycosyl-
transferase has been found in Streptomyces species. Glycosyltransferase 
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E. coli, Enterobacter, Klebsiella, Citrobacter, Proteus species and Providencia 
stuartii can resist macrolides by the production of an erythromycin esterases, 
coded by ere genes, which hydrolyze the lactone ring of the antibiotic (Ounissi 
and Courvalin, 1985; Arthur et al., 1987; Plante et al., 2003; Ojo et al., 2004) 
 
 
1.7. Peptide Mediated Macrolide Resistance 
 
The discovery of peptide mediated resistance mechanism came from an 
observation that overexpression of a short segment of E. coli 23S rRNA 
(positions 1235–1268) rendered cells resistant to erythromycin (Tenson et al., 
1996). Mutational and biochemical analyses demonstrated that resistance is 
caused by translation of a pentapeptide open reading frame, encoded in E. coli 
23S rRNA. The rRNA encoded pentapeptide is not normally expressed, because 
the Shine-Dalgarno region of the peptide ORF is sequestered in the 23S rRNA 
secondary structure. However, peptide expression can be activated by site-
specific fragmentation of rRNA or by rRNA mutations that increase accessi-
bility of the Shine-Dalgarno region of the erythromycin resistance peptide ORF 
(Dam et al., 1996).  
The peptide enters the site of it’s action cotranslationally and acts in cis, 
affecting properties of only that ribosome on which it has been translated 
(Tenson et al., 1996). Analysis of more than 70 pentapeptides that can confer 
resistance to erythromycin (E-peptides) revealed a consensus sequence 
(MXLXV), which could be recognized in the majority of erythromycin resis-
tance peptides and was especially pronounced in the most active erythromycin 
resistance peptides that could confer very high levels of erythromycin resistance 
(Tenson et al., 1997).  
Peptides that confer resistance to other macrolides have been also described 
(Tripathi et al., 1998; Tenson and Mankin, 2001). 
A mechanism for peptide mediated resistance has been proposed (Tenson et 
al., 1996; Tripathi et al., 1998; Verdier et al., 2002). A nascent resistance 
peptide is suggested to remove the macrolide from the ribosome by which it has 
been synthesized. These peptides act probably as a “bottle brush” that “clean” 
the ribosome from the bound antibiotic (Tenson et al., 1996; Tripathi et al., 




1.8. The Prevalence of Mechanisms  
of Macrolide Resistance in Clinical Isolates 
 
The usage of macrolides has led to increased macrolide resistance in clinical 
isolates. Main mechanisms of the macrolide resistance found in clinical isolates 
are ribosomal RNA modification and efflux of macrolide. The prevalence of 
resistance mechanisms in some bacteria has been summarized in tabel 2.  
 
Table 2. The prevalence of types of macrolide resistance in clinical isolates. 
Bacteria Rank of prevalence of macrolide resistance 
mechanisms 
Reference 
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2. RESULTS AND DISCUSSION 
 
2.1. Translation Initation Region Sequence 
Preferences in Escherichia Coli 
 
The mRNA translation initiation region (TIR) comprises the initiator codon, 
Shine-Dalgarno sequence and translation enhancer. Probably the most abundant 
class of enhancers contains A/U-rich sequences. We have tested the influence of 
SD sequence length and the presence of enhancers on the efficiency of 
translation initiation.  
 
 
2.1.1. Effect of the Translation Initiation Region  
on the Level of Protein Synthesis (Reference I) 
 
Design of the model constructs 
Three sets of TIRs were designed and cloned in front of GFP coding reporter 
gene. Each set contained 10 variants of the SD sequence. The SD variants were 
constructed by mutating the sequence, forming an 8 base pair duplex with the 
complementary aSD, and reducing its length from 8 nucleotides to 1. Each set 
contained a unique sequence upstream of the SD: one contained no translational 
enhancer, one with a previously described strong A/U rich enhancer, and one 
with a weak enhancer (Komarova et al., 2002; Reference I).  
 
SD and enhancer 
Irrespective of the enhancer context, protein expression was highest for the  
6-nucleotide SD AGGAGG (Reference I). Both shorter and longer SD 
sequences were less efficient. Shorter SD sequences may be less efficient 
because binding to ribosome is weaker. Longer SDs, probably, make ribosome 
mRNA interaction too strong, therefore, it might take more time for the 
ribosome to leave translation initiation site and proceed with protein elongation 
(Komarova et al., 2002).  
In the absence of enhancer, there were only slight differences between weak 
and strong SD sequences. When strong enhancer was introduced into the TIR, 
the differences between the SD sequences were increased greatly. A/U-rich 
enhancer worked in positive cooperativity with the SD sequence, enhancing the 
efficiency of selection of the strongest SD sequence and having only a minor 
effect on the weakest one (Reference I).  
 
Importance of enhancer in translation 
mRNA conformation, not stabilized by interactions with proteins, is labile. The 
time window when SD is exposed to the ribosome attachment is very short, 
especially, when TIRs are burried in the stable hairpin structures (de Smit and 
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van Duin, 2003; Studer and Joseph, 2006). In order to increase the probability 
of the 30S ribosomal subunit attachment and the initiation of the translation 
bacterial mRNAs contain standby sites that are used for the primary binding of 
the small ribosomal subunits in the vicinity of the SD and start codon sequences 
(de Smit and van Duin, 2003; Studer and Joseph, 2006). This interaction is 
mediated by the S1 protein on the ribosome and A/U rich sequence on the 
mRNA (Subramanian, 1983). It was previously speculated that all highly 
expressed proteins in bacteria possess the A/U rich sequences upstream of the 
SDs (Komarova et al., 2002). The fact that bearly all protein synthesis in 
bacteria is S1 protein dependent assists to that proposal (Sorensen et al., 1998). 
 
TIR efficiency in different media 
The efficiency of the TIRs was determined solely by the strength of TIR 
interaction with the 30S ribosomal subunit and were not influenced by different 
media, growth rate (Reference I), and overexpression of translation initiation 
factors (data not shown). 
Although, there were quantitative differences in the TIR selection pattern, 
the ranking order did not change. 
 
Effect of temperature on TIR selection 
The energy of base pairing between two RNA strands depends on the tem-
perature. Therefore, the strength of SD:aSD interaction is temperature 
dependent. If the free energy of this interaction determines the efficiency of 
translation then at lower temperature shorter SD:aSD duplexes would be 
preferred. Alternatively, the SD:aSD interaction might be a trigger for confor-
mational changes in the ribosome. This trigger effect might be temperature 
independent and it would be rather the helix length that determines the 
efficiency. In this case it could be similar to the way a codon:anticodon helix is 
recognized in the A site of the ribosome. To test these possibilities, we 
measured the TIR preference pattern at 20ºC and compared to the data collected 
at 37ºC (Reference I). At 37ºC the most efficient SD sequence was AGGAGG 
(∆G 7.7 kcal/mol); at 20ºC the GGAGG sequence (∆G 9.4 kcal/mol) – with 
decrease in temperature the optimum shifted to a shorter sequence. This result 
indicated that the strength of SD:aSD interaction determines the SD efficiency. 
It also suggested that the length of SD sequence could be used for temperature 
dependent regulation of gene expression. Unfortunately, we were not able to 
analyze the length of SD sequences in the known cold shock genes of E. coli as 
the dataset is too small for statistically meaningful conclusions. 
 
Correlation between SD length and predicted expression level 
We have looked for the relationship between the levels of the predicted protein 
expression by CAI (codon adaptation index) and the free energy changes of the 
SDs in the Escherichia coli (Refernce I). The base pairing potential of the SD 
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sequences did not correlate with the codon adaptation index, which is used as an 
estimate of gene expression level (Sharp and Li, 1987). 
Why do most E. coli mRNAs, including those coding for highly expressed 
genes, have SDs that are not expected to direct the highest level of translation at 
37ºC? We suggest two possibilities. First, E. coli has to grow in the mammalian 
gut but also to survive at lower temperatures outside the host. The temperatures 
of both environments may have contributed to the selection of SD sequences. 
Second, the noise in gene expression levels may be involved. A particular 
expression level could be achieved by different contributions from transcription 
and translation. The theoretical calculations have suggested and experimental 
data confirmed that high level of transcription combined with low level of 
translation creates considerably smaller fluctuations in gene expression as 
compared to the situation when the same expression level is achieved by 
combining low level of transcription with highly efficient translation (Ozdubak 
et al., 2002; Swain et al., 2002; Raser and O’Shea, 2005). Therefore, using 
suboptimal TIRs might reduce noise in gene expression.  
 
 
2.2. Peptide Mediated Macrolide Resistance 
 
Peptide mediated macrolide resistance is a phenomenon where correlations 
between the structures of nascent peptides and macrolide antibiotics are 
observed (Tenson et al., 1996; Tenson et al., 1997; Tripathi et al., 1998; Tenson 
and Mankin, 2001; Reference I). 
Purposes of the present studies are  
1. to select josamycin resistance peptides 
2. to establish spectrum of resistance afforded by resistance peptides 
3. to clarify molecular mechanism of peptide mediated resistance 
4. to determine role of macrolide efflux in antibiotic resistance 
 
 
2.2.1 Josamycin Resistance Peptides (Reference II) 
 
Josamycin resistance (JOS) peptides were selected from a five-codon random 
mini-gene expression library (Tenson et al., 1997). In this library, the plasmid-
encoded mini-genes are composed of an initiation codon, four randomized 
codons and a termination codon. The mini-genes are equipped with a translation 
initiation sequence and are expressed under the control of the isopropyl-ß-D-
thiogalactopyranoside inducible Ptac promoter.  
All JOS peptides contained an aromatic amino acid, phenylalanine or 
tyrosine, in the second amino acid position. Amino acid conservation in other 
positions of josamycin resistance peptides was not observed.  
34 
The property of the second amino acid in the JOS peptides appears to be 
crucial for peptide activity. 
 
 
2.2.2. Peptide Mediated Resistance  
is Macrolide Specific (Reference II) 
 
Peptides, conferring resistance to telithromycin, erythromycin, oleandomycin 
have been described (Tripathi et al., 1998; Tenson and Mankin, 2001; Reference 
II). The spectrum of resistance caused by KET, ERY, OLE, JOS peptides was 
examined.  
The experimental data showed that peptide mediated resistance is specific. 
Peptides selected on a particular antibiotic provided the highest level of resis-
tance to this drug. In most cases peptides conferred little or no cross-resistance 
to other types of macrolides.  
 
 
2.2.3. Classification of Resistance Peptides  
(Reference II) 
 
Comparison of all known resistance peptides gives a clear evidence for 
correlation between the amino acid sequences and the structures of antibiotics 
they confer resistance (Figure 6).  
Peptides with similar consensus amino acid sequences confer resistance to 
macrolides with similar structure. Significant changes in the structure of 
macrolide are reflected in significant changes in resistance peptide sequences. If 
the structural differences between macrolides are only slight then resistance 
peptides’ consensus sequences are identical or very similar. 
We classified all known resistance peptides into five structural classes 
(Table 3). 
 
ERY group peptides 
The resistance peptides of the ERY group include those that confer resistance to 
the erythromycin type macrolides (erythromycin, clarithromycin, roxithromycin 
and RU69874) (Tenson and Mankin, 2001). Erythromycin type macrolides are 
14-membered lactone ring macrolides with L-cladinose at position 3 and 
desosamine at position 5 of the lactone ring. The peptides are characterized by 
the presence of Leu or Ile in the third position, the preference of bulky 













































































































































































































































































































































































































































































































































































































































































































































AZI group peptides  
AZI group peptides confer bacteria resistance to azithromycin and azaerythro-
mycin. 
Azithromycin and azaerythromycin are 15-member ring macrolides. Exten-
ding the 14-atom lactone ring by an additional nitrogen atom alters the ring 
conformation resulting in a novel interaction with 23S rRNA base 2586 as seen 
in the crystallographic complexes of azithromycin with the Deinococcus radio-
durance ribosome (Schlünzen et al., 2003). 
AZI peptides, which include azithromycin and azaerythromycin resistance 
peptides, are generally similar to ERY peptides. As with the ERY peptides the 
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AZI peptides contain Leu in the third amino acid position and show preference 
for a bulky hydrophobic amino acid in the second position (Leu, Ile, Phe, Val). 
However, in contrast to the ERY peptides, the peptides selected with azithro-
mycin show a strong preference for a positively charged amino acid (Lys or 
Arg) in the fourth position. 
The structural differences between azaerythromycin and azithromycin are 
minute. Azaerythromycin lacks a single methyl group at the nitrogen atom of 
the azithromycin azalide ring. This small alteration in drug structure appears to 
result in reduced requirements for Leu in the third peptide position and for the 
positively charged amino acid in the fourth position (Reference II). 
 
KET group peptides 
KET group peptides confer resistance to ketolides (telithromycin, RU64399, 
HMR3004, ABT377). 
Ketolides contain keto group at position 3 of the lactone ring and alkyl-aryl 
side chain, attached to the 11,12-carbamate group on the opposite side of the 
lactone ring. In the ribosome-bound form of the drugs, the side chain extends 
towards helix 35 in domain II of 23S rRNA and establishes interactions, which 
are important both for the high affinity of the ketolide as well as the positioning 
of the drug molecule in the ribosome (Schlünzen et al., 2003). 
The second position in KET peptides is represented predominantly by 
positively charged amino acids.  
The KET peptides show amino acid preference in positions 3 and 4, which 
are commonly represented by either hydrophobic or positively charged amino 
acids. It is not clear wether the amino acid preference in third and fourth 
positions of the peptide is determined by the nature of alkyl-aryl and 
quinolylallyl side chains.  
 
OLE group peptides 
Surprisingly, the peptides conferring resistance to oleandomycin, another  
14-member ring cladinose-containing macrolide, were substantially different 
from the ERY peptides. Oleandomycin structurally is similar to erythromycin. 
None of the oleandomycin resistance peptides had Leu or Ile in the third 
position; instead a positively charged amino acid was frequently present at 
position 3 and/or 4 of the peptide. Because of the high content of positively 
charged amino acids, OLE peptides appear to more closely resemble the KET 
peptides than the peptides conferring resistance to other 14-member cladinose-
containing macrolides. 
Oleandomycin differs from erythromycin and related compounds by the 
presence of an 8-oxirane cycle, a methyl instead of an ethyl group attached at 
C13 of the lactone ring and the lack of a 12-hydroxyl. Variations in sub-
stitutions at C12 and C13 may directly contribute to the unusual binding of 
oleandomycin. The C13 ethyl of erythromycin reaches towards the loop of helix 
35 in domain II of 23S rRNA (Schlünzen et al., 2001). Shortening this side 
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chain by one carbon atom in oleandomycin may affect possible interaction with 
this rRNA region. The C12 hydroxyl of erythromycin forms a hydrogen bond 
with O4 of rRNA residue U2609 (Schlünzen et al., 2001). The lack of this 
hydroxyl in oleandomycin should destabilize this contact. Interestingly, both 
helix 35 and U2609 are implicated in specific interactions with ketolides 
(Hansen et al., 1999; Xiong et al., 1999; Schlünzen et al., 2001; Garza-Ramos et 
al., 2002; Hansen et al., 2002).  
Thus, some of the peculiar contacts of oleandomycin with the ribosome 
affect the ribosome-drug interactions and make them different in comparison 
with erythromycin. It is conceivable that the position of oleandomycin in the 
ribosome may structurally resemble more closely the binding of ketolides than 
that of the erythromycin-type antibiotics, which can account for the similarity of 
oleandomycin and ketolide resistance peptides.  
 
JOS group peptides 
Josamycin, a 16-member lactone ring macrolide, contains a mycaminose-
mycarose-isobutyrate side chain that, by analogy with carbomycin, is likely to 
reach into the ribosomal peptidyl transferase centre (Hansen et al., 2002). The 
drug leaves a fairly small space for the nascent peptide and allows synthesis of 
di- or tripeptides (Hansen et al., 2002; Lovmar et al., 2004). 
JOS peptides’ consensus sequence is drastically different from that seen with 
other macrolides. The second amino acid position in all JOS peptides is 
occupied by an aromatic amino acid, phenylalanine or tyrosine. 
 
 
2.2.4. Mechanism of Macrolide Displacement  
from Ribosome 
 
Drawing clues from the correlation between the amino acid sequences of 
resistance peptides and the chemical structures of the drugs, one can envision a 
possible mechanism of drug displacement based on a direct interaction between 
the macrolide molecule and the peptide.  
Structure-specific interaction with the nascent resistance peptide may alter 
drug conformation resulting in reduced affinity to the ribosome. Although no 
high-affinity binding between synthetic resistance peptides and antibiotics was 
observed in solution (Tenson et al., 1996) such interaction may be possible in 
the ribosome where peptide structure is expected to be constrained by its 
contacts with the exit tunnel.  
 
ermC leader peptide interaction with erythromycin 
Tu et al. (2005) modelled eight N-terminal amino acids of the ermC operon 
leader peptide bound at the peptidyl transferase centre end of the peptide exit 
tunnel in the presence of erythromycin. The tunnel is not so occluded by 
erythromycin that a peptide cannot get past it. The N-termial residue of an eight 
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residue long peptide reaches a point in the tunnel that essentially pasts the drug. 
ErmC leader peptide interacts with the erythromycin (Tu et al., 2005). 
Interaction between SIFV amino acid residues of the ErmC leader peptide and 
the erythromycin occurs (Tu et al., 2005). This is consistent with the fact that 
SIFVI amino acids are crucial for the ribosome stalling during induction of 
ErmC synthesis by erythromycin (Weisblum, 1995a, b).  
 
ermC leader peptide and ERY peptides 
It is obvious that ermC leader peptide’s amino acid sequence is quite similar to 
the amino acid sequence of the ERY peptides, charactarized by the presence of 
valine and isoleucine, and bulky hydrophobic amino acids.  
According to the structural model for the mechanism of resistance peptide 
action proposed by Lovmar et al. (2006), ERY peptides interact with the 
erythromycin molecule through conserved valine – third amino acid residue of 
the peptide (Reference III).  
 
Resistance peptides and macrolides 
Alterations in the amino acid sequence of resistance peptides change the 
spectrum of antibiotics to which the peptide confers resistance. This occures due 
to the change in spectrum of interactions the resistance peptides can make with 
the macrolides. 
Based on the correspondence between resistance peptides’ sequences and the 




2.2.5. Mechanism of Peptide Mediated Erythromycin 
Resistance (Reference III) 
 
Erythromycin dissociation  
The length of peptide conferring resistance to erythromycin is of great 
importance for the erythromycin dissociation from the ribosome. 
In a cell free system the rate constant for erythromycin dissociation increases 
gradually by a factor of six as the peptide grows from fMet to di- and then to 
penta-peptide. In addition, when translation termination factor is added, the rate 
constant for erythromycin release is further enhanced by a factor of two 
(Reference III).  
The resistance peptide shortening or lenthening abolishes erythromycin 
resistance in vivo (Reference IV). 
 
Model of peptide mediated resistance 
Based on the “bottlebrush“ model for the erythromycin ejection from the 
ribosome and biochemical data, the mathematical model for the erythromycin 
resistance has been constructed (Reference III).  
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The nascent resistance peptide removes the macrolide from the ribosome by 
which it has been synthesised. The effect is only contemporary, since the 
macrolide molecule may bind to the ribosome again. Translation of the 
resistance peptide increases the pool of the ribosomes free of antibiotic. 
Consequently, this increases the probability that translating ribosomes pass the 
critical length of the nascent protein after which the ribosomes become 
inaccessible to the drug and finish protein synthesis (Andersson and Kurland, 
1987; Reference III). 
The model accounts for dilution of all compounds due to cell volume growth 
and for a finite rate of diffusion across the cell membrane and takes into account 
the efflux pumps, used by E. coli to actively transport erythromycin from the 
membrane and cytoplasm to the growth medium (Figure 7).  
The validity of the model simulations has been confirmed by observations 
from experiments in which the expression level of resistance peptide was varied 
for bacteria growing in media containing varying concentrations of 
erythromycin. The increasing expression level of resistance peptide in a 
bacterial population led to increasing erythromycin resistance until a plateau, 
specific for each concentration of the erythromycin, was reached. 
 
Resistance peptide coding mRNA concentration 
As measured by real-time PCR, there should be approximately 20 times more 
copies of resistance peptide coding mRNAs than EF-Tu mRNA to confer the 
highest level of resistance to the macrolide (Reference III).  
The copy number of EF-Tu mRNA, one of the most abundant mRNA in the 
Escherichia coli cells, is approximately 2000 copies per cell (Vimberg and 
Tenson, unpublished results). This means that it is impossible to confer 
erythromycin resistance by expressing resistance peptide at the level of bacterial 
mRNA. The only suitable source for the adequate copy number of ERY peptide 
coding mRNAs are ribosomal RNA (approximately 17000 molecules per cell) 
or transcription from a high copy number plasmid (Dennis and Bremer, 1974; 
Reference III).  
This is in a good agreement with the fact that the peptide mediated resistance 
was first demonstrated for a pentapeptide encoded in Escherichia coli 23S 
rRNA (Tenson et al., 1996). 
 
 
2.2.6. Clinical Significance of Peptide Mediated Resistance  
 
In the absence of direct evidence for expression of the macrolide resistance 




Resistance peptide expression 
Although the expression of erythromycin resistant peptide, coded by 23S 
rRNA, is impaired, because its’ ribosome binding site is sequestered in the 
rRNA secondary structure (Tenson et al., 1996), expression can be activated by 
a specific rRNA fragmentation (Tenson et al., 1996). For example, a spon-
taneous deletion of 12 nucleotides (positions 1219–1230) from the 23S rRNA 
gene has been described as causing resistance to erythromycin (Douthwaite et 
al., 1985). The 12 nucleotide deletion could destabilize the rRNA secondary 
structure that masks ribosome binding site, thus activating peptide’s expression 
and resistance to erythromycin.  
It is not clear whether the presence of a functional peptide coding gene in E. 
coli rRNA is a coincidence or a result of evolutionary selection. Nevertheless, 
many, but not all, prokaryotic 23S rRNA sequences contain a pentapeptide 
mini-gene at the junction of domains II and III. 
 
Resistance mediated by resistance peptide expression in clinical bactera 
isolates 
Is it possible that macrolide resistance peptide expression would confer macro-
lide resistance in clinical isolates?  
Maximum observed erythromycin concentration in serum after a single 500 
milligram oral dose is 2.37 microgrammes per milliliter (Kroboth et al., 1982).  
This concentration is sufficient for inhibition of gram-positive bacteria (Lin 
et al., 2005; Sunakawa and Farrell, 2007) and some gram-negative bacteria 
(Blondeau et al., 2002). Macrolides cannot be used for the treatment of an 
infection with some species of gram-negative bacteria, because bacteria have 
intrinsic resistance, due to the cell permiability barrier and due to the active 
macrolide efflux (Walsh, 2003; Piddock, 2006; Reference III). 
The only evidence of peptide mediated resistance in bacteria that can be 
inhibited by erythromycin at concentration present in serum comes from the 
work of Novikova et al. (2000). Novikova et al. (2000) studied peptide 
mediated resistance in Bacillus subtilis, the model organism to study gram-
positive bacteria. For Bacillus subtilis the minimal inhibitory concentration of 
the erythromycin is 0.125 µg/ml (Lin et al., 2005), the concentration 20 times 
lower than erythromycin concentration in serum after macrolide oral 
administartion (Kroboth et al., 1982). However, erythromycin concentration in 
the serum is 12 time lower than the erythromycin concentration tolareted by 
Bacillus subtilis, expressing erythromycin resistance peptide (Novikova et al., 
2000).  
Therefore, it is quite probable that macrolide resistance observed in clinical 




2.2.7. The Mechanisms of Peptide Mediated Erythromycin and 
Josamycin Resistance Differ (Reference IV) 
 
Josamycin resistance dependency on the length of the resistance peptide 
Change in the length of JOS peptides did not affect the peptide’s activity. It was 
enough to code for dipeptide MF in order to provide resistance against josa-
mycin. Termination of translation was not required for the JOS peptide 
mediated resistance as well (Reference IV).  
 
Mechanism of josamycin resistance peptide action 
We propose that expression of the JOS peptides containing phenylalanine in the 
second position transfer ribosomes containing josamycin into translationally 
inactive complexes, thus taking those ribosomes away from the protein 
synthesis system. 
There are two arguments that support this hypothesis. First, the main 
difference between josamycin and erythromycin is that the former has much 
slower binding and dissociation kinetics than the latter. The rate constant for 
association of erythromycin to the ribosome is about 30 times larger than the 
association rate constant for josamycin. The dissociation rate constant for the 
complex between erythromycin and the ribosome is about 60 times faster than 
the corresponding parameter for josamycin. These differences in rate constants 
determine that the average lifetime on the ribosome is 3 hours for josamycin 
and less than 2 minutes for erythromycin (Lovmar et al., 2004).  
Second, josamycin slows down formation of a first peptide bond of a nascent 
peptide in an amino acid-dependent way and completely inhibits formation of 
the second or third peptide bond (Lovmar et al., 2004). The formation of fMet-
Val-tRNAVal in the presence of josamycin is decreased 5-fold. At the same 
conditions synthesis of fMet-Phe-tRNAPhe is decreased 1000-fold (Lovmar et 
al., 2004).  
Taking into consideration these two arguments it is more simple for the cell 
to remove josamycin containing ribosomes from the translation than to try to 
brake the very stable ribosome-josamycin complex. 
 
Consequences of josamycin binding to ribosome 
Josamycin bound to the ribosome causes the dissociation of di- or tripeptidyl-
tRNAs (Lovmar et al., 2004). Increased drop off of the dipeptidyl-tRNAs might 
decrease the pool of free tRNAs, thus inhibiting bacterial growth (Dincbas et 
al., 1999). Overexpression of peptidyl-tRNA hydrolase enzyme in E. coli 
conferred low resistance against josamycin, probably, by relieving the effect of 
free tRNA depletion (Soosar et al., unpublished results). Transferring the 
ribosomes, containing josamycin, into translationally inactive complexes by 
translating JOS peptide coding mRNAs would not allow the ribosomes, 
containing josamycin, to accumulate dipeptidyl-tRNAs in the cell and deplet the 
pool of the free tRNAs. 
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In addition to the increased peptidyl-tRNA accumulation, josamycin might 
impair translation of proteins with phenylalanine in the second position (Table 
4). If second codon of mRNA’s open reading frame codes for phenylalanine 
amino acid, ribosome in complex with josamycin stops this mRNA translation 
and turns into translationally inactive complexes. Impairing of translation of 
proteins, involved in cell division process (FtsZ), in ribosome formation (L25), 
in regulation of gene expression (Fis) would stop growth of bacteria (Table 4). 
Transferring the ribosomes, containing josamycin, into translationally 
inactive complexes by translating JOS peptide coding mRNAs would take 
ribosome-josamycin complexes away from the protein synthesis system and 
allow translation of proteins with the phenylalanine in the second codon. 
 
Table 4. List of E. coli genes coding proteins, that contain phenylalanine in the second 
position of the amino acid sequence. 
GENE FUNCTION N-SEQUENCE 




SbmA Possibly envelope protein (fuses permease 
and ATPase components) 
MFKSFFPKPG... 
CyoB Cytochrome O ubiquinol oxidase subunit I 
(aerobic respiration) 
MFGKLSLDAV... 
LysR Putative transcriptional regulator LYSR-type MFDPETLRTF... 
Fes Enterocholin esterase (transport of cations) MFEVTFWWRD... 
Mip Aquaporin Z (transport of small molecules) MFRKLAAECF... 
TyrB Aspartate aminotransferase MFENITAAPA... 
Fis DNA-binding protein MFEQRVNSDV... 
UmuC DNA Polymerase IV MFALCD... 
Rnb Exoribonuclease II (3’–5’ degradation) MFQDNPLLAQ.. 
RibE Riboflavin synthase subunit alpha MFTGIVQGTA... 
RplY 50S ribosomal protein L25 MFTINAEVR... 
Ffh GTP-binding export factor (binds to signal 
sequence, GTP, RNA; transport of large 
molecules) 
MFDNLTDRLS... 
EscV Type III secretion apparatus protein MFNKVLVGLR... 




2.2.8. Antibiotic Efflux in Peptide Mediated Resistance 
(Reference IV) 
 
Mathematical modelling of peptide mediated erythromycin resistance predicted 
the requirement of a fast outflow rate of the drug over the cell membrane to 
confer resistance (Reference III).  
The AcrAB-TolC pump system is the major contributor of erythromycin 
resistance in gram-negative bacteria (Zhong and Shortridge, 2000).  
To validate the model’s prediction we have done experiments with wild-type 
and tolC mutant E. coli cells, expressing resistance peptide. No resistance was 
observed in the tolC mutant bacteria (Reference IV).  
 
Resistance and erythromycin efflux 
In the case of erythromycin, where expression of a resistance peptide actively 
removes a bound drug molecule from the ribosome (Reference III), resistance is 
a consequence of an increased disssociation of erythromycin. According to the 
mathematical model, such a resistance mechanism is sensitive to the fate of the 
drug molecule after ejection. It either leaves the cell by passive diffusion over 
the membrane or is actively transported by efflux pumps or it reassociates to 
another ribosome (Figure 7).  
The value of the rate constant for leaving the cell in relation to the 
association rate constant of the antibiotic becomes very important. The fast 
outflow rate for erythromycin resistance mechanism to work is then a 
requirement. The AcrAB-TolC efflux pump system provides the required high 
efflux rate.  
 
Josamycin 
Results of the experiment have shown no josamycin resistance in the tolC 
mutant cells, expressing JOS peptide, which resistance mechanism clearly 
differs from that of erythromycin.  
The details of josamycin resistance need to be further clarified experi-
mentally. Since the antibiotic is not actively removed from the ribosome 
(Lovmar et al., 2004) there is most likely another reason for the absence of 
resistance in the TolC mutant.  
 
 
2.2.9. Antibiotic Efflux in Erythromycin Resistance  
Conferred by L22 and L4 Mutations (Reference V) 
 
The restoration of erythromycin susceptibility in the absence of drug’s efflux 
has been described in Haemophilus influenzae, Campylobacter jejuni and 
Campylobacter coli L4, L22 erythromycin resistance mutants (Peric et al., 
2004; Cagliero et al., 2006). In addition, Campylobacter jejuni and Campy-
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lobacter coli, inactivation of CmeABC efflux pump lead to restoration of the 
susceptibility in 23S rRNA A2057G erythromycin resistance mutants (Cagliero 
et al., 2005). 
We checked if the fast outflow rate of the drug over the cell membrane is 
important for E.coli erythromycin resistance, conferred by L22 and L4 
mutations. The erythromycin resistance in E. coli, conferred by the L22 and L4 




Figure 7. Cartoon illustrating the fate of erythromycin 
 
 
The erythromycin sensitivity for the ribosomal wild-type was greatly increased 
by ∆acrB deletion, but the largest sensitivity was conferred by the ∆tolC 
deletion. We suggest that the erythromycin efflux pump activity is insignificant 
for the ∆tolC strain, and the ∆acrB strain retains a small but significant efflux 
pump activity. 
We propose that low macrolide efflux efficiency completely masks the 
effects of a target resistance mutations that would give a clear fitness advantage 
at high drug efflux efficiency (References IV, V). 
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There are no experimental evidences that elimination of macrolides efflux 
out of the cytosol of gram-positive bacteria, resistant to erythromycin, would 
restore bacteria erythromycin susceptibility. Taking into account the prediction 
of the mathematical modelling of erythromycin resistance (References IV, V), 
that fast rate of erythromycin outflow from cell compared to slow rate of 
antibiotic association to the ribosome is the requirement for erythromycin 
resistance mechanism to work, gram-positive bacteria should possess very 
effective erythromycin efflux pumps to provide high antibiotic efflux rate. 
Macrolide efflux pumps are well known in gram-positive bacteria, for example 
mefA in Streptococcus species. These pumps might be capable of efficient 
macrolide export from the bacterial cell (Masaoka et al., 2000; Walsh, 2003; 
Piddock, 2006).  
 
 
2.2.10. Interplay Between Antibiotic Efflux and Resistance 
Described in Other Studies 
 
It appears to be a general phenomen that low antibiotic efflux efficiency 
completely masks the effects of a large set of target resistance mutations. 
Resistance to fluoroquinolone family drugs (inhibitors of DNA topo-
isomerase) often occurs as combination of drug efflux and target site mutations. 
It has been shown that efflux pump inhibitors reverse acquired fluoriquinolone 
resistance attributable to DNA topoisomerase mutations, conferring fluori-





Initiation of translation 
1. Shine-Dalgarno selection preferences are influenced by the growth 
temperature. 
2. Shine-Dalgarno selection preferences are not influenced by the growth rate. 
3. The A/U rich enhancers stimulate translation considerably by acting co-
operatively with the Shine-Dalgarno sequence. 
 
Peptide mediated macrolide resistance 
4. Peptide mediated resistance is macrolide specific. Peptides selected on a 
particular antibiotic provide the highest level of resistance to this drug. 
5. Peptides with similar consensus amino acid sequences confer resistance to 
macrolides with similar structure. Significant changes in the structure of the 
macrolide are reflected in significant changes in resistance peptide 
sequences. 
6. The peptide mediated resistance mechanisms against josamycin and 
erythromycin are different. 
 
Macrolides’ efflux out of the cell 
7. The fast outflow of the erythromycin is required for the peptide mediated 
erythromycin resistance mechanism to work. The AcrAB-TolC efflux pump 
system provides the required high efflux rate in E. coli. 
8. Low macrolide efflux efficiency masks the effects of the erythromycin 
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Ribosoom on oluline valgusünteesi läbi viiv makromolekulaarne kompleks. 
Ribosoom koosneb suurest ja väikesest subühikust. Väike subühik osaleb 
geneetilise informatsiooni dekodeerimises, samal ajal kui suur subühik 
assambleerib aminohapped polüpeptiidi ahelasse.  
Väikese subühiku seondumine mRNA translatsiooni initsiatsiooni regiooni 
on translatsiooni efektiivsuse peamine determinant. Me avastasime, et kuuest 
nukleotiidist koosnev „Shine-Dalgarno” järjestus (AGGAGG) on efektiivsem 
võrreldes lühemate ja pikkemate järjestustega, kui Escherichi coli kasvab 37ºC 
juures. A/U rikas tugevdaja soodustab initsiatsiooni efektiivsust, avaldades 
kõige suurema efekti bakterite eksponentsiaalse kasvufaasi ajal. Bakterite 
kasvukiirus ei mõjuta tranlatsiooni initsiatsiooni regiooni selekteerimismustrit. 
Teisest küljest kasvutemperatuur mõjutab translatsiooni initsiatsiooni regiooni 
valikut: lühemad SD järjestused on eelistatud madalama kasvutemperatuuri 
juures. See tulemus näitab, et SD:aSD interaktsiooni tugevus on peamine trans-
latsiooni efektiivsuse determinant. 
Suur ribosomaalne subühik on paljude antibiootikumide sihtmärk. Anti-
biootikumide seondumine peatub valkude sünteesi. Makroliidid on antibioti-
kumid, mis seonduvad suure ribosomaalse subühikuga peptidüültransferaast-
sentri ja kasvava peptiidi väljumistunneli vahele, seega häirivad translatsiooni. 
Spetsiifiliste peptiidide ekspressioon tagab bakteriraku resisentsust makroliidide 
vastu.  
Antud uuringus me selekteerisime peptiidid, mis tagavad resistentsuse 
josamütsiini, 16-aatomilise laktoonringiga makroliidi, vastu. Kõigil josamütsiini 
resistentsuspeptiididel oli teises positsioonis fenüülalaniini või türosiini jääk. 
Spetsiifilised resistentsuspeptiidid tagavad bakterite resistentsust ainult 
makroliididele millega nemad olid selekteeritud ja ei põhjusta ristresistentsust 
struktuurselt erinevatele makroliididele. Vastavalt resistentsuspeptiidide amino-
happelistele jätjestustele ja makroliidide struktuuridele, mille vastu resistentsus 
tekib, me klassifitseerisime kõik teadaolevad resistentsuspeptiidid 5-ks klassiks. 
Resistentsuspeptiidide poolt vahendatud resistentsuse tekkeks peab resis-
tentsuspeptiidi kodeeriva mRNA hulk olema 20 korda suurem kui EF-Tu’d 
kodeeriva mRNA hulk. Järelikult peab resistentsuspeptiidi kodeeriva mRNA 
tase olema võrdeline ribosomaalse RNA tasemega rakus. 
Josamütsiini ja erütromütsiini resistentsuspeptiidide pikkuse muutmine omas 
erinevaid efekte resistentsusele. Josamütsiini resistentsuspeptiidi pikendamine 
või lühendamine ei mõjutanud resistentsust. Seevastu erütromütsiini resis-
tentsuspeptiidi pikendamine või lühendamine täiesti elimineeris aktiivsuse. 
Arvestades erütromütsiini ja josamütsiini aktiivsuse kineetikat me oletame, et 
nende kahe peptiidi klassi toimemehhanismid on erinevad. 
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Makroliidresistentsus on tundlik antibiootikumsaatusele pärast makroliidi 
dissotsieerumist ribosoomist. Peptiidide poolt vahendatud makroliidresistent-
suse matemaatiline modelleerimine ennustas, et resistentsuse tekkeks rakk peab 
antibiootikumi efektiivselt välja pumpama. Escherichia coli AcrAB-TolC pump 
tagab makroliidide välja pumpamist rakust. Makroliidresistentsus oli elimi-
neeritud tolC mutantsetes bakterites.  
AcrAB-TolC pumba inaktiveerimine elimineerib mitte ainult resistentsus-
peptiidi poolt tagatud erütromütsiini resistentsust aga samuti resistentsust, mis 
on tagatud L22 ja L4 valkude mutatsiooniga. 
Tundub, et madal antibiootikumi äravool varjab antibiootikumi sihtmärgi 
resistentsusmutatsiooni, on üldine fenomeen. See fenomeen võib olla raken-
datud antibakteriaalsete antibiootikumide kliinilises kasutuses, aga samuti euka-
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Abstract
Background: The mRNA translation initiation region (TIR) comprises the initiator codon, Shine-
Dalgarno (SD) sequence and translational enhancers. Probably the most abundant class of
enhancers contains A/U-rich sequences. We have tested the influence of SD sequence length and
the presence of enhancers on the efficiency of translation initiation.
Results: We found that during bacterial growth at 37°C, a six-nucleotide SD (AGGAGG) is more
efficient than shorter or longer sequences. The A/U-rich enhancer contributes strongly to the
efficiency of initiation, having the greatest stimulatory effect in the exponential growth phase of the
bacteria. The SD sequences and the A/U-rich enhancer stimulate translation co-operatively: strong
SDs are stimulated by the enhancer much more than weak SDs. The bacterial growth rate does
not have a major influence on the TIR selection pattern. On the other hand, temperature affects
the TIR preference pattern: shorter SD sequences are preferred at lower growth temperatures.
We also performed an in silico analysis of the TIRs in all E. coli mRNAs. The base pairing potential
of the SD sequences does not correlate with the codon adaptation index, which is used as an
estimate of gene expression level.
Conclusion: In E. coli the SD selection preferences are influenced by the growth temperature and
not influenced by the growth rate. The A/U rich enhancers stimulate translation considerably by
acting co-operatively with the SD sequences.
Background
The efficiency of initiation is the most important determi-
nant of translation efficiency [1]. In bacteria, the 30S
ribosomal subunit, assisted by initiation factors (IF) 1, 2
and 3 and fMet-tRNAfMet, recognizes the translation initi-
ation region (TIR) of the mRNA. This event is followed by
binding of the 50S ribosomal subunit and release of the
initiation factors [1]. The rate-limiting step in this process
is binding of the 30S subunit to the TIR [2]. There are two
alternative pathways for mRNA recognition by 30S subu-
nits. In the first, the 30S subunit complexed with IF1 and
IF3 binds to the mRNA, followed by IF2 and GTP-depend-
ent binding of fMet-tRNAfMet [2]. In the second, the
IF2:GTP:fMet-tRNAfMet complex binds to the 30S subunit
followed by mRNA recognition [3]. The relative frequen-
cies with which these pathways are used in bacterial cells
are currently not clear.
The following sequence elements of the TIR contribute to
its efficiency: (a) the initiation codon, which is most com-
Published: 31 October 2007
BMC Molecular Biology 2007, 8:100 doi:10.1186/1471-2199-8-100
Received: 2 July 2007
Accepted: 31 October 2007
This article is available from: http://www.biomedcentral.com/1471-2199/8/100
© 2007 Vimberg et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
BMC Molecular Biology 2007, 8:100 http://www.biomedcentral.com/1471-2199/8/100
Page 2 of 13
(page number not for citation purposes)
monly AUG but sometimes GUG and very rarely UUG,
AUU or CUG [4-7]; (b) the Shine-Dalgarno (SD)
sequence [8,9]; (c) regions upstream of the SD sequence
and downstream of the initiation codon, which are often
described as enhancers of translation [10-15]. In addition,
the spacing between these sequence elements is often crit-
ical. For example, the distance between the SD sequence
and the initiation triplet has a marked effect on the effi-
ciency of translation [16].
The SD sequence base-pairs directly with the anti-Shine-
Dalgarno (aSD) sequence on the 3' end of the 16S rRNA
[8]. The maximum known length of the SD:aSD duplex is
12 or 13 nucleotides [17]; in most E. coli genes the SD
sequence is shorter. Free energy calculations for all possi-
ble duplexes between the 16S rRNA 3' end and a region 21
nucleotides upstream from the start codon in 1159 E. coli
genes show that the average number of paired
mRNA:rRNA nucleotides is 6.3 [18]. A similar calculation
has been made for the ribosomal protein genes and indi-
cates that the average SD length is 4.4 nucleotides [19].
Studies have shown that mRNAs lacking an SD sequence
cannot bind the 30S subunit efficiently without the con-
tribution of translational enhancers, additional sequences
in the TIR able to increase the efficiency of translation
[20]. Also, SD sequences longer than six nucleotides are
not very efficient, probably because more time is needed
for clearance of the TIR [19,21]. On the other hand, other
studies have questioned the importance of the SD for the
initiation of translation: Lee et al. [22] report that transla-
tion efficiency correlates very poorly with the strength of
the SD:aSD interaction. Unfortunately, no systematic
study to date has established the correlation between the
SD:aSD interaction strength and the efficiency of transla-
tion.
Recently, it has been shown that before the SD:aSD inter-
action occurs, the 30S ribosomal subunit can bind to a
standby site in the vicinity of the SD [23,24]. Binding to
this standby site might increase the local concentration of
30S subunits at the TIR. The ribosome may remain
attached to the standby site until the SD sequence is in a
conformation appropriate for binding the aSD. Through
this mechanism, the standby site could stimulate transla-
tion of mRNAs in which the SD can be trapped by second-
ary structures. One possible way in which a standby site in
mRNA could be created is by binding to S1, the largest
protein component of the small ribosomal subunit. S1
consists of two major domains with a freely rotatable
region between them [25]. One domain is attached to the
30S; the second is exposed on the surface of the small sub-
unit, scanning the space around the ribosome and search-
ing for A/U-rich sequences [14,19,26] that are recognized
with the help of four RNA-binding motifs [27]. It has been
shown that S1 can destabilize RNA secondary structures
[28]. Cross-linking studies have shown that the nucleic
acid-binding domain of S1 is aligned with a region of the
mRNA upstream of the SD, suggesting that S1 may inter-
act with 5' parts of the TIR [29,30]. Consistent with this
observation, A/U-rich sequences in front of the SD or
downstream of the initiator codon enhance protein syn-
thesis [15,19]. To date, nine sequences have been shown
experimentally to act as translational enhancers. They are
all A/U-rich and contain very few Gs [19]. Disruption of
the E. coli gene coding for S1 has been reported to be
lethal [31]. A decreased level of S1 protein in the cell leads
to a rapid decrease in total protein synthesis [32]. Thus it
can be speculated that the SD sequence alone cannot
mediate efficient initiation of translation but has to be
complemented with an enhancer sequence. Unfortu-
nately, information about the effects of combining the
enhancers with different SD sequences is very limited
[19].
In the current study we have constructed a set of SD
sequences, ranging between 1 and 8 nucleotides, and
tested their efficiency with a reporter gene. This allowed
the most efficient SD sequences in E. coli to be defined. In
addition, we have combined all the SD sequences with
translational enhancers and determined the effects on
reporter gene expression. We have tested all the TIR vari-
ants at different bacterial growth phases, growth rates and
temperatures.
Results
Design of the model constructs
Three sets of TIRs were designed and cloned in front of the
GFP coding reporter gene (Figure 1, Additional file 1).
Each set contained 10 variants of the SD sequence. The SD
variants were constructed by mutating the sequence,
forming an 8 base pair duplex with the complementary
aSD, and reducing its length from 8 nucleotides to 1. Each
set contained a unique sequence upstream of the SD: one
containing no translational enhancer ("no enhancer"),
one containing a previously-described strong A/U rich
enhancer, and one with a weak enhancer [19,33]. Tran-
scription of the reporter genes was controlled by the IPTG
inducible tac promoter [34]. The mRNAs synthesized
from the tac promoter contained a lacO operator sequence
in front of the TIRs. We suspected that the lacO sequence
might influence the activity of the TIR. Therefore a fourth
set of SD sequences was cloned under a different pro-
moter, the arabinose-inducible araBAD promoter [35].
In our constructs, a 6-nucleotide spacer sequence sepa-
rated the SD from the initiation codon (Additional file 1).
The particular sequence used has been reported to direct
translation efficiently [36]. This spacing between the SD
and the AUG codon has been shown to be optimal for
efficient gene expression [16]. The spacer sequence (5'-
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AACAAU-3') provides no opportunities for forming
strong alternative SD:aSD interactions, although the
"AGG", "GG" and "G" SD sequences could possibly give
alternative interactions, which would create AGGA, GGA
and GA SD sequences closer to the initiation codon. How-
ever, this alternative interpretation of the results concerns
only the weakest SD sequences and therefore would not
influence the conclusions of the current work.
It is known that RNA secondary structure involving the
TIR can influence the efficiency of initiation [37-39].
Therefore we have used the Mfold RNA folding program
[40,41] to study the possible secondary structures in the 5'
untranslated leader regions of our mRNAs. This model-
ling suggests that in all our constructs the SD region is not
involved in strong secondary structure interactions.
Our aim was to determine the translational activities of
the different TIR sequences. It has been reported that
sequences in the 5' part of mRNA could influence mRNA
stability in the cell [42]. We therefore used quantitative
RT-PCR to detect any differences in the levels of mRNAs
expressed from our constructs. The results (Additional file
2) indicate that all our constructs expressed mRNA at very
similar levels, the differences among them being less than
13%.
Effects of the TIR variations on the level of protein 
synthesis
The plasmids coding for mRNAs with different TIRs were
transformed into E. coli MG1655 cells and the levels of
protein synthesis were measured by the fluorescence of
the GFP reporter gene. The bacterial cultures were inocu-
lated and aliquots were taken after every hour. GFP
expression was induced in these aliquots for one hour and
the fluorescence was measured. Bacterial growth was
monitored by optical density. In addition, mRNA levels
were monitored by real time PCR. To eliminate errors that
occurred during mRNA preparation, the levels of both
GFP and EF-Tu mRNAs were measured; the "normalized
mRNA level" is defined as the molar amount of GFP
mRNA divided by the molar amount of EF-Tu mRNA. The
"expression level" (Figure 2) is calculated by dividing the
fluorescence signal by the "normalized mRNA level".
Thus, the "expression level" indicates the amount of GFP
that is produced per mRNA. We also present the ratios of
the fluorescence values to the optical density values,
reflecting the amount of the protein synthesized per cell
(Additional file 3). As the particular GFP variant matures
in considerably less than 1 hour [43] and no degradation
of the protein occurs during this time [44], our data show
the total accumulation of the protein during the induction
period.
When the different sets of constructs with and without
enhancers were compared, the expected pattern [19] was
observed: the weak enhancer caused a small increase in
reporter gene expression while the strong enhancer caused
the greatest increase (Figure 2). The two sets of constructs
that lacked an enhancer, expressed from the tac (Figure 2)
or the araBAD promoter (Additional file 3), produced the
lowest amounts of GFP. The results with the tac and ara-
BAD promoters were nearly identical (Additional file 3),
showing that the operator sequences have no specific
Sequences used in the current studyFig re 1
Sequences used in the current study. The SD sequences and enhancers were inserted in front of the ORF coding for green flu-
orescent protein (GFP). Different SD variants were constructed by mutating the sequence into complementary nucleotides. 
The enhancers used were the "A/U-rich enhancer" (the boxA sequence of rrnB [19, 33]) and its mutant with decreased activity 
("weak enhancer") [19]. All SD variants in combination with the enhancers were inserted under control of the tac promoter 
regulated by IPTG.
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influence on the TIR activity. In addition, we have tested
the different SD sequences in front of lacZ gene (data not
shown). Also in this case the relative differences between
the efficiencies of TIRs are similar to the results obtained
in the context of the GFP gene. Thus, in our different sets
of constructs the sequences upstream (tac or araBAD oper-
ator) or downstream (lacZ or GFP coding gene) of the TIR
have been replaced causing no changes in the relative effi-
ciencies. These results suggest that our conclusions are
valid for TIRs in different sequence context although we
cannot exclude that certain contexts might have major
effects on the relative order of SD efficiencies.
Irrespective of the enhancer context, protein expression
was highest for the 6-nucleotide SD AGGAGG (Figure 2).
In the absence of enhancer, there are only small differ-
ences between weak and strong SD sequences (Figure 2A).
When a strong enhancer is introduced into the TIR (Figure
2C), the differences between the SD sequences are greatly
increased: the A/U-rich enhancer works cooperatively
with the SD sequence, enhancing the efficiency of selec-
tion of the strongest SD sequence and having only a
minor effect on the weakest one.
The growth phase of the bacterial culture has a considera-
ble effect on reporter gene expression (Figure 2). During
the lag phase (1 hour time point) the mRNA is rapidly
induced (Additional file 2) but the amount of protein per
mRNA is very small. The efficiency of mRNA translation
increases in both the exponential (3 hour time point) and
stationary (6 hour time point) phases. There is also an
enhancer-specific effect: the A/U rich enhancer has a
greater stimulatory effect in the exponential phase than in
the stationary phase (Additional file 3).
Effect of temperature on TIR selection
The differences in SD length lead to differences in the
strength of the SD:aSD interaction. We calculated the
change of free energy of these interactions for all SD vari-
ants tested (Table 1) using a previously-described method
[18]. At 37°C the optimal SD:aSD base pairing free energy
value is around -7.7 kcal/mol. Translation is less efficient
The effect of the TIR on GFP synthesisFigure 2
The effect of the TIR on GFP synthesis. GFP synthesis directed by mRNAs lacking enhancer (A). GFP synthesis directed by 
mRNAs containing weak enhancers (B). GFP synthesis directed by mRNAs containing A/U-rich enhancers (C). Growth curve 
of the cultures shown on panel C (D). The bacterial cultures were inoculated and aliquots were taken at the indicated time 
points. GFP expression was induced in these aliquots for one hour and the fluorescence was measured. In addition, mRNA lev-
els were monitored by real time PCR. The expression level was calculated according to the following formula: expression level 
= fluorescence/(molar amount of GFP mRNA/molar amount of EF-Tu mRNA).
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when the strength of the interaction is greater or less than
this (Table 1; Figure 2). TIRs containing the A/U-rich
enhancer are especially sensitive to the strength of the
SD:aSD interaction (Figure 2, Table 1).
The binding of SD to the aSD sequence in the 3' end of the
16S rRNA is mediated by base-pairing, which is tempera-
ture-dependent. Therefore, temperature change should
influence the strength of the SD:aSD interaction. This
change in interaction strength could lead to changes in the
SD preference pattern. We decided to repeat the measure-
ments of TIR efficiency at a lower growth temperature,
20°C. To visualize the results, all GFP fluorescence values
were divided by the fluorescence measured for GAGG SD
and plotted against time (Figure 3). A similar calculation
was made from the data collected at 37°C (Figure 3). The
differences in SD preference were smaller at 20°C than at
37°C (Additional files 3, 4): in constructs without
enhancer or with weak enhancer the differences were
hardly detectable. When the A/U-rich enhancer was incor-
porated into the TIR, the 5-nucleotide SD GGAGG gave
the highest level of protein synthesis at 20°C (Figure 3).
In contrast, the 6-nucleotide SD gave the highest level of
translation at 37°C.
We calculated the Gibbs energy values of the SD:aSD
interactions at 20°C and 37°C using hybrid-min software
[45] (Table 1). The ∆G value for the 5-nucleotide SD inter-
action with the aSD sequence is -9.4 kcal/mol at 20°C; at
37°C the ∆G of interaction between the optimal 6-nucle-
otide SD AGGAGG with aSD is -7.7 kcal/mol. This indi-
cates that the optimal free energy of the interaction is
between -7.5 and -9.5 kcal/mol.
TIR efficiency in different media
It has been shown that the concentrations of cellular com-
ponents responsible for protein synthesis (ribosomes,
tRNA) vary with growth rate [46,47]. Therefore, the
growth rate-dependent regulation might influence the TIR
preference pattern. Therefore we measured the efficiency
of different TIRs during growth in different media. Bacte-
ria were grown at 37°C in LB or MOPS medium [48] con-
taining either glucose or sodium acetate as a carbon
source. The doubling time of the bacteria grown in LB
medium is 26 minutes (Figure 4D), in MOPS medium
with glucose as energy source 30 minutes (Figure 4H), and
in MOPS medium with sodium acetate 340 minutes (Fig-
ure 4I). To visualize the results, the GFP fluorescence val-
ues were divided by the fluorescence measured for the
GAGG SD sequence (Figure 4). The results show that
although there are quantitative differences in the TIR
selection pattern among the different media, the ranking
order does not change.
Correlation between SD length and predicted expression 
level
We showed experimentally that the highest translation
level at 37°C is achieved by constructs with 6 paired
nucleotides in the SD:aSD region (Figure 2). Which SD
sequences are used most often in E. coli mRNAs? Are the
most efficient sequences used in highly expressed genes?
To answer these questions, we analyzed the SD sequences
of 4243 E. coli genes. We calculated the number of paired
nucleotides for the strongest possible base pairing
between the 13 3' terminal nucleotides of 16S RNA and
the 21-nucleotide sequence upstream of the mRNA initia-
tion codon. Our analysis gave results similar to the con-
clusions of a study by Schurr et al. [18] in which a smaller
dataset was used. The average number of paired nucle-
otides in genomic SD is 5.8 and the median number is 6
(Figure 5). This result is in good agreement with our
observation that a 6-nucleotide SD is optimal at 37°C. In
our experimental constructs the optimal 6-nucleotide
base pairing between SD and aSD has free energy of -7.7
kcal/mol at 37°C (Table 1). On the other hand, the
SD:aSD interaction in the genomic sequences is often
shifted to more A/U-rich regions and contains mis-
matches. (The antiSD sequence is GAUCACCUCCUUA.
Different regions of this sequence can be involved in the
base pairing interaction. For example, 5 base pair long
helix containing the AUCAC sequence is weaker than the
similarly 5 base pair long helix containing antiSD
sequence CCUCC.) Therefore the average ∆G of this inter-
action in the E. coli genomic sequences is lower (only -6
kcal/mol) than in the optimal experimental construct. The
reason for this difference is not clear. It might indicate that
genomic SD sequences are suboptimal, but it could also
be caused by biases in the free energy calculation algo-
rithm (see Discussion).
The codon adaptation index (CAI) [49] characterizes the
similarity of synonymous codon usage in a given gene to
that in the highly expressed genes. CAI values vary













∆G of SD:aSD interactions at 37°C and 20°C, including 8 nucleotides 
from mRNA and 8 nucleotides from 16S rRNA. Free energy was 
calculated using hybrid-min from the UNAFold package [45].
BMC Molecular Biology 2007, 8:100 http://www.biomedcentral.com/1471-2199/8/100
Page 6 of 13
(page number not for citation purposes)
between 0 and 1. A CAI value of 1 is achieved when all
amino acids in a given protein are coded by the best
codon in each synonymous codon family. The correlation
between CAI and gene expression level is well docu-
mented [50-52]. Therefore, we used CAI as a measure of
gene expression level and plotted it against the number of
paired nucleotides in the SD:aSD region. The results indi-
cate that the base pairing potential of the SD sequences
does not correlate with CAI: the average CAI is the same
for all gene groups with different numbers of base pairs in
SD:aSD interactions (Figure 5). Very similar results were
obtained when CAI was plotted against the ∆G of the
SD:aSD interactions [52], data not shown).
Discussion
In this study we have investigated the influence of SD
sequence length on the efficiency of translation. Variants
of the SD sequence were tested with the help of a reporter
gene coding for GFP. Shortening of the SD from the 8-
nucleotide UAAGGAGG to the single-nucleotide paired G
by mutating the sequence into complementary nucle-
otides reveals an optimal SD length: the 6-nucleotide SD
Effect of the growth temperature on TIR selectionFigure 3
Effect of the growth temperature on TIR selection. The cells were grown either at 20°C (A) or at 37°C (C). All the TIRs 
shown contain strong, A/U-rich enhancers. The bacterial cultures were inoculated and aliquots were taken at the indicated 
time points. GFP expression was induced in these aliquots for one hour and the fluorescence was measured. Relative fluores-
cence was calculated by dividing the fluorescence values measured for cells containing particular constructs by the fluorescence 
measured for the GAGG SD sequence. In addition, growth curves at 20°C (B) and 37°C (D) are shown.
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TIR selection in different mediaFigure 4
TIR selection in different media. The cells were grown in either LB (A, B, C, D), MOPS medium containing glucose, "MOPS 
Glc" (E, F, G, H), or MOPS containing sodium acetate, "MOPS NaAcetate" (I, J, K, L) at 37°C. mRNAs lacking enhancer (A, 
E, I), containing the weak enhancer (B, F, J) or containing the strong A/U-rich enhancer (C, G, K) were tested. The bacterial 
cultures were inoculated and aliquots were taken at the indicated time points. GFP expression was induced in these aliquots 
for one hour (LB, MOPS Glc) or 3 hours (MOPS NaAcetate) and the fluorescence was measured. Relative fluorescence was 
calculated by dividing the fluorescence values measured for cells containing particular constructs by the fluorescence measured 
for the GAGG SD sequence. In addition, growth curves in different media are shown (D, H, L).
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AGGAGG causes the highest level of protein synthesis
(Figure 2). Both shorter and longer SD sequences are less
efficient. Shorter SD sequences may be less efficient
because binding to the ribosome is weaker. For very long
SDs it has been proposed that the interaction of the 30S
ribosomal subunit with mRNA is stronger than optimal,
increasing the time required for the ribosome to leave the
translation initiation site and proceed with protein elon-
gation [19].
Several studies of the influence of SD length on gene
expression have been published. According to Rinquist et
al. [53] the 8-nucleotide SD UAAGGAGG is 4 times more
efficient than the 5-nucleotide AAGGA sequence. Komar-
ova et al. [19] compared the 10-nucleotide AAGGAG-
GUGA, the 8-nucleotide AAGGAGGU and the 6-
nucleotide AAGGAG SD sequences and found that AAG-
GAG confers the highest expression level of the reporter
gene. Chen et al. [16] reported that GAGGU is twice as
active as the UAAGG sequence. Although these earlier
results are fragmentary and do not allow the most active
SD sequence to be defined, the data are consistent with
our current finding that the 6-nucleotide SD is the most
efficient.
In order to increase the probability of 30S ribosomal sub-
unit attachment and the initiation of translation, bacterial
mRNAs contain standby sites that are used for the primary
binding of the small ribosomal subunits in the vicinity of
the SD and start codon [23,24]. One class of these standby
sites contains A/U-rich sequences that can bind the ribos-
omal protein S1 [26,29] and/or reduce mRNA local sec-
ondary structure in the TIR [10]. It has been suggested that
all highly expressed mRNAs possess the A/U-rich
sequences upstream of the SDs [19]. The fact that nearly
all protein synthesis in E. coli is dependent on S1 [32] sup-
ports this proposal.
In our study we have investigated the effect of adding
enhancers in front of the SDs. The sequences upstream of
the SD did not change the SD preference qualitatively:
AGGAGG still remained the most efficient SD sequence at
37°C (Figure 2). On the other hand, the A/U-rich
enhancer and SD influence the efficiency of protein syn-
thesis cooperatively: a marked increase in protein synthe-
sis was observed for 5- to 8-nucleotide SDs combined
with the enhancer; the yield of GFP from 1-, 2- and 3-
nucleotide SDs was only slightly increased after the
enhancer sequence was added. This result indicates that
for efficient initiation of translation both a strong SD and
the enhancer sequences are important. Our observations
also explain the previous reports that in some cases the
strength of the SD:aSD interaction does not determine the
efficiency of TIR [22]. Our data show that large differences
between the SD sequences are observed only in case the
SD is combined with enhancer sequences. What might be
the origin of co-operativity between the SD sequences and
enhancers? We suggest that the SD sequence determines
the maximal rate of initiation; enhancer might increase
the local concentration of initiation complexes allowing
the strong SD sequences to work most efficiently.
Another sequence element that has been shown to influ-
ence the efficiency of TIR is the spacer separating SD from
initiation codon. In the current study we have used a
spacer sequence that has been reported to direct efficient
initiation of translation [36]. It has the optimal length:
shorter and longer variants of the spacer are less efficient
[16,54]. It has been pointed out previously that the opti-
mal spacing of SD sequences correlates with gene expres-
sion level [55]. Therefore it would be interesting to
measure experimentally the interaction of suboptimal
spacers with SD sequences: does the spacer context influ-
ence the SD preference pattern? These experiments remain
to be performed in the future.
The concentrations of translation apparatus components
depend on the growth phase and growth rate of the bacte-
rial culture [46,47]. As the concentration of ribosomes
available for initiation of translation changes, the selec-
tion of the TIR may depend on the growth parameters. To
investigate this possibility we grew the bacteria in three
media that give different growth rates. To detect possible
growth phase-dependent variations we followed the
induction of the reporter gene throughout the growth
curve. The results (Figures 2 and 4) indicate that there are
no qualitative differences in the TIR selection pattern,
although some quantitative effects were observed. For
example, weak enhancer sequences are active only in
Distribution of the number of paired nucleotides in SD:aSD interactions and the CAI values for 4243 E. coli ge esFigure 5
Distribution of the number of paired nucleotides in SD:aSD 
interactions and the CAI values for 4243 E. coli genes. The 
figure shows the number of genes (grey bars, left axis) and 
the average CAI with 95% confidence intervals (black dots, 
right axis).
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media where growth rate is low. Also, the enhancer
sequences are more active in the exponential growth
phase than in the lag and stationary phases.
The free energy of base pairing between two RNA strands
depends on the temperature. Therefore, the strength of the
SD:aSD interaction is temperature-dependent. If the opti-
mal free energy of this interaction determines the effi-
ciency of translation, then shorter SD:aSD duplexes
should be preferred at lower temperatures. To test this pre-
diction, we measured the TIR preference pattern at 20°C
and compared it to the data collected at 37°C (Figure 3).
At 37°C the most efficient SD sequence is AGGAGG and
at 20°C it is GGAGG; the optimum shifts to a shorter
sequence when the temperature is lowered. This result
indicates that a certain optimal strength of SD:aSD inter-
action is required for efficient translation. It also suggests
that the length of the SD sequence could be used for tem-
perature-dependent regulation of gene expression. Unfor-
tunately, we cannot analyze the length of SD sequences in
the known cold shock genes of E. coli as the dataset is too
small for a statistically meaningful conclusion.
We found that the most efficient SD at 37°C is AGGAGG,
with 6 paired nucleotides. Are the most efficient
sequences also commonly used in the E. coli genome? To
answer this question, we used bioinformatics tools to ana-
lyze the SD:aSD interactions in all E. coli mRNAs. We
found that the average SD length is 5.8 nucleotides, which
agrees with the observation that a 6-nucleotide SD is opti-
mal at 37°C. On the other hand, the SD:aSD interaction
is often shifted to more A/U-rich regions compared to the
AGGAGG sequence and contains one or more mis-
matches. Therefore the average ∆G of this interaction is
only -6 kcal/mol rather than -7.7 kcal/mol as achieved
with the best experimental SD.
Why do most E. coli mRNAs, including those coding for
highly expressed genes, have SDs that are not expected to
direct the highest level of translation at 37°C? We suggest
three possibilities. First, E. coli has to grow in the mamma-
lian gut but also to survive at lower temperatures outside
the host. The temperatures of both environments may
have contributed to the selection of SD sequences. Sec-
ond, the noise in gene expression levels may be involved.
A particular expression level could be achieved by differ-
ent contributions from transcription and translation. The-
oretical calculations have suggested, and experimental
data confirmed, that a high level of transcription com-
bined with a low level of translation creates considerably
smaller fluctuations in gene expression than a combina-
tion of a low level of transcription with highly efficient
translation resulting in the same overall expression level
[56-58]. Therefore, using weak TIRs might reduce noise in
gene expression. Third, the effect may be attributable to
differences in SD structure between the experimental con-
structs and genes in the E. coli genome. Our experimental
constructs contain continuous stretches of paired nucle-
otides without mismatches, whereas E. coli genes contain
longer paired areas with one or more mismatches. It is not
possible to estimate the energetic effect of the mismatches
accurately in the context of the ribosome where the
SD:aSD helix is stabilized by contacts with ribosomal
RNA and proteins [17,59]. Further experiments are
needed to evaluate the effect of mismatches in SD
sequences.
Conclusion
In E. coli the SD selection preferences are influenced by the
growth temperature and not influenced by the growth
rate. The A/U-rich enhancer contributes strongly to the
efficiency of initiation. The SD sequences and the A/U-
rich enhancer stimulate translation co-operatively: strong
SDs are stimulated by the enhancer much more than weak
SDs. Further experiments are needed to elucidate the bio-
chemical nature of this co-operativity.
Methods
Oligonucleotides
Sequences of the oligonucleotides used are provided in
the Appendix.
TIR cloning
The gene gfpmut2 [60] was PCR amplified from the plas-
mid pMS201 using Tac and Reverse primers. The PCR
product contained the tac promoter [34], a BamHI clon-
ing site for TIR insertions and the trp terminator (Addi-
tional files 1, 5). The gfpmut2 PCR product was ligated
into pGEM-T easy vector (Promega). From pGEM-T easy
vector, gfpmut2 was excised using the restriction enzymes
SphI and SacI (Fermentas) and cloned into pET41A vector
(Novagene) resulting a plasmid pETGFP (Additional file
5). TIRs generated by PCR with SD general (1, 2 or 3) and
TIR-specific primers were inserted into the BamHI restric-
tion site in the pETGFP vector.
To express GFP under the bad promoter, gfpmut2 was PCR-
amplified from pMS201 using Forward NheI and Reverse
primers. The PCR product contained a BamHI cloning site
for TIR insertions, trp terminator and NheI and SacI
restriction sites at the ends. The PCR product was ligated
into pGEM-T easy vector. gfpmut2 was excised from this
vector using NheI and SacI (Fermentas) and cloned into
pBAD33 vector (Additional file 5) [35] under the control
of the araBAD promoter. TIRs were generated by PCR as
described above and inserted into the BamHI restriction
site.
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Growth of bacteria and measurement of GFP expression
Plasmids coding for GFP mRNAs with different TIRs were
transformed into E. coli MG1655 [61]. Bacteria bearing
the plasmids were grown in the presence of 25 µg/ml kan-
amycin in 2.5 ml LB medium at 37°C or 20°C, MOPS
medium supplemented with 0.1% glucose (MOPS Glc),
or MOPS medium supplemented with 0.3% sodium ace-
tate (MOPS NaAcetate) [48] at 37°C. Overnight cell cul-
tures were diluted with fresh medium to an optical density
of 0.05 (A600 nm). Growth was monitored by the increase
in optical densities of the cultures. For bacterial cultures
grown at 37°C in LB or MOPS Glc media, samples were
taken every hour; in LB medium at 20°C every 2 hours; in
MOPS NaAcetate medium at 37°C every 6 hours. Aliquots
(50 µl) of each bacterial culture were transferred to black
96-well plates where GFP expression was induced by add-
ing IPTG (final concentration 1 mM) or arabinose (final
concentration 10 mM). The 96-well plates were incubated
for 1 hour at 37°C (LB, MOPS Glc), for 3 hours at 37°C
(MOPS NaAcetate) or for 1 hour at 20°C (LB, 20°C) and
GFP fluorescence was measured using a TECAN Fluoroim-
ager. Experiments were repeated at least 3 times and
standard deviations of the results were calculated.
Reverse transcription Real-Time PCR
Sequences coding for GFP (mut2) or E. coli EF-Tu were
inserted under the control of the T7 promoter (pGEM-T
easy, Promega), transcribed in vitro and purified. These in
vitro transcribed mRNAs were used as standards. Bacteria
bearing the plasmids coding for GFP mRNAs with differ-
ent TIRs were grown in 2.5 ml LB medium at 37°C. After
1, 3 or 6 hours of growth, GFP expression was induced by
adding IPTG (final concentration 1 mM), followed by
incubation for 1 hour. Cells were harvested from 1 ml of
the growing cultures and total RNA was isolated using a
Macherey-Nagel RNA extraction kit. Reverse transcription
was performed in 5 µl volumes containing 0.5 mM of each
NTP (Fermentas), 1500 nM GFP Reverse primer, 2 U ribo-
nuclease inhibitor (Fermentas), 10 U Revert-Aid reverse
transcriptase (Fermentas) and mRNA in the range 10 fg to
1 ng in Revert-Aid reverse transcription buffer (Fermen-
tas). RNA was reverse transcribed at 42°C for 1 hour and
the reverse transcriptase was inactivated by heating at
70°C for 10 minutes. After the reverse transcription reac-
tion, 20 µl PCR reaction components (300 nM GFP For-
ward primer, 0.0005 µl of SYBR Green I (10,000×
concentrate in DMSO; Molecular Probes), 5 mM MgCl2,
10 µl 2× PCR Master Mix (Fermentas)) were added, fol-
lowed by PCR steps: prePCR (95°C for 10 seconds) and
40 PCR cycles (95°C for 5 seconds, 60°C for 10 seconds
and 72°C for 10 seconds). Real-time PCR was performed
using a SmartCycler (Cepheid). The amount of GFP
mRNA was normalized with EF-Tu mRNA, which was
determined using the same reverse transcription-PCR pro-
tocol as described above, replacing the primers with EF-Tu
Reverse and EF-Tu Forward.
Calculation of minimal free energy of SD:aSD interaction
The mRNA coding sequences of Escherichia coli K-12 [61]
were retrieved from the National Center of Biotechnology
Information [62]. For each mRNA we used a region of 21
nucleotides upstream from the start codon, as described
by Schurr et al. [18]. For anti-SD sequence we used 13
nucleotides from the 3' end of 16S rRNA (GAUCACCUC-
CUUA). The minimal free energy values for rRNA-mRNA
duplexes were calculated by the hybrid-min program from
UNAFold package downloaded from the DINAMelt web
server [45,63].
Calculation of codon adaptation index
The codon adaptation index (CAI) was calculated using
the program CodonW [64]. This calculation is based on a
dataset of highly expressed genes including those encod-
ing ribosomal proteins, outer membrane proteins, elon-
gation factors, heat shock proteins and RNA polymerase
subunits [49].
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Appendix
Sequences of the oligonucleotides






Amplification of TIRs without enhancer
SD general 2: tgggggtaccttttgacaattaatcatcggctcgtataatgtgt-
ggaattgtgagcggataacaatttg ggatcca; UAAGGAGG 2: caatcg-
gatcctttcatattgttcctccttatggatcccaaattgttatcc; AAGGAGG 2:
caatcggatcctttcatattgttcctccttttggatcccaaattgttatcc;
AGGAGG 2: caat cggatcctttcatattgttcctcctattggatcccaaattgt-




tatcc; AGG 2: caatcggatcctttc atattgttcctggaattggatcccaaatt-
gttatcc; GAG 2: caatcggatcctttcatattgttgctcgaattggatcccaa
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attgttatcc; GG 2: caatcggatcctttcatattgttccaggaattggatc-
ccaaattgttatcc; G 2: caatcggatcc tttcatattgttcgaggaattggatc-
ccaaattgttatcc.
Amplification of TIRs with weak enhancer











GG: caatcggatcctttcatattgt tccaggaattggatctgataactcg; G:
caatcggatcctttcatattgttcgagga attggatctgataactcg.
Amplification of TIRs with A/U-rich enhancer
SD general 3: acaatttgggatccactgctctttaacaatttatcagatcca;
UAAGGAGG 3: tgaatcgga tcctttcatattgttcctccttatggatctga-
taaattgttaaag; AAGGAGG 3: tgaatcggatcctttcatattgttcc
tccttttggatctgataaattgttaaag; AGGAGG 3: tgaatcggatcctttcat-
attgttcctcctattggatctgataa attgttaaag; GGAGG 3:
tgaatcggatcctttcatattgttcctcctattggatctgataaattgttaaag;
GAGG 3: tgaatcggatcctttcatattgttcctcgaattggatctgataaattgt-




taaag; GG 3: tgaatcggatcctttcatattgttccaggaattggatctga-
taaattgttaaag; G 3: tgaatcggatcctttcatattgttcga
ggaattggatctgataaattgttaaag.
Reverse transcription real-time PCR
GFP Forward: gttccatggccaaccttagtcactactttc; GFP Reverse:
agcaaaac attgaagaccatacgcgaa; EF-Tu Forward: gagatgga-
gaatacgtcttcga; EF-Tu Reverse: accagagcgtgcgattg.
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Summary
Expression of specific short peptides can render cells
resistant to macrolide antibiotics. Peptides conferring
resistance to structurally different macrolides includ-
ing oleandomycin, azithromycin, azaerythromycin,
josamycin and a ketolide cethromycin were selected
from a random pentapeptide expression library. Anal-
ysis of the entire collection of the resistance peptides
allowed their classification into five distinct groups
according to their sequence similarity and the type of
resistance they confer. A strong correlation was
observed between the structures of macrolide antibi-
otics and sequences of the peptides conferring resis-
tance. Such a correlation indicates that sequence-
specific interactions between the nascent peptide and
the macrolide antibiotic and/or the ribosome can
occur in the ribosomal exit tunnel.
Introduction
 
The nascent peptide exit tunnel is one of the most enig-
matic regions in the ribosome and was originally viewed
as a passive conduit for the growing polypeptide. It is now
starting to emerge as a functional entity where specific
interactions between the ribosome, the nascent peptides,
and sometimes auxiliary molecules, can actively affect
ribosomal functions (Gong and Yanofsky, 2002; Nakato-
gawa and Ito, 2002; Tenson and Ehrenberg, 2002; Jenni
and Ban, 2003). The results of such interactions may have
profound effects on the expression of specific proteins, or,
when it comes to drugs that bind in the exit tunnel, on the
overall protein synthesis in the cell. Nevertheless, the
molecular details of interactions that occur in the exit
tunnel remain obscure.
Macrolides are a large family of clinically important anti-
biotics that inhibit bacterial growth by binding to the exit
tunnel of the large ribosomal subunit and interfering with
protein synthesis (Vazquez, 1975) and large ribosomal
subunit assembly (Chittum and Champney, 1995). The
core structure of macrolide drugs is a 14-, 15- or 16-
member lactone ring decorated with one or several neutral
or amino sugars (Fig. 1). The 14-member ring erythromy-
cin represents the first generation of macrolides and was
the first widely used drug of this class. Later on, several
derivatives with improved efficacy were developed. These
include 14-member ring drugs like clarithromycin and
roxithromycin, the 15-member ring azithromycin, as well
as some 16-member ring derivatives, such as josamycin
(Bryskier, 1995). The continuous spread of macrolide-
resistant pathogens prompted a search for new com-
pounds capable of overcoming common resistance mech-
anisms, especially methylation of the rRNA target site.
This quest resulted in the development of ketolides, which
exhibit increased affinity to the ribosome as well as appar-
ent lower sensitivity to known mechanisms of resistance.
These 14-member ring drugs are characterized by the
presence of a keto group instead of the cladinose sugar
at the C3 position of the lactone ring, an 11,12-carbamate
cycle and an extended alkyl-aryl or quinollyallyl side
chains (Alvarez-Elcoro and Enzler, 1999; Bryskier, 2001;
Zhong and Shortridge, 2001).
The binding site of macrolides is located just outside
the peptidyl transferase centre near the narrowest portion
of the nascent polypeptide exit tunnel (Mao and


















., 2003a,b). Tight binding of the mac-
rolide is achieved through hydrophobic and van der Waals
interactions of the lactone ring with the RNA-based tunnel
surface as well as hydrogen bonding of the macrolide








., 2002). Different macrolide compounds bind to the
ribosome with a similar orientation of the lactone ring,
sharing a set of contacts with 23S rRNA. The universal
interactions of macrolides with the target site are addition-
ally supplemented by drug-specific contacts with RNA.
For example, the acetaldehyde group at the C6 position
of 16-member ring macrolides may form a covalent bond
with N6 of rRNA residue A2062; whereas the extended
alkyl-aryl side chains of ketolides and the mucinose sugar







































The location of the drug binding site, the chemical struc-
ture of the antibiotic and the mode of drug–ribosome
interactions define the mechanism of macrolide action.
Macrolides can bind to either the vacant ribosome or a
translating ribosome carrying a very short nascent peptide
while ribosomes that carry longer nascent peptide chains




., 1974; Contreras and




., 2003). Binding of macrolides at the exit tunnel con-
striction jams the tunnel, leading to arrest of protein syn-
thesis during early rounds of translation. Inhibition of
translation elongation, at a step when the nascent peptide
is only few amino acids long, leads eventually to the dis-
sociation of peptidyl-tRNA from the ribosome (Otaka and





2003). Because the dissociated peptidyl-tRNAs are not
recycled in the cell efficiently, this ‘drop-off’ causes deple-
tion of free tRNA pools and is apparently another impor-














., 1999). A correlation appears to exist
between the space available for the nascent peptide within
the drug-bound ribosome and the average length of pep-
tides on the peptidyl-tRNAs that dissociate from ribo-




., 2003). Josamycin, a 16-member macrolide that has
a C5 mycaminose-mycarose sugar moiety that extends
towards the peptidyl transferase centre, can hamper for-






















efficient  dissociation  of  peptidyl-tRNAs  containing  2-,













., 2003). Erythromycin, which lacks a mycaminose-
mycarose sugar, leaves more room and induces dissoci-
ation of peptidyl-tRNAs containing 6-, 7- or 8-amino acid
residues. Telithromycin, a representative of ketolides that
all lack the cladinose sugar, allows polymerization of 9- to
10-amino acid residues before peptidyl-tRNA dissociates.
Furthermore, side chain idiosyncrasies among the various
macrolide drugs result in the presentation of different
functional groups for interaction with the nascent polypep-
tide synthesized by the ribosome. This suggests that the
effect of macrolides on nascent peptide elongation and
peptidyl-tRNA dissociation may be protein sequence-
specific.
Peptide mediated macrolide resistance is another phe-
nomenon where correlation between the structures of
nascent peptides and macrolide antibiotics is observed.
Translation of specific short peptides in the bacterial cell
was found to render cells resistant to macrolides (in this










are thought to displace the macrolide molecule from its
binding site in the ribosome, thus increasing the fraction
of drug-free ribosomes in the cell. While hydrophobic pen-
tapeptides containing Leu or Ile in the third amino acid
position confer resistance to erythromycin and some of its
derivatives, R-peptides conforming to a different consen-
sus sequence (containing a positively charged amino acid









., 1998; Tenson and Mankin,
2001).
In order to gain better understanding of the correlation
between the sequences of the resistance pentapeptides
and the structures of the macrolide drugs, we extended
our study of peptide-mediated resistance. Here, we
include drugs that differ substantially in the structure of
the lactone ring as well as the nature of the side chains:
oleandomycin (a 14-member macrolide), cethromycin
(formerly ABT 773, a ketolide), azithromycin and aza-
erythromycin (15-member macrolides) and josamycin (a
16-membered macrolide). Significantly different peptides
were found to confer resistance to diverse macrolide
drugs. The results of the current study indicate that not
only each macrolide antibiotic forms distinctive contacts
with the ribosome, but that they also may establish spe-




Peptides causing resistance to macrolide antibiotics (R-
peptides) were selected from a five-codon random mini-





this library, the plasmid-encoded mini-genes are com-
posed of an initiation codon, four randomized codons and
a termination codon. The mini-genes are equipped with a
Shine–Dalgarno translation initiation sequence (Shine
and Dalgarno, 1975) and are expressed under the control













 clones  expressing
R-peptides were selected on LB agar plates containing
ampicillin and IPTG that were supplemented with one of









 MIC. A total of 0.1–0.2% of the clones showed
resistance. Retransforming the plasmids isolated from the




 cells, and ver-
ifying the IPTG dependence of the resistant phenotype
established the causative relation between mini-gene
expression and macrolide resistance.
Five different macrolide antibiotics were used to select
the R-peptides. These include cethromycin (a 14-member
ring ketolide), and the following cladinose-containing
macrolides: oleandomycin (14-member ring), azithromy-
cin and azaerythromycin (both 15-member ring) and josa-




Cethromycin, a ketolide, contains a quinolylallyl side
chain, which is attached to C6 of the lactone ring (R4 in
Fig. 1). In the ribosome-bound form of the drug, the side
chain extends towards helix 35 in domain II of 23S rRNA
and establishes interactions, which are important both for
the high affinity of the ketolide as well as the positioning









., 2003). Previously we identified
peptides that confer resistance to ketolides of the telithro-
mycin group, which all had an alkyl-aryl side chain
attached to the 11,12-carbamate group on the opposite





Tenson and Mankin, 2001). Those peptides were charac-
terized by the presence of a positively charged amino acid
in the second amino acid position and high representation
of hydrophobic amino acids throughout the rest of the
peptide sequence. It remained unclear whether the nature




The structure of a random-sequence mini-gene region in the 





1997). Positions of the mini-gene, including its start codon, four ran-
dom codons (12 random nucleotide positions), terminator codon as 
well as its Shine–Dalgarno translation initiation signal (SD) are 


















R1 restriction sites used for construction of the random mini-
















attachment of the functionally important side chain of the
ketolide drugs.
The cethromycin R-peptides selected in this study are
shown in Fig. 3. All but one of the cethromycin R-peptides
contain either Lys or Arg in the second amino acid posi-
tion. All of the other variable peptide positions (with the
exception of Tyr in the MRVYR peptide) were represented
exclusively by either hydrophobic or positively charged
amino acids. Thus, cethromycin R-peptides share the
major characteristics with R-peptides of the telithromycin
group. This similarity indicates that the site of attachment




Amino acid sequences of the R-peptides conferring resistance to various macrolides. For convenience, the one-letter abbreviations of 


















ring of the ketolide molecule does not significantly affect
the binding of ketolides to the ribosome and/or their inter-
action with the nascent peptide. This conclusion corre-
lates well with the similar protection patterns produced by


















., 2002) and with the



















R-peptides selected previously with 14-member ring, cla-
dinose-containing drugs such as erythromycin and its
derivatives (clarithromycin, roxithromycin and RU 69874)
were characterized by a well-defined consensus
sequence: a bulky hydrophobic amino acid in the second
position, Leu or Ile, in the third position, a preference for
a hydrophobic amino acid in the fourth position and a





Tenson and Mankin, 2001). Surprisingly, the peptides con-
ferring resistance to oleandomycin, another 14-member
ring cladinose-containing macrolide, were substantially
different from the erythromycin R-peptides (Fig. 3). None
of the oleandomycin R-peptides had Leu or Ile in the third
position; instead a positively charged amino acid was
frequently present at position 3 and/or 4 of the peptide.
Because of the high content of positively charged amino
acids, oleandomycin R-peptides appear to more closely
resemble the ketolide R-peptides than the peptides con-
ferring resistance to other 14-member cladinose-contain-
ing macrolides.
Oleandomycin differs from erythromycin and related
compounds by the presence of an 8-oxirane cycle, a
methyl instead of an ethyl group attached at C13 of the
lactone ring and the lack of a 12-hydroxyl. Variations in
substitutions at C12 and C13 may directly contribute to
the unusual binding of oleandomycin. The C13 ethyl of
erythromycin reaches towards the loop of helix 35 in





ing this side chain by one carbon atom in oleandomycin
may affect possible interaction with this rRNA region. The
C12 hydroxyl of erythromycin forms a hydrogen bond with





lack of this hydroxyl in oleandomycin should destabilize
this contact. Interestingly, both helix 35 and U2609 are

















., 2002). Thus, some of the
peculiar contacts of oleandomycin with the ribosome
affect the ribosome–drug interactions that distinguish
ketolides from cladinose-containing macrolides. It is con-
ceivable therefore, that the position of oleandomycin in the
ribosome may structurally resemble more closely the
binding of ketolides than that of the erythromycin-type
antibiotics, which can account for the similarity of olean-
domycin and ketolide R-peptides. Noteworthy, troleando-





 ribosomes in a configuration notably








Azithromycin and azaerythromycin are 15-member ring
macrolides. Extending the 14-atom lactone ring by an
additional nitrogen atom alters the ring conformation
resulting in a novel interaction with rRNA base 2586 as










Most of the selected azithromycin R-peptides adhere to
a well-defined consensus (Fig. 3). As with the previously
studied erythromycin R-peptides, all but one of the
azithromycin R-peptides contain Leu in the third amino
acid position and show preference for a bulky hydrophobic
amino acid in the second position (Leu, Ile, Phe, Val).
However, in contrast to the erythromycin R-peptides, the
peptides selected with azithromycin show a strong prefer-
ence for a positively charged amino acid (Lys or Arg) in
the fourth position.
In order to verify the importance of a positively charged
penultimate amino acid for azithromycin resistance, we
compared the ability of an azithromycin R-peptide,
MLLRV, and a previously selected erythromycin R-pep-
tide, MLLLV, to confer resistance to these drugs. The











), however, the MLLRV peptide





























) (data not shown). Thus, the presence of a
positively charged amino acid in the fourth position con-
tributes specifically to the R-peptide’s ability to confer
resistance to azithromycin.
Remarkably, while most of the azithromycin R-peptides
conformed to the consensus sequence, one of the
selected peptides (MYKIY) was notably different. It lacked
both Leu in the third position and a positively charged
amino acid in the fourth position. Nevertheless, in spite of
the deviation from the consensus, the level of azithromycin
resistance conferred by the MYKIY peptide was compar-
able to that exerted by the ‘consensus’ peptides (Fig. 4).
The structural differences between azaerythromycin
and azithromycin are minute. Azaerythromycin lacks a
single methyl group at the nitrogen atom of the azithromy-
cin azalide ring (Fig. 1). However, this small alteration in
drug structure appears to result in reduced stringency of
















requirements for Leu in the third peptide position and for
the positively charged amino acid in the fourth position
were more relaxed in the case of the azaerythromycin R-
peptides (Fig. 3). Because the N-methyl group of azithro-
mycin does not contribute significantly to interactions














Josamycin, a 16-member ring macrolide, contains a
mycaminose-mycarose-isobutyrate side chain that, by
analogy with carbomycin, is likely to reach into the ribo-





The drug leaves a fairly small space for the nascent pep-
tide, and may cause the drop-off of peptidyl-tRNA with a




., 2003). However, longer peptides can apparently be
synthesized by a ribosome complexed with josamycin, as
some of the pentapeptides expressed in the mini-gene
library conferred resistance to this macrolide (Fig. 3). The
consensus sequence of the josamycin peptides was dras-
tically different from that seen with other macrolides. Leu-
cine, which was frequently seen in position 3 in the
erythromycin R-peptides, is often found at the C-terminus
of the josamycin pentapeptides. The second amino acid
position in all of the josamycin R-peptides was occupied
by an aromatic amino acid, phenylalanine or tyrosine.
Among these two amino acids, phenylalanine rendered
peptides more active as these R-peptides conferred
slightly higher levels of josamycin resistance than R-pep-
tides containing tyrosine at the same position (data not
shown).
 
High specificity of peptide-mediated resistance
 




., 1997) indicated that at
least some of the erythromycin R-peptides could increase
cell resistance to other macrolides. This prompted us to
examine the spectrum of resistance afforded by R-pep-
tides, including ketolide-, oleandomycin-, and josamycin
R-peptides. The experimental data show that R-peptide
resistance is rather specific (Fig. 5). Peptides selected
with a particular antibiotic provide the highest level of
resistance to this drug. In most cases peptides confer little
or no cross-resistance to other types of macrolides. In
agreement with our conclusion of the clustering of the
oleandomycin- and ketolide R-peptides, a considerable
cross-resistance to oleandomycin was conferred by one




Here, we report the isolation of peptide mini-genes whose
expression renders cells resistant to various macrolide
antibiotics. Different peptides confer resistance to struc-
turally different macrolides and generally, little cross-resis-
tance is observed.
Strictly speaking, the selection experiments cannot
directly distinguish whether the immediate cause of drug
resistance is the peptide itself or its mRNA (or even the
mini-gene). Previously reported data indicated the impor-
tance of mini-gene translation for manifestation of the
resistance phenotype (Tenson 
 
et al., 1996). Furthermore,
examination of the peptide sequences and sequences of
their respective mini-genes show an extensive variation in
mRNA structure compared to the structure of the encoded
peptides (Fig. 3). For example, two of the mini-genes iden-
tified in cethromycin-resistant clones code for the same
R-peptide, MKLKL, while four out of the 12 random nucle-
otide positions in the mini-gene are different. Similarly, the
MRFFV R-peptide was encoded in two independently iso-
lated mini-genes that differed at three out of 12 random
positions. These observations are in agreement with the
view that it is the peptide structure and possible interac-
tions of the peptide with the drug and/or ribosome, rather
than the mRNA sequence, that are responsible for the
resistance.
How does translation of short peptides render cells
resistant to ribosome-targeted macrolide antibiotics? A
few years ago we proposed a ‘bottle-brush’ model in which
synthesis of an R-peptide on the ribosome leads, through
an unknown mechanism, to displacement of the drug from
the ribosome. The drug-free ribosome may have enough
time to initiate synthesis of one of the cellular proteins and
polymerize its first few amino acids before the antibiotic
Fig. 4.
 
Effect of azithromycin on growth of cells expressing one of 
the azithromycin consensus R-peptides, MFLKV, a ‘non-consensus’ 


















binds again. When the nascent peptide chain becomes
longer than 5–10 amino acids, it precludes the binding of
a macrolide molecule in the nascent peptide exit tunnel,
thus allowing the ribosome to finish synthesis of the
polypeptide. In this model, active expression of R-peptide
mini-genes simply increases the fraction of drug-free ribo-
somes in the cell, facilitating protein synthesis in the pres-
ence of the drug. The model is supported by the previous
findings that the peptides work 
 
in cis, rendering the ribo-
some on which they were synthesized resistant to mac-
rolides, as well as the inability of exogenously added
synthetic R-peptides to cause macrolide resistance in a
cell-free translation system (Tenson 
 
et al., 1996). The
model is in agreement with the recent finding that the
translation of R-peptides in a cell-free system leads to
displacement of the drug from the ribosome (M. Lovmar,
T. Tenson and M. Ehrenberg, in preparation).
A large variety of R-peptides conferring resistance to
different classes of macrolides have been isolated in this
and previous studies. Comparison of all of the known R-
peptides shows a clear correlation between the amino acid
sequences of R-peptides and structures of antibiotics to
which they confer resistance. Similar peptides confer resis-
tance to similar drugs, while significant changes in the
macrolide structure call for peptides with notably different
consensus sequences. Thus, similar, and often the same,
peptides were found in selection experiments with cladi-
nose-containing macrolides of the erythromycin group
(Tenson et al., 1997; Tenson and Mankin, 2001). However,
when the structure of the drug was significantly changed
(as in the transition from erythromycin to ketolides), very
different peptides were found to render cells drug-
resistant. Even smaller variations in the drug structure may
affect the sequence of the peptide required to confer resis-
tance. For example, expanding the erythromycin lactone
ring by an additional nitrogen atom, as in azithromycin (a
relatively small alteration from the structural standpoint)
changes the consensus of the resistance peptides.
Analysis of R-peptides selected in this study as well as
those characterized previously allows classification of
currently known resistance peptides into five structural
classes (Table 1). The peptides of the ERY group include
those that confer resistance to 14-member ring mac-
rolides of the erythromycin type (erythromycin, clarithro-
mycin, roxithromycin and RU 69874) (Tenson and Mankin,
2001). The most notable feature of these peptides is the
presence of Leu or Ile in the third position. AZI peptides,
which include azithromycin and azaerythromycin R-
Fig. 5. Relative macrolide resistance of cells expressing erythromycin- (red), oleandomycin- (green), ketolide- (blue-) or josamycin- (magenta) 
R-peptides. Ketolide R-peptides include the MRFFV peptide, which was selected with cethromycin and ketolides HMR3004 as well as the MLYKP 
peptide, which was selected previously with the ketolides telithromycin and HMR3004 but did not show up in the cethromycin selection (Tenson 
and Mankin, 2001). The growth of control cells expressing an unselected peptide, MNAIK, is shown by a white bar. Shown resistance values are 
the average of at least three independent experiments.
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peptides, are generally similar to ERY peptides, but they
fall into a separate group because of a strong preference
for a positively charged amino acid in the fourth position.
Positively charged amino acids are also prevalent in the
third and fourth position of the OLE (oleandomycin) R-
peptides. The high frequency of occurrence of Arg or Lys
in the third peptide position distinguishes OLE peptides
from the ERY and AZI R-peptides. KET (ketolide) R-pep-
tides, which include R-peptides conferring resistance to
cethromycin, telithromycin, HMR3004 and RU64399
ketolides, show mixed amino acid preference in positions
3 and 4, which are commonly represented by either hydro-
phobic or positively charged amino acids. However, the
second amino acid position in these peptides is repre-
sented predominantly by positively charged amino acids.
Finally, JOS (josamycin) R-peptides require an aromatic
amino acid, phenylalanine or tyrosine, at position 2.
Drawing clues from the correlation between the amino
acid sequences of R-peptides and the chemical structures
of the drugs, one can envision a possible mechanism of
drug displacement based on a direct interaction between
the macrolide molecule and the peptide. Structure-spe-
cific interaction with the nascent R-peptide may alter drug
conformation resulting in reduced affinity for the ribosome.
Although no high-affinity binding between synthetic R-
peptides and antibiotics was observed in solution (Tenson
et al., 1996), such interaction may be possible in the ribo-
some where peptide structure is expected to be con-
strained by its contacts with the exit tunnel. Reduced
flexibility of the peptide in the tunnel should reduce the
entropic cost of the peptide–drug interaction.
Though we favour the model of a direct drug–peptide
interaction, an alternative model cannot be excluded in
which specific interactions between the peptide and the
ribosome may allosterically affect rRNA conformation in
the drug binding site resulting in a lower affinity of the drug
for the ribosome. Such a view would be in line with the
recent findings of sequence-specific interactions between
the ribosome and the nascent peptide observed in other
experimental systems (Gong and Yanofsky, 2002; Nakato-
gawa and Ito, 2002; Fang et al., 2004), reviewed in Tenson
and Ehrenberg (2002) and with NMR studies of peptide–
ribosome interactions (Verdier et al., 2002). However, this
model does not provide a direct explanation of why differ-
ent drugs are removed by different R-peptides.
Only short peptides, 3- to 6 amino acids long, are able
to confer macrolide resistance, while longer peptides are
not active (Tenson et al., 1997). What is the reason for
such a strict peptide size constraint? One interesting pos-
sibility is that termination of translation plays an active role
in the dissociation of the drug from the ribosome. Binding
of a release factor or other factors involved in translation
termination may affect rRNA conformation in the vicinity
of the peptidyl transferase centre (Polacek et al., 2003;
Rawat et al., 2003) possibly resulting in a reduced affinity
for the macrolide molecule. Combined with the direct or
an allosteric effect of the R-peptide on drug binding, the
structural transitions in rRNA that accompany translation
termination might be sufficient to oust a drug from the
ribosome.
At the moment, peptide-mediated drug resistance
appears to be confined to the macrolide class of ribo-
some-targeted antibiotics. Even though macrolides have
overlapping binding sites with the structurally dissimilar
streptogramin-B and lincosamide drugs (Schlünzen et al.,
2001; Hansen et al., 2003; Harms et al., 2004), we were
unable to select R-peptides that could render cells resis-
tant to either clindamycin (lincosamide) or quinupristin
(streptogramin B) (V. Vimberg, T. Tenson, L. Xiong and A.
Mankin, unpubl. results). This restriction of the peptide-
mediated resistance to macrolide antibiotics could reflect
specific structural differences in drug–ribosome interac-
tions or in the kinetics of drug binding.
The recent advances in crystallographic studies of ribo-





Reference1 2 3 4 5
ERY Erythromycin Met Bulky Leu or Ile Hydrophobic Val Tenson et al. (1997)
Clarithromycin Hydrophobic Tenson and Mankin (2001)
Roxithromycin Tenson and Mankin (2001)
RU69874 Tenson and Mankin (2001)
AZI Azithromycin Met Bulky Leu or Ile Arg or Lys ¥a This study
Azaerythromycin Hydrophobic This study
OLE Oleandomycin Met ¥ Arg or Lys Arg or Lys Tyr or Ile This study
KET Telithromycin Met Arg or Lys Hydrophobic or Arg Hydrophobic or Lys ¥ Tenson and Mankin (2001)
RU64399 Tenson and Mankin (2001)
HMR3004 Tripathi et al. (1998)
ABT377 This study
JOS Josamycin Met Phe or Tyr ¥ ¥ Leu This study
a. ¥ – no obvious amino acid preference.
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some–drug interactions reveal the differences in precise
positioning of individual macrolides in the ribosome. How-
ever, the poor understanding of peptide placement in the
ribosomal exit tunnel precludes direct modelling of the R-
peptide–ribosome or R-peptide–drug contacts. The better
we understand how the ribosome ‘deals’ with the nascent
peptide, the more we will learn about the mode of action of
macrolide antibiotics and their mechanisms of resistance.
There is hope, however, that studying R-peptides may in
turn advance the general knowledge of how the ribosome
works and how it interacts with nascent peptides. Sus-
pected specific interactions between R-peptides and ribo-
some-bound antibiotics may reveal these peptides as
favourable candidates for biochemical and crystallographic
investigation of ribosome–nascent peptide complexes.
Experimental procedures
Antibiotics, strains and plasmids
Erythromycin, oleandomycin and josamycin were purchased
from Sigma, telithromycin was obtained from Aventis
Pharma, azithromycin and azaerythromycin were from US
Pharmacopeia and cethromycin was from Abbott. E. coli
strain JM109 [endA1, recA1, gyrA96, thi, hsdR17 (rK–,mK+),
relA1, supE44, D(lac-proAB), (F¢, traD36, proAB, lacIq
D(lacZ)M15] (Yanisch-Perron et al., 1985) was used in the
selection experiments. Construction of the random five-
codon mini-gene expression plasmid library was described
previously (Tenson et al., 1997).
Selection of mini-genes conferring macrolide resistance
E. coli cells, strain JM109, were transformed with the
random five-codon mini-gene expression plasmid library
and plated onto LB agar plates containing 100 mg ml-1
ampicillin, 1 mM IPTG and either oleandomycin
(1.5 mg ml-1), azithromycin (100 mg ml-1), azaerythromy-
cin (75 mg ml-1), josamycin (1.2 mg ml-1), or Cethromycin
(100 mg ml-1). Plates were incubated 24–48 h at 37∞C.
Colonies that appeared were streaked onto a pair of plates
(with or without 1 mM IPTG) containing 100 mg ml-1 ampi-
cillin and the macrolide that was used in the first step of
selection. Plasmids were isolated from the clones that
exhibited IPTG-dependent macrolide resistance and the
mini-gene was sequenced. In addition, the plasmids were
retransformed into fresh cells to confirm that the plasmid
markers cause the macrolide resistance phenotype.
Testing effects of mini-gene expression on the level of 
macrolide resistance and cross-resistance
Overnight cultures of cells expressing different R-peptides
were grown in YT or LB medium containing 100 mg ml-1 ampi-
cillin. Cultures were diluted in the same medium to the final
density of A600 = 0.01, followed by the addition of IPTG (1 mM
final concentration) and one of the macrolide antibiotics: josa-
mycin (300 mg ml-1), erythromycin (50 mg ml-1), oleandomy-
cin (400 mg ml-1) or telithromycin (50 mg ml-1). Control
cultures lacked the macrolide drug. The optical densities of
the cultures were recorded when control culture reached A600
of c. 1. Relative resistance was calculated as a ratio of the
optical density of the cultures growing with and without the
macrolide. The values were normalized to the control culture
expressing the peptide MNAIK. This control clone was ran-
domly picked from the original unselected library; the steady-
state level of pentapeptide mRNA in this clone was compa-
rable to levels of peptide mRNAs in macrolide resistant
clones (data not shown).
Acknowledgements
We are grateful to Aventis Pharma and Abbott Laboratories
for providing some of the drugs used in this study and to
Joerg Harms for assisting in comparison of structures of
ribosome-bound antibiotics. This work was supported in part
by a Research Grant from Abbott Laboratories (to A.S.M.)
and The Wellcome Trust International Senior Fellowship
(070210/Z/03/Z) and grant from Estonian Science Founda-
tion (5311) (to T.T.).
References
Alvarez-Elcoro, S., and Enzler, M.J. (1999) The macrolides:
erythromycin, clarithromycin, and azithromycin. Mayo Clin
Proc 74: 613–634.
Andersson, S., and Kurland, C.G. (1987) Elongating ribo-
somes in vivo are refractory to erythromycin. Biochimie 69:
901–904.
Berisio, R., Harms, J., Schluenzen, F., Zarivach, R., Hansen,
H.A., Fucini, P., and Yonath, A. (2003a) Structural insight
into the antibiotic action of telithromycin against resistant
mutants. J Bacteriol 185: 4276–4279.
Berisio, R., Schluenzen, F., Harms, J., Bashan, A., Auer-
bach, T., Baram, D., and Yonath, A. (2003b) Structural
insight into the role of the ribosomal tunnel in cellular
regulation. Nat Struct Biol 10: 366–370.
de Boer, H.A., Comstock, L.J., and Vasser, M. (1983) The
tac promoter: a functional hybrid derived from the trp and
lac promoters. Proc Natl Acad Sci USA 80: 21–25.
Bryskier, A. (1995) Antibiotic therapy: past, present and
future. Presse Med 24: 55–66.
Bryskier, A. (2001) Telithromycin – an innovative ketolide
antimicrobials. Jpn J Antibiot 54 (Suppl. A): 64–69.
Chittum, H.S., and Champney, W.S. (1995) Erythromycin
inhibits the assembly of the large ribosomal subunit in
growing Escherichia coli cells. Curr Microbiol 30: 273–279.
Contreras, A., and Vazquez, D. (1977) Cooperative and
antagonistic interactions of peptidyl-tRNA and antibiotics
with bacterial ribosomes. Eur J Biochem 74: 539–547.
Douthwaite, S., Hansen, L.H., and Mauvais, P. (2000) Mac-
rolide-ketolide inhibition of MLS-resistant ribosomes is
improved by alternative drug interaction with domain II of
23S rRNA. Mol Microbiol 36: 183–193.
Fang, P., Spevak, C.C., Wu, C., and Sachs, M.S. (2004) A
nascent polypeptide domain that can regulate translation
elongation. Proc Natl Acad Sci USA 101: 4059–4064.
Garza-Ramos, G., Xiong, L., Zhong, P., and Mankin, A.
Peptide-mediated macrolide resistance 385
© 2004 Blackwell Publishing Ltd, Molecular Microbiology, 54, 376–385
(2002) Binding site of macrolide antibiotics on the ribo-
some: new resistance mutation identifies a specific inter-
action of ketolides with rRNA. J Bacteriol 183: 6898–6907.
Gong, F., and Yanofsky, C. (2002) Instruction of translating
ribosome by nascent peptide. Science 297: 1864–1867.
Hansen, L.H., Mauvais, P., and Douthwaite, S. (1999) The
macrolide-ketolide antibiotic binding site is formed by struc-
tures in domains II and V of 23S ribosomal RNA. Mol
Microbiol 31: 623–632.
Hansen, J., Ippolito, J.A., Ban, N., Nissen, P., Moore, P.B.,
and Steitz, T.A. (2002) The structures of four macrolide
antibiotics bound to the large ribosomal subunit. Mol Cell
10: 117–128.
Hansen, J.L., Moore, P.B., and Steitz, T.A. (2003) Structures
of five antibiotics bound at the peptidyl transferase center
of the large ribosomal subunit. J Mol Biol 330: 1061–1075.
Harms, J.M., Schluenzen, F., Fucini, P., Bartels, H., and
Yonath, A.E. (2004) Alterations at the peptidyl transferase
centre of the ribosome induced by the synergistic action of
the streptogramins dalfopristin and quinupristin. BMC Biol
2: 4.
Heurgué-Hamard, V., Mora, L., Guarneros, G., and Bucking-
ham, R.H. (1996) The growth defect in Escherichia coli
deficient in peptidyl-tRNA hydrolase is due to starvation for
Lys-tRNALys. EMBO J 15: 2826–2833.
Heurgué-Hamard, V., Dinçbas, V., Buckingham, R.H., and
Ehrenberg, M. (2000) Origins of minigene-dependent
growth inhibition in bacterial cells. EMBO J 19: 2701–2709.
Jenni, S., and Ban, N. (2003) The chemistry of protein syn-
thesis and voyage through the ribosomal tunnel. Curr Opin
Struct Biol 13: 212–219.
Liu, M., and Douthwaite, S. (2002) Resistance to the mac-
rolide antibiotic tylosin is conferred by single methylations
at 23S rRNA nucleotides G748 and A2058 acting in syn-
ergy. Proc Natl Acad Sci USA 99: 14658–14663.
Mao, J.C.-H., and Robishaw, E.E. (1971) Effects of mac-
rolides on peptide-bond formation and translocation. Bio-
chemistry 10: 2054–2061.
Menninger, J.R., and Otto, D.P. (1982) Erythromycin, carbo-
mycin, and spiramycin inhibit protein synthesis by stimulat-
ing the dissociation of peptidyl-tRNA from ribosomes.
Antimicrob Agents Chemother 21: 810–818.
Nakatogawa, H., and Ito, K. (2002) The ribosomal exit tunnel
functions as a discriminating gate. Cell 108: 629–636.
Nissen, P., Hansen, J., Ban, N., Moore, P.B., and Steitz, T.A.
(2000) The structural basis of ribosome activity in peptide
bond synthesis. Science 289: 920–930.
Ontiveros, C., Valadez, J.G., Hernández, J., and Guarneros,
G. (1997) Inhibition of Escherichia coli protein synthesis by
abortive translation of phage lambda minigenes. J Mol Biol
269: 167–175.
Otaka, T., and Kaji, A. (1975) Release of (oligo) peptidyl-
tRNA from ribosomes by erythromycin A. Proc Natl Acad
Sci USA 72: 2649–2652.
Polacek, N., Gomez, M.G., Ito, K., Nakamura, Y., and Man-
kin, A.S. (2003) The critical role of the universally con-
served A2602 of 23S ribosomal RNA in the release of the
nascent peptide during translation termination. Mol Cell 11:
103–112.
Poulsen, S.M., Kofoed, C., and Vester, B. (2000) Inhibition of
the ribosomal peptidyl transferase reaction by the
mycarose moiety of the antibiotics carbomycin, spiramycin
and tylosin. J Mol Biol 304: 471–481.
Rawat, U.B., Zavialov, A.V., Sengupta, J., Valle, M., Gras-
succi, R.A., Linde, J., et al. (2003) A cryo-electron micro-
scopic study of ribosome-bound termination factor RF2.
Nature 421: 87–90.
Schlünzen, F., Zarivach, R., Harms, J., Bashan, A., Tocilj, A.,
Albrecht, R., et al. (2001) Structural basis for the interaction
of antibiotics with the peptidyl transferase centre in eubac-
teria. Nature 413: 814–821.
Schlünzen, F., Harms, J.M., Franceschi, F., Hansen, H.A.,
Bartels, H., Zarivach, R., and Yonath, A. (2003) Structural
basis for the antibiotic activity of ketolides and azalides.
Structure (Camb) 11: 329–338.
Shine, J., and Dalgarno, L. (1975) Determinant of cistron
specificity in bacterial ribosomes. Nature 254: 34–38.
Tai, P.C., Wallace, B.J., and Davis, B.D. (1974) Selective
action of erythromycin on initiating ribosomes. Biochemis-
try 13: 4653–4659.
Tenson, T., and Ehrenberg, M. (2002) Regulatory nascent
peptides in the ribosomal tunnel. Cell 108: 591–594.
Tenson, T., and Mankin, A.S. (2001) Short peptides confer-
ring resistance to macrolide antibiotics. Peptides 22: 1661–
1668.
Tenson, T., DeBlasio, A., and Mankin, A. (1996) A functional
peptide encoded in the Escherichia coli 23S rRNA. Proc
Natl Acad Sci USA 93: 5641–5646.
Tenson, T., Xiong, L., Kloss, P., and Mankin, A.S. (1997)
Erythromycin resistance peptides selected from random
peptide libraries. J Biol Chem 272: 17425–17430.
Tenson, T., Herrera, J.V., Kloss, P., Guarneros, G., and Man-
kin, A.S. (1999) Inhibition of translation and cell growth by
minigene expression. J Bacteriol 181: 1617–1622.
Tenson, T., Lovmar, M., and Ehrenberg, M. (2003) The mech-
anism of action of macrolides, lincosamides and strepto-
gramin B reveals the nascent peptide exit path in the
ribosome. J Mol Biol 330: 1005–1014.
Tripathi, S., Kloss, P.S., and Mankin, A.S. (1998) Ketolide
resistance conferred by short peptides. J Biol Chem 273:
20073–20077.
Vazquez, D. (1975) The macrolide antibiotics. In Antibiotics
III. Mechanism of Action of Antimicrobial and Antitumor
Agents. Corcoran, J.W., and Hahn, F.E. (eds). New York,
Heidelberg, Berlin: Springer-Verlag, pp. 459–479.
Verdier, L., Gharbi-Benarous, J., Bertho, G., Mauvais, P., and
Girault, J.P. (2002) Antibiotic resistance peptides: interac-
tion of peptides conferring macrolide and ketolide resis-
tance with Staphylococcus aureus ribosomes:
conformation of bound peptides as determined by trans-
ferred NOE experiments. Biochemistry 41: 4218–4229.
Xiong, L., Shah, S., Mauvais, P., and Mankin, A.S. (1999) A
ketolide resistance mutation in domain II of 23S rRNA
reveals proximity of hairpin 35 to the peptidyl transferase
centre. Mol Microbiol 31: 633–639.
Yanisch-Perron, C., Vieira, J., and Messing, J. (1985)
Improved M13 phage cloning vectors and host strains:
nucleotide sequences of the M13mp18 and pUC19 vec-
tors. Gene 33: 103–119.
Zhong, P., and Shortridge, V. (2001) The emerging new




Lovmar, M., Nilsson, K., Vimberg, V., Tenson, T.,  
Nervall, M., Ehrenberg, M. 2006.  
The molecular mechanism of peptide-mediated  
erythromycin resistance. J Biol Chem. 281(10):6742–50. 
The Molecular Mechanism of Peptide-mediated Erythromycin
Resistance*□S
Received for publication, November 4, 2005, and in revised form, December 21, 2005 Published, JBC Papers in Press, January 12, 2006, DOI 10.1074/jbc.M511918200
Martin Lovmar‡1, Karin Nilsson‡§1, Vladimir Vimberg¶, Tanel Tenson¶, Martin Nervall, and Måns Ehrenberg‡2
From the ‡Department of Cell and Molecular Biology, Molecular Biology Program, Uppsala University, Uppsala S-75124, Sweden
§Department of Biometry and Engineering, Swedish University of Agricultural Sciences, S-75007 Uppsala, Sweden, ¶Institute of
Technology, Tartu University, 51010 Tartu, Estonia, and Department of Cell and Molecular Biology, Structural Biology Program,
Uppsala University, S-75124 Uppsala, Sweden
The macrolide antibiotic erythromycin binds at the entrance of
the nascent peptide exit tunnel of the large ribosomal subunit and
blocks synthesis of peptides longer than between six and eight
amino acids. Expression of a short open reading frame in 23 S rRNA
encoding five amino acids confers resistance to erythromycin by a
mechanism that depends strongly on both the sequence and the
lengthof thepeptide. In thisworkwehaveused a cell-free system for
protein synthesis with components of high purity to clarify the
molecular basis of the mechanism.We have found that the nascent
resistance peptide interacts with erythromycin and destabilizes its
interaction with 23 S rRNA. It is, however, in the termination step
when the pentapeptide is removed from the peptidyl-tRNA by a
class 1 release factor that erythromycin is ejected from the ribosome
with high probability. Synthesis of a hexa- or heptapeptide with the
same five N-terminal amino acids neither leads to ejection of eryth-
romycin nor to drug resistance. We propose a structural model for
the resistance mechanism, which is supported by docking studies.
The rate constants obtained from our biochemical experiments are
also used to predict the degree of erythromycin resistance conferred
by varying levels of resistance peptide expression in living Esche-
richia coli cells subjected to varying concentrations of erythromy-
cin. These model predictions are compared with experimental
observations from growing bacterial cultures, and excellent agree-
ment is found between theoretical prediction and experimental
observation.
Erythromycin is a clinically important broad-spectrumantibiotic that
belongs to themacrolide class. It binds to a site in 23 S rRNAon the large
ribosomal subunit (50 S)3 close to the peptidyl transferase center, near
the entrance to the nascent peptide exit tunnel (1). Erythromycin-
bound ribosomes can synthesize peptides with lengths between six and
eight amino acids, but further peptide elongation is inhibited, and pep-
tidyl-tRNA dissociates prematurely from the ribosome in the drop-off
pathway (2). Different macrolides allow formation of peptides with dif-
ferent lengths depending on the space available between the macrolide
and the peptidyl transferase center. This suggests thatmacrolides act by
preventing the nascent peptide from entering the peptide exit tunnel in
the 50 S subunit (2). Once a nascent peptide has passed the erythromy-
cin binding site and entered the peptide exit tunnel of a drug-free ribo-
some, erythromycin cannot bind to the 50 S subunit, which makes the
ribosome refractory to the drug until peptide elongation is terminated
by a class 1 release factor (3).
The way nascent peptides interact with the exit tunnel is important
both for regulation of messenger RNA (mRNA) translation and protein
export (4). For example, expression of the ErmC methyltransferase,
which causes erythromycin resistance by methylating base A2058
(Escherichia coli numbering) at the erythromycin binding site in 23 S
rRNA, is regulated by nascent peptide-erythromycin interactions in the
peptide exit tunnel. That is, when there is erythromycin in a cell carrying
the ermC gene, ribosomes are stalled during translation of an open
reading frame present in the leader of the ermC mRNA. This causes
rearrangements of the secondary structure of the leader mRNA, which
make the ribosome binding site available for initiation of translation of
the ErmC encoding the open reading frame of the ermC mRNA. This
regulation requires a special sequence of the leader-encoded peptide,
suggesting the existence of specific interactions between the peptide,
the peptide exit tunnel, and erythromycin (5).
Another example of such specific interactions is the mechanism by
which expression of a small open reading frame buried in the E. coli 23
S rRNA and encoding a pentapeptide causes low level resistance to
erythromycin. This pentapeptide can only work in cis, meaning that
resistance is conferred only to a ribosome on which the peptide is syn-
thesized (6). Random libraries have been used to determine a consensus
sequence for peptides that cause erythromycin resistance, i.e. fMet-
(bulky/hydrophobic)-(Leu/Ile)-(hydrophobic)-Val (7). The random
library approach has also been used to select resistance peptides to
macrolides other than erythromycin. These studies have established
correlations between macrolide structures and resistance peptide
sequences, suggesting a unique peptide-drug interaction in the riboso-
mal tunnel for each tested macrolide (8–10). It has been suggested that
synthesis of the cis-acting peptide that confers resistance to erythromy-
cin removes the drug from the ribosome in an unknown manner (8).
However, there has been no direct experimental evidence to support
this proposal, and themolecularmechanism bywhich peptide synthesis
could putatively remove erythromycin from the ribosome has remained
obscure.
Wehave used a cell-free translation systemwith purified components
from E. coli (11) to study the mechanism of peptide-mediated erythro-
mycin resistance. We have found that, indeed, translation of the resist-
ance peptide mRNA ejects the peptide, and we have identified the
very step where this occurs. Based on our biochemical data and with
support from docking simulations, we propose a structural model for
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erythromycin ejection by peptide synthesis.Wehave, furthermore, used
our kinetic data in conjunction with mathematical modeling to make
quantitative predictions of the degree of resistance conferred by varying
levels of resistance peptide expression in living cells subjected to varying
external concentrations of erythromycin. Thesemodel predictions have
been validated by observations from experiments in which the expres-
sion of resistance peptide was varied for bacteria growing in media
containing varying concentrations of erythromycin.
EXPERIMENTAL PROCEDURES
Chemicals and Buffers
GTP, ATP, and [3H]Met were from Amersham Biosciences. Putres-
cine, spermidine, phosphoenolpyruvate, myokinase, inorganic pyro-
phosphatase, erythromycin, and non-radioactive amino acids were
from Sigma-Aldrich. Pyruvate kinase was from Roche Applied Science.
[14C]Erythromycin was from PerkinElmer Life Sciences, and josamycin
was from Alexis Biochemicals (Lausen, Switzerland). All experiments
were performed in polymix buffer at working strength containing 5mM
magnesium acetate, 5 mM ammonium chloride, 95mM potassium chlo-
ride, 0.5mM calcium chloride, 8mMputrescine, 1mM spermidine, 5mM
potassium phosphate, and 1 mM dithioerythritol (12).
mRNA
The template DNAs for in vitro transcription were prepared by
annealing the following oligonucleotides at the complementary
sequences (underlined) and filling the gaps by PCR: forward oligo,
CTCTCTGGTACCGAAATTAATACGACTCACTATAGGGAATT-
CGGGCCCTTGTTAACAATTAAGGAGG; reverse oligo forMRLFV,
TTTTTTTTTTTTTTTTTTTTTTAAACAAACAGACGCATAGT-
ATACCTCCTTAATTGTTAACAAGGGCCCG; reverse oligo for
MRLFVA, TTTTTTTTTTTTTTTTTTTTTTATGCAACAAA-
CAGACGCATAGTATACCTCCTTAATTGTTAACAAGGGCCCG;
reverse oligo for MRLFVAN, TTTTTTTTTTTTTTTTTTTTTTA-
ATTTGCAACAAACAGACGCATAGTATACCTCCTTAATTGT-
TAACAAGGGCCCG; reverse oligo for MNAIK, TTTTTTTTTT-
TTTTTTTTTTTTATTTAATTGCATTCATAGTATACCTCCTT-
AATTGTTAACAAGGGCCCG. In vitro transcription and purification
of mRNAs containing a poly(A) tail were as described in Pavlov and
Ehrenberg (13).
The Components of the Purified Translation System
Components of the translation system were purified as described in
Tenson et al. (2), except for RF1, RF2, and RF3, which were purified as
described in Freistroffer et al. (11), andRRF, as described inMacDougall
et al. (14). All experiments were performed at 37 °C in polymix buffer
with the addition of ATP (1 mM), GTP (1 mM), and phosphoenolpyru-
vate (10 mM).
Recycling Experiments
The initiation mixture contained ribosomes (0.24 M, 70% active),
[3H]fMet-tRNAfMet (5 M), mRNA (0.5 M), IF2 (0.5 M), IF1 (1 M),
IF3 (1 M), and erythromycin (0.6 M in the chase and 6 M in the
experiments with only erythromycin). The recyclingmixture contained
EF-G (2M), EF-Tu (40M), EF-Ts (1M), RF2 (2M), RF3 (2M), RRF
(2 M), tRNAbulk (0.18 mM), inorganic pyrophosphatase (5 g/ml),
myokinase (3 g/ml), pyruvate kinase (50 g/ml), the relevant amino-
acyl-tRNA synthetases (0.15 units/l) (defined in Ehrenberg et al. 15),
and amino acids (alanine 1.5 mM, leucine 300 M, and 100 M concen-
trations of each of the others). Josamycin (165M)was also added to the
recycling mix when relevant.
Both initiationmix and recyclingmixwere preincubated for 10min at
37 °C to allow for formation of ribosomal initiation complexes and ter-
nary complexes, respectively. After mixing 10 l of the initiation mix
with 10l of the recyclingmix, reactionswere quenched at the specified
time points by adding 135 l of 20% formic acid, and peptide formation
was analyzed using reverse phaseHPLCas described inTenson et al. (2).
The amount of peptide P that is produced per time unit depends on
the ribosome recycling rate, k1, and the amount of active ribosomes, R,
dP
dt
 k1R (Eq. 1)
Without josamycin, which inhibits formation of these short peptides,
the amount of active ribosomes is constant, R  Rtot, and the recycling
rate can be determined from the slope of a curve where the amount of
peptides is plotted versus time, P  Rtotk1t.
However, if erythromycin is chased with a large excess of josamycin
when an erythromycin molecule dissociates from the ribosome, it is
immediately replaced by a josamycin molecule, which shuts down pro-
tein synthesis. Accordingly, the amount of active ribosomes becomes
R  Rtote
k2t (Eq. 2)
where k2 is the rate constant for erythromycin dissociation. Insertion of









1  ek2t (Eq. 4)
Using the k1 value estimated from the experiment performed in the
absence of josamycin, the parameter k2 was varied to fit the Equation 4
model to experimental data with the help of the Marquardt algorithm
(16) implemented in Origin 7 (OriginLab Corp.).
Erythromycin and Peptide Dissociation Rates
The mixture for initiation of protein synthesis contained ribosomes
(1.4M,70% active), [3H]fMet-tRNAfMet (1M), mRNA (2.5 M), IF2
(0.5 M), IF1 (1 M), IF3 (1 M), and when, relevant [14C]eryhtromycin
(2 M). The protein elongation mixture contained EF-G (1.6 M),
EF-Tu (40 M), EF-Ts (1 M), and tRNAbulk (0.18 mM), inorganic
pyrophosphatase (5 g/ml), myokinase (3 g/ml), pyruvate kinase (50
g/ml). Elongation was halted at the desired peptide lengths by exclu-
sion of the amino acid and the aminoacyl-tRNA synthetase necessary to
form the ternary complex that was reading next down-stream codon.
The concentrations of the added aminoacyl-tRNA synthetase were
(0.15 units/l) (defined in Ehrenberg et al. (15)), and the added amino
acids were (alanine 1.5 mM, leucine 300 M, and 100 M concentrations
of each of the others). When stated, RF1 (3 M) or RF2 (3 M) was also
added to the elongationmix, and unlabeled erythromycin (150 M) was
added to prevent rebinding of the [14C]erythromycin. Both initiation
mix and elongation mix were preincubated for 10 min at 37 °C to allow
for formation of initiation and ternary complexes, respectively.
Nitrocellulose Filter Binding Assays—Ribosomes stick to the nitrocel-
lulose filters, whereas erythromycin, peptides, and peptidyl-tRNA do
not. Hence, the nitrocellulose filter assay allows us to separate ribosome
bound from other labeledmolecules. Aftermixing 20l of the initiation
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mix with 20 l of the elongation mix, reactions were quenched by the
addition of 1 ml of ice-cold polymix and applied to nitrocellulose filters.
The filters were washed twice with 1ml of polymix, and both the 3H and
14C activity were counted for both the flow-through and the filters.
Formic Acid Precipitation Assay—After mixing 20 l of the initiation
mix with 20 l of the elongation mix, reactions were quenched by the
addition of 150 l of 20% formic acid, and the precipitates were pelleted
by centrifugation. The 3H activities in the supernatants, containing
released peptides were counted directly, whereas160 l of 0.5 mMKOH
was added to the pellets. After 10 min of incubation at room tempera-
ture, 10 l of 100% formic acid was added, and the precipitates were
pelleted again. The 3H activities in the supernatants at this second step
correspond to the peptides that were still bound to tRNA at the time
point when the reaction was quenched.
Data Evaluation—The dissociation rate constants for erythromycin
leaving the ribosome were estimated by fitting the data to a single expo-
nential model. The corresponding peptide- and peptidyl-tRNA dissoci-
ation rate constantswere also estimated by fitting to a single exponential
because the peptide synthesis was much faster than the dissociation
(data not shown), and thus, the dissociation could be approximatedwith
a single step reaction. The fitting was performed using the Marquardt
algorithm (16) implemented in Origin 7 (OriginLab Corp.).
Docking of the Peptides to the Ribosome
Computational modeling was done to investigate the possible modes
of interaction between peptides and erythromycin in different stages of
peptide elongation. We used docking of the resistance peptide, fMet-
Arg-Leu-Phe-Val-Stop (fMRLFV), to find a specific pattern of interac-
tion with erythromycin. Furthermore, we used the peptide fMet-Asn-
Ala-Ile-Lys-Stop (fMNAIK) as the negative control, in line with the
experimental work (9). For this purpose we used GOLD 3.0 (CCDC,
Cambridge, UK) in combination with the crystal structure 1YI2 (1),
which contains the ribosome in complex with erythromycin. The
docked peptide was covalently constrained to tRNA in either the A
(acceptor) or the P (peptidyl) site. The position of the tRNA was taken
from the crystal structure 1QVG (17). The docking study was carried
out using 2,000,000 operations per docking. Atom c21 in erythromycin
was defined as the floodfill center, and a radius of 10 Å was used in the
floodfill. Thus an “active site” was defined around the erythromycin
facing the A and P sites. The two peptides were docked as tri-, tetra-,
penta- and hexapeptides (extended with Ala). Each peptide was docked
20 times, and the 15 best solutions were saved.We used the Chemscore
option in GOLD for scoring the generated binding poses (18).
Simulations of Peptide-mediated Resistance in the Living Cell
Based on ourmodel for erythromycin ejection from the ribosome and
biochemical data, we set up a system of differential equations of ribo-
somes in different states (see Fig. 3A). The model accounts for changes
in the total concentration of intracellular erythromycin by the inflow
and outflow of the macrolide over the membrane and the change of
resistance peptide mRNA and protein mRNA through synthesis and
degradation. All components are also diluted by cell growth. The system
was solved numerically by Euler’s method (26), after the introduction of
a certain macrolide concentration in the medium. Cell growth was reg-
istered as volume expansion during the first 8 h after induction. Before
macrolide exposure, the system resided at steady state for a certain
synthesis rate of resistance peptide mRNA (rpmRNA). The used pro-
gram software was MATLAB 6.5 (The MathWorks, Inc., Natick, MA).
A detailed description of the model and the parameters used is pre-
sented in the supplemental material.
Measurements on Cell Cultures
Strains—E. coli DH5 strain (F80dlacZ (lacZYA-argF)U169 deoR
recA1 endA1 hsdR17 (rk, mk) phoA supE44 -thi-1 gyrA96 relA1/F
proAB lacIqZM15 Tn10(tetr)) was used in all experiments.
Effects of Mini-gene Expression on Macrolide Resistance—Overnight
cultures of cells expressing resistance peptide (9) were grown at 37 °C in
LBmediumcontaining 100g/ml ampicillin. Cultureswere diluted into
96-well plates with fresh LB medium containing erythromycin and
IPTG at different concentrations to final densities of A600  0.01.
The cell cultures were grown in the shaker at 37 °C for 8 h, and the
optical densities at A600 were recorded using the TECAN SUNRISE
instrument.
RNA Copy Number—Cells expressing the resistance peptide were
grown overnight in LB medium containing 100 g/ml ampicillin at
37 °C. Cultures were diluted with fresh LB medium containing IPTG
and erythromycin at the concentrations as indicated. The cultures were
grown for 2 h before 1-ml cultures were taken for total RNA isolation.
Total RNAwas purified withNucleoSpin RNA II kit (Macherey-Nagel).
Concentrations of the resistance peptide and EF-Tu mRNAs were
measured by reverse transcription real-time PCR using the TaqMan
Gold reverse transcription PCR kit (Applied Biosystems). The reverse
transcription real-time PCR programwas as follows; 1) annealing of the
forward primer tomRNA (75 °C for 2min, 65 °C for 5min, and 53 °C for
5 min); 2) reverse transcription reaction, started by adding TaqMan
reverse transcription buffer, dNTPs, RNase inhibitor, and reverse tran-
scriptase followed by incubation at 45 °C for 10 min, 48 °C for 30 min,
and 95 °C for 30 min; 3) real-time PCR, started by the addition of PCR
buffer, dNTP, AmpliTaq Gold DNA polymerase, and the respective
reverse primers and Taqman probes followed by PCR steps (prePCR
(50 °C for 2 min and 95 °C for 10 min) and 40 PCR cycles (95 °C for 15 s,
50 °C for 30 s, and 60 °C for 15 s). The final reaction volume was 25 l.
The concentrations of forward and reverse primers were 900 nM each,
and the probe concentration was 100 nM. Annealing and reverse tran-
scription steps were done in GeneAmp PCR System 2700 (Applied Bio-
systems). Real-time PCR was run and monitored in Rotor-Gene 5.0.47.
Primers—Specific primers for resistancepeptide encodingmRNAwere:
forward, d(AAAAGCCCGCTCATTAGG), reverse, d(TGCTAGTCT-
TAAGGAGGTCACAT), and Taqman probe, d(CTAGAGAATTCA-
GCTAGTTAAACAAACAAAACCA). Specific primers forEF-TumRNA
were: forward, d(GAGATGGAGAATACGTCTTCGA), reverse, d(AC-
CAGAGCGTGCGATTG), and Taqman probe, d(CGGCAGCAG-
GAACGGCTT). Taqman probes had the 5 end modified with a FAM
fluorophore and the 3 endmodified with a TAMRA fluorophore.
RESULTS
Stoichiometric Removal of Erythromycin by Resistance Peptide
Synthesis—To study the effects of resistance peptide synthesis on the
rate of dissociation of erythromycin from the 50 S subunit, we took
advantage of a cell-free translation system with purified components
from E. coli (11). The resistance pentapeptide fMRLFV and a control
pentapeptide, fMNAIK, were synthesized (9) on ribosomes in recycling
mode (19). Erythromycin insignificantly affected the rate of synthesis of
resistance and control peptide, whereas their synthesis was shut down
by the presence of josamycin (Fig. 1). We took advantage of this by
chasing the erythromycin, originally on the recycling ribosomes, with
josamycin (Fig. 1). Because the two drugs have overlapping ribosomal
binding sites (1, 20, 21), josamycin cannot bind and shut down peptide
synthesis until after dissociation of erythromycin from the 50 S subunit.
The josamycin concentration used in the chase (83 M) leads to an
association rate of 2.7 s1 (21). Thus, the rate-limiting step in the josa-
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mycin-induced inhibition of peptide formation is the erythromycin dis-
sociation. The value of the rate constant for dissociation of erythromy-
cin from ribosomes synthesizing the control peptide was estimated as
0.01 s1 (Fig. 1B), which corresponds to the rate constant for spontane-
ous dissociation of erythromycin from empty ribosomes (21). In con-
trast, the value of the rate constant for dissociation of erythromycin
from ribosomes synthesizing the resistance peptide was estimated as
0.03 s1, a value coinciding with the rate (s1) of pentapeptide synthesis
per ribosome in the absence of josamycin (Fig. 1A). From these results
follows that erythromycin was removed with high probability from the
ribosome during each cycle of resistance, but not control peptide syn-
thesis. Identification of the step at which drug dissociation was induced
by the cis-acting peptide required further experiments, to be described
in the next paragraph.
Dissociation of Erythromycin during Different Stages of Resistance
Peptide Synthesis—To estimate the rate constants for dissociation of
erythromycin at different stages of resistance peptide synthesis, we used
nitrocellulose filtration techniques.
Ribosomes were initiated for synthesis of resistance (fMRLFV) or
control (fMNAIK) peptides. By selective exclusion of amino acids and
aminoacyl-tRNA synthetases in the peptide elongation assays, ribo-
somes carrying fMR, fMRL, fMRLF, or fMRLFV as well as fMN, fMNA,
fMNAI, or fMNAIK peptides ester-bonded to the P-site tRNA were
produced. Subsequently, [14C]erythromycin was chased from each one
of these ribosome complexes by the addition of unlabeled erythromycin
in excess, and the fraction of [14C]erythromycin-containing ribosomes
was monitored by nitrocellulose filtration at different incubation times.
From these data, rate constants for the dissociation of erythromycin
were estimated, and the results are summarized in Table 1. The rate
constant for dissociation of erythromycin increased from its smallest
value (0.011 s1) in the initiation complex with every amino acid that
was added, in accordance with the resistance peptide sequence to its
largest value of 0.068 s1 when the pentapeptidewas completed (Fig. 2A
and Table 1). There was at the same time little effect on the rate of
erythromycin dissociation by amino acid addition, in accordance with
the control peptide sequence (Fig. 2B and Table 1).
It has been shown that active resistance peptides must have lengths
between four and six amino acids (7). To clarify why this is so, we
prepared mRNAs encoding the hexapeptide fMet-Arg-Leu-Phe-Val-
Ala-Stop, which is the resistance peptide with a C-terminal addition of
Ala, and the heptapeptide fMet-Arg-Leu-Phe-Val-Ala-Asn-Stop, which
is the resistance peptide with a C-terminal addition of Ala-Asn. Both
these C-terminal additions reduced the rate constant for erythromycin
dissociation from 0.068 s1 (in the presence of the authentic resistance
peptide) to 0.014 s1 (in the presence of the C-terminal extension)
(Table 1).
These results show thatwhen the resistance peptide grew from two to
five amino acids, this led to successively faster dissociation of erythro-
mycin. Because, however, synthesis of the resistance peptide was con-
siderably faster than the largest rate of erythromycin dissociation, these
data cannot explain why every round of resistance peptide synthesis
resulted in near-stoichiometric removal of the 50 S-bound erythromy-
cin (Fig. 1). This pointed at class 1 release factor-induced peptide release
from the ribosome as the critical step for resistance peptide action.
Experiments addressing this question follow.
Termination of Resistance Peptide Synthesis Drives Dissociation of
Erythromycin—The largest rate constant for erythromycin dissociation
(0.14 s1) was obtainedwhen either one of the class 1 release factors was
also present to terminate the synthesis of the resistance peptide at the
UAA codon of its mRNA (Fig. 2C, Table 2). At the same time, there was
no effect on the rate of erythromycin dissociation by release factor addi-
tion in the case of the control peptide (Fig. 2C, Table 2). To further
investigate class 1 release factor action, we used nitrocellulose binding
to monitor the release of different peptides from the ribosome and
formic acid precipitation followed by peptide identification by HPLC to
directly monitor hydrolysis of the ester bond connecting peptide and
P-site tRNA. The rate of dissociation from the ribosome and the rate of
ester bond hydrolysis were similar in the cases described below in this
section of text, suggesting fast dissociation of peptides from the ribosome
after the rate-limiting ester bond hydrolysis.
The rate of resistance peptide release from the ribosome, as induced
by either one of the class 1 release factors (0.073 s1) as monitored by
the ribosome-bound 3H-labeled fMet, was significantly smaller than the
rate constant for dissociation of erythromycin (0.14 s1). At the same
time, the rate of control peptide release as induced by RF2 (0.22 s1) was
almost 30 times larger than the rate constant for erythromycin dissoci-
ation (Fig. 2E). These results in conjunctionwith the observation (Fig. 1)
that every cycle of resistance peptide synthesis removed the ribosome-
bound erythromycin with high probability suggest, first, that binding of
a class 1 release factor to an erythromycin-containing ribosome carry-
ing a resistance pentapeptide further destabilized the binding of the
FIGURE 1. Erythromycin chased with josamycin in a recycling experiment. The
amounts of resistance peptide (MRLFV, panel A) and control peptide (MNAIK, panel B) are
plotted against time. Erythromycin (Eryt. (F) allows formation of both pentapeptides
almost as well as without any antibiotic (), whereas josamycin (Josa. Œ) does not allow
any pentapeptide formation. When erythromycin dissociates in the chase experiment
(f) it is replaced by josamycin, and further pentapeptide formation is inhibited. The
dashed lines correspond to the amount of active ribosomes in the experiments (1.7
pmol). Translation of the resistance peptide (MRLFV, panel A) is inhibited already after a
single round of translation, which means that all erythromycin has dissociated and been
replaced by josamycin before the next round of translation initiates. This is in contrast to
the several rounds of recycling that is allowed when expressing the control peptide
(MNAIK, panel B). The pentapeptide synthesis rate per ribosome in the absence of josa-
mycin (k1) is 0.03 s
1 (3 pmol min1/1.7 pmol of ribosomes  1.8 min1  0.03 s1). The
erythromycin dissociation rate (k2) can be estimated from the value of k1 and the plateau
level in the josamycin chase experiments (see “Experimental Procedures”).
TABLE 1
Erythromycin dissociation rate constants
Translated peptide Erythromycin dissociation rate constant
s1
Initial complex 0.011 	 0.001
MR 0.017 	 0.005
MRL 0.025 	 0.004
MRLF 0.051 	 0.004
MRLFV 0.068 	 0.006
MRLFVA 0.014 	 0.001
MRLFVAN 0.014 	 0.001
MN 0.011 	 0.001
MNA 0.015 	 0.001
MNAI 0.016 	 0.001
MNAIK 0.017 	 0.001
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drug to the ribosome and, second, that termination was slow enough to
allow dissociation of erythromycin from the ribosomewith a probability
close to one, in accordance with the results in Fig. 1. It cannot be
excluded that dissociation of erythromycin was strictly required for ter-
mination to occur, in which case the probability for drug rejection
would be exactly 100%. The reason for the ambiguity relates to the
experimental design in which [14C]erythromycin was chased with unla-
beled erythromycin at a high concentration (75 M), which could allow
for rapid rebinding of an unlabeled erythromycin after dissociation of
the labeled one (21), before significant termination could occur. In this
latter scenario, which leads to the simplest interpretation of the peptide
release data, termination in our in vitro experiments occurred in the
presence of erythromycin.
The addition of RF2 to ribosomes carrying the resistance peptidewith
aC-terminal addition of one amino acid (the hexapeptide) led to peptide
release with a rate constant of 0.015 s1, virtually identical with the rate
constant of 0.014 s1 for dissociation of erythromycin (Figs. 2, D and E
and Table 2). The addition of RF2 to the resistance peptide with a C-ter-
minal addition of two amino acids (the heptapeptide) led to peptide
release with a considerably smaller rate constant of 0.006 s1 but to a
similar rate constant of 0.014 s1 for dissociation of erythromycin (Figs.
2, D and E, and Table 2). This rate constant for dissociation of erythro-
FIGURE 2. Erythromycin and peptide dissociation rates. Panels A–D show the amount of ribosome bound (or released) [14C]erythromycin as a function of time. Essentially all
ribosomes contain [14C]erythromycin at time 0, and a 75-fold excess of cold erythromycin was added to the pre-initiated ribosome complexes together with the elongation mix to
prevent re-binding of [14C]erythromycin. Panel E shows dissociation of the peptide labeled with [3H]fMet as a function of time. The black symbols in panels A–E show the amount that
is bound to ribosomes and thereby stick to the nitrocellulose filters, whereas the gray symbols show the amount that have gone through the filters. Panel F shows the release
factor-mediated hydrolysis of the peptidyl-tRNA and the puromycin reaction as a function of time. The black symbols show the peptides that are still bound to tRNA and thereby
precipitable with formic acid, whereas the gray symbols show the peptides in the supernatant. All lines are obtained by simultaneously fitting the data shown by black and gray
symbols to single exponentials using least square fits. The estimated rate constants are collected in Tables 1 and 2.
TABLE 2
Erythromycin and peptide dissociation rate constants






MRLFV RF1 0.14 	 0.02 0.073 	 0.007
MRLFV RF1 No erythromycin 0.22 	 0.02
MRLFV RF2 0.13 	 0.01 0.074 	 0.01 0.10 	 0.01
MRLFV RF2 No erythromycin 0.25 	 0.01 0.26 	 0.03
MRLFV Puromycin 0.067 	 0.009 Not determinedc 0.23 	 0.02
MRLFV Puromycin No erythromycin Not determinedc 0.31 	 0.03
MRLFVA RF2 0.014 	 0.001 0.015 	 0.002 0.015 	 0.001
MRLFVA RF2 No erythromycin 0.29 	 0.03 0.32 	 0.03
MRLFVAN RF2 0.014 	 0.001 0.006 	 0.0004 0.004 	 0.0004
MRLFVAN RF2 No erythromycin 0.27 	 0.03 0.44 	 0.03
MNAIK RF2 0.015 	 0.001 0.26 	 0.03 0.28 	 0.02
MNAIK RF2 No erythromycin 0.25 	 0.02 0.27 	 0.02
a Measured by nitrocellulose filter binding.
b Measured by formic acid precipitation.
c Could not be determined because fMRLFV-puromycin bind to NC-filters.
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mycin is similar to the corresponding rate constant for the peptide-
lacking initiation complex. These experiments show that release of the
extended peptides did not accelerate dissociation of erythromycin, in
line with the previous observation of a strong sequence length depend-
ence of resistance activity (7).
Treatment of ribosomes carrying full-length resistance peptides with
puromycin, an antibiotic mimicking the aminoacylated 3-adenosine of
an aminoacylated tRNA (17), did not alter the rate of dissociation of
erythromycin (Fig. 2D and Table 2). It was not possible to monitor
release of the resistance peptide-puromycin complex from the ribo-
some, since it remained filter-bound in free as well as ribosome-bound
configuration. We could, however, monitor peptidyl transfer to puro-
mycin using HPLC after formic acid precipitation. We found that the
rate constant for transfer of the resistance peptide to puromycin (0.23
s1) was much larger than the rate constant for dissociation of erythro-
mycin (0.067 s1) (Figs. 2, D and F). This means that transfer of the
resistance peptide to puromycin was unhindered by the presence of
erythromycin, in contrast to the hydrolytic reaction induced by a class 1
release factor (Fig. 2C and Table 2). It is normally assumed that when a
small peptide is transferred to puromycin, it rapidly leaves the ribosome.
However, if this were the case, one would expect that the rate constant
for erythromycin release would be reduced from its value of 0.068 s1 in
the absence of puromycin to its value of 0.011 s1 in the absence of
peptide. The experiments show, in contrast, that in response to puro-
mycin treatment dissociation of erythromycin remained unaltered at
0.067 s1. This suggests that the resistance peptide-puromycin complex
remained ribosome-bound long enough to allow for dissociation of the
radio-labeled erythromycin.
Docking of the Resistance Peptide to the Ribosome—Previous genetic
studies (7) and the biochemical data in this work suggest the existence of
specific interactions between the resistance peptide and ribosome-
bound erythromycin. To test this, we performed docking simulations
with a resistance or a control peptide anchored to an A-site- or a P-site-
bound tRNA of a ribosome in complex with erythromycin. In 8 of the
top 15 simulations for the resistance pentapeptide anchored to the
P-site tRNA, the leucine in fMRLFV was bound to a small hydrophobic
cavity on the surface of erythromycin, between the cladinose and des-
osamine residues (see Fig. 4, E and F), and a similar result was obtained
for the tetrapeptide fMRLF. Similar, but less pronounced leucine bind-
ing patterns were observed also for fMRLFV and fMRLF anchored to
the A-site tRNA. At the same time, no distinct binding patterns were
observed for amino acids other than leucine in the resistance peptide or
for any of the amino acids in the control peptide fMNAIK. In the case of
the resistance tripeptide, the leucine did not reach into the erythromy-
cin cavity, and in the case of the resistance hexapeptide, the leucine
binding pattern was gone, possibly due to steric hindrance.
Validation of the Model for Resistance Peptide Action by Cell Popula-
tion Experiments—From the biochemical experiments described above,
kinetic constants for resistance peptide action were obtained (Table 2).
We constructed a model for erythromycin resistance in bacterial pop-
ulations (Fig. 3A) based on these and other parameters (listed in the
supplementalmaterial) for protein synthesis obtained fromour cell-free
mRNA translation system (21). The model (detailed description in the
supplemental material) contains seven different states of the large ribo-
somal subunit (50 S) (Fig. 3A); it accounts for dilution of all compounds
due to cell volume growth and for a finite rate of diffusion across the cell
membrane, which reduces the intracellular concentration in relation to
the outer concentration of erythromycin. Furthermore, themodel takes
into account the efflux pumps used by E. coli to actively transport eryth-
romycin and other antibiotic drugs from the membrane and cytoplasm
to the growth medium (22).
To validate the model, we varied the expression of rpmRNA under
tac promoter control from a multicopy plasmid by varying the concen-
tration of IPTG in an erythromycin-containing growth medium (6, 9).
Cell growth at different IPTG and erythromycin concentrations was
monitored along with reverse transcription real-time PCR analysis of
the intracellular concentration of rpmRNA relative to the concentra-
tion of EF-Tu mRNA (Fig. 3C, inset). The tac promoter was leaky, and
the response in rpmRNA synthesis to the external IPTG level was linear.
At the highest IPTG concentration (600M) in themedium, themRNA
level was 3-fold higher than in the absence of IPTG (Fig. 3C, inset).
Increasing IPTG concentrations led to increasing erythromycin resist-
ance until a plateau, specific for each concentration of erythromycin,
was reached (Fig. 3C). The increase in bacterial mass (optical density)
during 8 h of growth at varying concentrations of erythromycin and
IPTG in the medium were monitored, and there was excellent agree-
ment between the experimentally observed and model-simulated
growth behavior in which the measured, relative rpmRNA levels had
been taken into account (Fig. 3B).
DISCUSSION
Erythromycin binds in the nascent peptide exit tunnel close to the
peptidyl transferase center (1, 23) (Fig. 4A) and prevents synthesis of
peptides longer than eight amino acids (2). Expression of a mini-gene
buried in the 23 S rRNA causes low level resistance to erythromycin (6),
and it has been suggested that synthesis of this resistance peptide on an
erythromycin-containing ribosome can clean it from the drug, thereby
making an erythromycin-free 50 S subunit available for a new round of
initiation of protein synthesis with another mRNA (8). When the nas-
cent peptide is longer than six to eight amino acids, it covers the eryth-
romycin binding site, which makes the ribosome refractory to further
inhibition by erythromycin, allowing for synthesis of full-length
proteins (3, 21).
The present experiments directly demonstrate that synthesis of a
resistance peptide can, indeed, remove erythromycin from the 50 S
subunit. During every cycle of resistance peptide synthesis erythromy-
cin dissociates with close to 100% probability, whereas the synthesis of a
control peptide does not induce dissociation of the drug (Fig. 1). As the
resistance peptide grows by successive amino acid additions, the rate
constant for dissociation of erythromycin increases in a stepwise man-
ner (Table 1). It is, however, not until class 1 release factor induced
termination of the full-length resistance pentapeptide, that erythromy-
cin is removed from the ribosomewith high probability. Termination is,
in other words, the crucial kinetic step for erythromycin dissociation
and, therefore, the point at which resistance is conferred.
To validate themechanism for resistance peptide action, wemodeled
it in the context of the cytoplasm of a living cell (Fig. 3A and supplemen-
tal material) using kinetic data from the present (Table 2) and earlier
(21) work. We describe in particular the degree to which inhibition of
the growth rate of a bacterial population due to the presence of varying
concentrations of erythromycin in the cytoplasm is expected to be
relieved by the expression of the resistance peptide at varying levels
(Fig. 3B).
These simulations were compared with experimental observations
from a bacterial population containing the resistance peptide gene
under tac promoter control on a multicopy plasmid. The cells were
grown in media containing varying concentrations of erythromycin as
well as IPTG to control the level of resistance peptide expression. The
increase in bacterialmass during 8 h of growthwasmonitored by optical
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density (Fig. 3C) along with the level of resistance peptide mRNA nor-
malized to the level of EF-Tu mRNA (Fig. 3C, inset), as measured by
reverse transcription real-time PCR. The simulated growth rates in Fig.
3B, where the experimentally measured resistance peptide mRNAs are
taken into account, are in excellent agreement with the measured
growth rates in Fig. 3C. This shows that the mechanism we propose for
peptide-mediated low level resistance against erythromycin (Fig. 3A)
and the rate constants obtained from our cell-free in vitro translation
system (Table 2 and Ref. 21) are sufficient to fully account for the in vivo
induced resistance in a large interval of erythromycin concentrations
and peptide expression levels (Figs. 3, B and C (and inset)).
The structural basis of resistance peptide action is of considerable
interest, not the least because it is one special case of the general and
poorly understood phenomenon of peptide-specific interactions with
the ribosomal peptide exit tunnel (4, 24). Our data show that when the
control peptide grows from a di- to a pentapeptide, there is little change
in the rate constant for erythromycin dissociation. When, furthermore,
RF2 is added to terminate peptide synthesis, hydrolysis of the ester bond
in the peptidyl-tRNA proceeds with the same rate as in the absence of
erythromycin (Tables 1 and 2). For the resistance peptide, in contrast,
our data show that the rate constant for erythromycin dissociation
increases gradually by a factor of six as the peptide grows from just the
fMet to di- and then to pentapeptide. In addition, when RF2 is added,
the rate constant for erythromycin release is further enhanced by a
factor of two, and the rate of ester bond hydrolysis is much smaller than
in the absence of erythromycin (Tables 1 and 2). We know from data
obtained fromopen reading frame libraries that the consensus sequence
for peptide-mediated erythromycin resistance has two outstanding fea-
tures; there is a leucine or isoleucine in the third position and a valine in
the fifth, C-terminal position (7, 9). Resistance peptides for different
FIGURE 3. The model, simulation data, and data from cell culture experiments. Panel A shows a schematic of the model we have developed for simulating translation in the
presence of erythromycin and the effect of translating a resistance peptide in the context of a growing E. coli cell. The 50 S subunits are in seven different states in the model. Free
50 S subunit (state 1) is susceptible to erythromycin binding and likewise is the newly initiated ribosomes (state 2 and state 6), whereas elongating ribosomes with a longer protein
become refractory to macrolide binding (state 3) and, thus, this state always results in full-length product. If erythromycin is bound to the 50 S subunit (state 4) it can still initiate and
translate the first codons before protein synthesis is inhibited (state 5). The ribosome is stuck in state 5 until either the peptidyl-tRNA drops off and the ribosome is recycled to state
4, or erythromycin dissociates and protein synthesis is resumed in state 3 and thus refractory to rebinding of erythromycin. If a ribosome with erythromycin (state 4) initiates on a
resistance peptide mRNA (rpmRNA) (state 7) it will be “cleaned” and recycled as an erythromycin free 50 S (state 1). The model also contains the cell membrane and erythromycin
efflux pumps present in E. coli that change the intracellular concentration in comparison to erythromycin concentration in the growth media. For further details about the model, see
the supplemental material. Panel B, simulated growth (defined as how many times the cell volume has increased) during the first 8 h after the addition of erythromycin plotted against
the rate of rpmRNA synthesis for different concentrations of erythromycin. Panel C, optical density (600 nm) measured 8 h after the addition of erythromycin plotted against the
concentration of IPTG. Inset, level of expression of rpmRNA in relation to EF-Tu mRNA plotted against the IPTG concentration.
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types ofmacrolides have different consensus sequences, suggesting spe-
cific and perhaps direct interactions between the conserved residues
and each type of ribosome bound macrolide (9, 10). From the present
kinetic data (Tables 1 and 2) and docking simulations (Fig. 4F) along
with previous open reading frame library data (7), we propose a struc-
tural model for peptide-mediated erythromycin resistance (Figs. 4,
A–D).
Our docking studies based on the crystal structure of aHaloarcula
marismortui 50 S subunit in complex with erythromycin (1) suggest
that the side chain of leucine in the resistance peptide binds to the
hydrophobic cleft between the two sugar moieties of erythromycin
(Figs. 4, E and F). To date, there is no crystal structure of an E. coli
50 S subunit in complex with erythromycin, but the similarity of the
50 S subunits from the two organisms near the erythromycin binding
site (1, 25) suggests that our docking data are relevant also for the
erythromycin-bound E. coli ribosome. Leucine binding to erythro-
mycin is observed both for resistance tetra- and pentapeptides, and
the binding pattern is more distinct for resistance peptides anchored
to the P-site than to the A-site tRNA. By hypothesis, the observed
interaction between the resistance tetrapeptide and the drug weak-
ens the affinity of erythromycin for the ribosome, which accounts for
the fact that a leucine (or an isoleucine) is critical for resistance
peptide action. Completion of the resistance pentapeptide by the
addition of valine further increases the erythromycin dissociation
rate constant, probably because the force by which the resistance
peptide pushes erythromycin out from its binding site increases (Fig.
4B). When a class 1 release factor binds to the pre-termination ribo-
some containing a resistance pentapeptide ester-bonded to the
P-site tRNA, the rate constant for erythromycin dissociation
increases by another factor of two. At the same time, the rate con-
stant for ester bond hydrolysis of the peptidyl-tRNA decreases very
significantly (Table 2), which partially accounts for the fact that
every cycle of peptide synthesis led to erythromycin dissociation
with near 100% probability (Fig. 1). It is, furthermore, possible that
the resistance peptide forms a specific hydrophobic structure that
prevents it from leaving the ribosome through the peptidyl transfer-
ase center after its release from the P-site tRNA. The peptide is then
forced to leave the ribosome through the peptide exit tunnel, where
its hydrophobic C terminus could interfere with the hydrophobic
interactions between erythromycin and the exit tunnel wall and
chase the drug out through the L4/L22 constriction in the tunnel
(Fig. 4C). This would lead to 100% probability of drug ejection per
cycle of resistance peptide synthesis. When instead of termination,
an additional amino acid is added to the resistance pentapeptide, our
simulations suggest that the leucine interaction with erythromycin
becomes lost and that, accordingly, the hexa-peptide is expected to
behave like any other peptide. It will fill up the space available
between drug and peptidyl transfer center until further protein syn-
thesis is inhibited by crowding (Fig. 4D).
FIGURE 4. A structural model for the mechanism of resistance peptide action. Panel A shows a schematic of the large ribosomal subunit cut along the nascent peptide exit tunnel
with an erythromycin molecule bound (red). The peptidyl transferase center (PTC) and the two ribosomal proteins (L4 and L22) constituting the constriction in the tunnel are indicated.
The black rectangle indicates the section shown in panels B–D where our hypothesis about the mechanism of the resistance peptide action is shown. Panel B shows the pentapeptidyl-
tRNA that interacts with erythromycin (Eryt). Panel C shows the resistance peptide that during termination of protein synthesis has removed erythromycin. Panel D shows the
hexapeptidyl-tRNA which has lost its contact with erythromycin and is trapped in a dead end that eventually leads to peptidyl-tRNA drop-off. Panel E shows the chemical structure
of erythromycin. Panel F presents the interaction between the conserved leucine residue (orange) in the resistance peptide and erythromycin as indicated by the docking studies.
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ABSTRACT 
Macrolide antibiotics bind at the entrance of the nascent peptide exit tunnel of 
the large ribosomal subunit, inducing premature termination of translation by 
drop-off of peptidyl-tRNA. Expression of specific cis-acting peptides confers 
resistance to macrolides. Recently the molecular mechanism behind 
erythromycin resistance was revealed. The resistance peptide works like a 
“bottle-brush” and expels erythromycin from the ribosome upon termination of 
translation. Here, we have used a cell-free translation system to study the 
mechanism of peptide-mediated josamycin resistance. Distinct from 
erythromycin resistance peptides, expression of a josamycin resistance peptide 
did not lead to an increased dissociation of the drug. Instead, the rate of 
resistance di-peptidyl-tRNA drop-off is decreased by an order of magnitude 
compared to the control peptide. Further, the level of resistance is independent 
of the length of the josamycin resistance peptide mRNAs while erythromycin 
resistance peptides show strict length dependence. We propose therefore that 
josamycin resistance peptides work by “quarantining” the josamycin bound 
ribosomes. A quantitative model of the josamycin resistance was constructed and 
it mimics the degree of resistance in Escherichia coli cells expressing a resistance 
peptide and subjected to varying concentrations of josamycin. Both this model 
and the previous model for erythromycin resistance predict that an active efflux 
pump system is required for the resistance peptide mechanism to function. This 
prediction was tested using an E. coli mutant lacking a functional AcrAB-TolC 
efflux pump system and, indeed, no peptide mediated resistance was detected in 
the mutant. 
INTRODUCTION 
Since the 1950s macrolide antibiotics have been used in the treatment of infections 
(Weisblum, 1995). Macrolides consist of several neutral or amino sugars attached to a 
14-, 15- or 16-membered lactone ring (Leclercq, 2002). The first generation contains 
naturally occurring 14-membered ring macrolides, and includes erythromycin, 
currently the best-known macrolide. Josamycin belongs to the second generation, with 
a 16-membered lactone ring (Weisblum, 1998). Macrolides bind to the large 
ribosomal subunit, in the vicinity of the peptidyl transferase centre (Hansen et al., 
2002; Schlunzen et al., 2001) and most likely inhibit protein synthesis by blocking the 
entrance to the tunnel through which nascent peptides exit the ribosome (Lovmar et 
al., 2004; Tenson et al., 2003). Resistance mechanisms to macrolide antibiotics 
include modifications of the drug-binding site, inactivation of the drug by degradation 
or modification and cellular efflux by specialized transporter proteins (Weisblum, 
1998). However, in the focus in this study is a unique resistance mechanism conferred 
by expression of specific cis-acting peptides (Tenson and Mankin, 2001). 
Peptides mediating macrolide resistance was first encountered in experiments where 
E. coli cells expressed random rRNA fragments of the rrnB operon (Tenson et al., 
1996). Biochemical and genetic studies revealed the presence of a 34 nucleotides long 
mini-gene ranging between positions 1235 and 1268 in domain II of the 23S rRNA in 
all resistant clones. Additional in vitro experiments, where resistance peptides or 
resistance peptide mRNA (rpmRNAeryt) were supplied, showed the necessity of active 
translation of the rpmRNAeryt for protection against erythromycin. Using selection 
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from random libraries it became clear that the resistance peptides require both specific 
length and sequence (Tenson et al., 1997). Tripathi et al. (1998) proposed a 
“bottlebrush” model based on these experiments and further library studies selecting 
resistance peptides against a ketolide. The “bottlebrush” model suggests that synthesis 
of a resistance peptide removes the drug molecule, by direct interaction between 
macrolide and resistance peptide, thus restoring the protein synthesis capability of the 
ribosome. The resistance peptide acts as a “bottlebrush” and “cleans” the ribosome. 
Recently, Lovmar et al. (2006) showed that synthesis of a cis-acting peptide indeed 
accelerates the rate of erythromycin dissociation by destabilizing the binding of the 
drug to the ribosome. In addition, it was shown that erythromycin was most probably 
always expelled from the ribosome during release factor mediated translation 
termination. The biochemical data was also used within the framework of a 
mathematical model to predict resistance and finally the predictions of the model 
could be validated by growth experiments in vivo. 
It has been suggested that the “bottlebrush” mechanism is general and work for all 
classes of macrolides with modulated specific sequences (Tenson and Mankin, 2001; 
Tripathi et al., 1998; Vimberg et al., 2004). However, in the case of josamycin there 
are at least two major features suggesting a closer examination of the effects of 
rpmRNAjosa expression. First, peptidyl transfer is inhibited already after 2 or 3 amino 
acids in the presence of josamycin (Lovmar et al., 2004; Tenson et al., 2003), and the 
selected resistance peptides, containing 4 or 5 amino acids (Vimberg et al., 2004), 
will therefore never reach the stop codon and thus never reach the termination step 
which seems to be crucial for the “bottlebrush” mechanism. Secondly, josamycin is 
bound to the ribosome 1.5 h on the average (Lovmar et al., 2004). This means that a 
dissociation rate increase of josamycin by a factor of 10 as measured for rpmRNAeryt 
will still not render resistance since the peptidyl-tRNA drop-off rate would still be 
much higher (Lovmar et al., 2006). 
We begin this study with a biochemical characterization of the peptide mediated 
josamycin resistance. In combination with an examination of how the activities of 
rpmRNAjosa and rpmRNAeryt depend on the length of the encoded peptides it enables 
us to conclude that they work through different mechanisms. Using the rate constants 
from the biochemistry in a mathematical model, similar to the previously published 
one (Lovmar et al., 2006), we propose that the effect of rpmRNAjosa is to “quarantine” 
a fraction of the josamycin containing ribosomes from the active pool of ribosomes. 
How expression of rpmRNAjosa can be connected to the growth and survival of cells 
at different concentrations of josamycin is examined in the model, and the result is 
compared to in vivo growth curves. 
Previous modeling of peptide-mediated erythromycin resistance resulted in one clear 
predicted requirement for the resistance mechanism to function; the intracellular 
concentration of erythromycin has to rapidly equilibrate with the surrounding media 
(Lovmar et al., 2006). However, all in vivo experiments were performed with gram-
negative Escherichia coli cells where the outer membrane offers an efficient barrier of 
permeation (Lovmar et al., 2006; Tenson and Mankin, 2001). It seemed therefore that 
either the prediction, and thus also the model, has to be wrong or there had to be more 
to the story than appreciated at first. In the previous paper we argued that broad-
specific multi-drug pumps located in the inner membrane, especially the AcrAB-TolC 
system (Zgurskaya and Nikaido, 1999), may account for the rapid antibiotic 
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equilibration required to confer peptide-mediated resistance (Lovmar et al., 2006). 
This prediction is tested in this study using a mutant without a working AcrAB-TolC 
system and both the resulting increase in sensitivity and the loss of peptide mediated 
resistance of the mutant corresponds well with the model predictions. 
EXPERIMENTAL PROCEDURES 
Chemicals and buffers 
GTP, ATP and [3H]Met were from GE Biosciences (Uppsala, Sweden). Putrescine, 
spermidine, phosphoenolpyruvate (PEP), myokinase (MK), inorganic 
pyrophosphatase (PPiase), erythromycin and non-radioactive amino acids were from 
Sigma-Aldrich (St. Louis, MO, USA). Pyruvate kinase (PK) was from Boehringer-
Mannheim (Mannheim, Germany). Josamycin was from Alexis Biochemicals 
(Lausen, Switzerland). 
All experiments were performed in polymix buffer, at working strength containing 5 
mM magnesium acetate, 5 mM ammonium chloride, 95 mM potassium chloride, 0.5 
mM calcium chloride, 8 mM putrescine, 1 mM spermidine, 5 mM potassium 
phosphate and 1 mM dithioerythritol (DTE) (Jelenc and Kurland, 1979). 
In vitro transcribed mRNA for the cell-free translation system 
The template DNAs for in vitro transcription were prepared by annealing the 
following oligonucleotides at the complementary sequences (underlined) and filling 
the gaps by PCR. 
Forward oligo: CTCTCTGGTACCGAAATTAATACGACTCACTATAGGGAATT 
CGGGCCCTTGTTAACAATTAAGGAGG. 
Reverse oligo for MFLV: TTTTTTTTTTTTTTTTTTTTTTATACTAGGAACATAG 
TATACCTCCTTAATTGTTAACAAGGGCCCG 
Reverse oligo for MVSN: TTTTTTTTTTTTTTTTTTTTTTAGTTAGAAACCATAG 
TATACCTCCTTAATTGTTAACAAGGGCCCG 
In vitro transcription and purification of mRNAs containing a poly(A) tail were as 
described in (Pavlov and Ehrenberg, 1996). 
DNA oligos used to create plasmids expressing peptides of variable lengths 
DNA sequences of different length, designed were amplified by annealing the 
following oligonucleotides and fill the gaps with PCR. The PCR products were 
subsequently cut with EcoRI and AflII restriction enzymes and cloned into a 
pPOT1AE vector (Tenson et al., 1996). 
Forward oligo for rpmRNAjosa: ATACAATTGCTAGTCTTAAGGAGGTCACAT 
ATGTTC 
Reverse oligo for rpmRNAjosa+LLA: CTAGAGAATTCAGCTAGTTACGCCAG 
AAGTACTAGGAACATATGTGACCTC 
Reverse oligo for rpmRNAjosa+LLASGS: CTAGAGAATTCAGCTAGTTAGCTGCC 
TGACGCCAGAAGTACTAGGAACATATGTGACCTC 
Reverse oligo for rpmRNAjosaMF: CTAGAGAATTCAGCTAGTTAGAACAT 
ATGTGACCTC) 
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Forward oligo for rpmRNAeryt: ATACAATTGCTAGTCTTAAGGAGGTCACAT 
ATGGTT 
Reverse oligo for rpmRNAeryt+LL: CTAGAGAATTCAGCTAGTTACAGAAGAAC 
AAACAAAACCATATGTGACCTC 
Reverse oligo for rpmRNAeryt+LLASG: CTAGAGAATTCAGCTAGTTAGCCTGAC 
GCCAGAAGAACAAACAAAACCATATGTGACCTC 
Reverse oligo for rpmRNAerytMV: CTAGAGAATTCAGCTAGTTAAACCAT 
ATGTGACCTC 
Procedures 
The components of the purified translation system 
Components of the translation system were purified as described in (Tenson et al., 
2003), except for RF1, RF2 and RF3 which were purified as described in (Freistroffer 
et al., 1997), RRF as described in (MacDougall et al., 1997) and peptidyl-tRNA 
hydrolase (PTH) as described in (Dincbas et al., 1999). All experiments were 
performed at 37 °C in polymix buffer with addition of ATP (1 mM), GTP (1 mM) and 
PEP (10 mM). 
Recycling experiments 
The initiation mixture contained ribosomes (0.2 µM, ~50% active), [3H]fMet-
tRNAfMet (5 µM), mRNA (0.5 µM), IF2 (0.5 µM), IF1 (1 µM), IF3 (1 µM) and 
josamycin (2.5 µMn). The recycling mixture contained EF-G (2 µM), EF-Tu (30 
µM), EF-Ts (1 µM), RF2 (2 µM), RF3 (2 µM), RRF (2µM), tRNAbulk (~0.18 mM), 
PPiase (5 µg/ml), MK (3 µg/ml), PK (50 µg/ml), the relevant aminoacyl-tRNA 
synthetases (aaRS) (0.15 Units/µl) (defined in (Ehrenberg et al., 1990)) and amino 
acids (aa) (leucine 300 µM and 100 µM each of the others). Erythromycin (100 µM) 
was also added to the recycling mixture when relevant. 
Both initiation mixture and recycling mixture were pre-incubated for 8 minutes at 
37 °C to allow for formation of ribosomal initiation complexes and ternary 
complexes, respectively. At time zero, the initiation mixture (10 µl) and the recycling 
mixture (10 µl) were mixed and at the specified time points the reactions were 
quenched by adding 155 µl 20% formic acid, and peptide formation were analyzed 
using RP-HPLC as described in (Tenson et al., 2003). Peptidyl-tRNA hydrolase 
(~250 Units (hydrolysed tRNA/s) was added to the reaction mixture 15 s prior to 
quenching to allow detection of the drop-off products on the HPLC in parallel to the 
full-length peptide. 
Measuring the length dependence for josamycin- and erythromycin resistance peptides 
Overnight cultures of cells expressing peptides of different length were grown in 
medium containing 100 µg/ml ampicillin. Cultures were diluted with fresh medium 
containing 100 µg/ml ampicillin, 1 mM IPTG, 75 µg/ml erythromycin or 200 µg/ml 
josamycin and in parallel with medium containing 100 µg/ml ampicillin, 1 mM IPTG 
to the final density of A600 = 0.01. Cells were grown until the optical densities of 
cultures grown in the absence of macrolide reached A600 of c.1. At this point the 
absorbance of the corresponding macrolide containing culture was measured, which is 
equal to the relative resistance because the absorbance of the culture grown without 
macrolide is one. 
 6
Measuring growth with varying josamycin concentration and rpmRNAjosa expression levels 
Overnight cultures of cells expressing rpmRNAjosa (MFLV-peptide) were grown in 
medium containing 100 µg/ml ampicillin. Cultures were diluted to A600 = 0.01 into 
96-well plates with fresh medium containing josamycin and IPTG at different 
concentrations. IPTG concentrations for rpmRNAjosa expressing cells were 0 µM; 
50 µM; 75 µM; 100 µM; 125 µM; 150 µM; 175 µM; 200 µM; 500 µM; 1000 µM. 
Josamycin concentrations were 0 µg/ml; 100 µg/ml; 150 µg/ml; 200 µg/ml; 
250 µg/ml; 300 µg/ml; 500 µg/ml; 1000 µg/ml. The cell cultures were grown 8 hours 
and the absorbance at 600 nm were measured using a TECAN Sunrise instrument. 
Measuring the effect of efflux pump mutants on josamycin sensitivity and resistance 
MG1655 cells and MG1655 TolC mutant cells, expressing rpmRNAeryt (MVLFV-
peptide) or rpmRNAjosa (MFLVLLA-peptide), or possessing empty vector pPOT1 
(Tenson et al., 1996) were grown overnight in 2*YT medium in the presence of 
ampicillin (100 µg/ml) at 37 °C. Overnight cultures were diluted to A600 = 0.01 with 
fresh 2*YT medium containing 100 µg/ml ampicillin, 100 µM IPTG and different 
concentrations of erythromycin and josamycin respectively. Cultures were grown in 
the microtiter plate for 4 hours at 37 °C and A600 was measured using a TECAN 
Sunrise instrument. Expression of rpmRNAjosa encoding MFLVLLA-peptide was 
used instead of the classical MFLV-peptide, because MFVVLLA expression does not 
inhibit bacterial growth. 
RESULTS 
Biochemical characterization of expression of josamycin resistance peptide 
Using a cell-free translation system with purified components from E. coli (Pavlov 
and Ehrenberg, 1996) we translated the rpmRNAjosa encoding fMet-Phe-Leu-Val 
(Vimberg et al., 2004) and a control mRNA encoding fMet-Val-Ser-Asn. The 
ribosomes were pre-incubated with either josamycin or erythromycin and used in 
recycling mode (Pavlov et al., 1997), i.e. each ribosome produced several copies of 
the encoded peptide. In order to probe the dissociation of josamycin we chased it with 
an excess of erythromycin, which competes with josamycin binding but allows 
formation of tetrapeptides (Lovmar et al., 2006; Lovmar et al., 2004). The amounts of 
resistance- and control tetrapeptides produced at different time points are shown in 
Figs. 1A and 1B, respectively. As expected from the previous studies, josamycin 
blocked formation of both tetrapeptides, while erythromycin allowed tetrapeptide 
formation. From the chase experiments it is clear that translation of the rpmRNAjosa 
does not significantly increase the josamycin dissociation rate over translation of the 
control peptide. From these chase experiments the josamycin dissociation rate 
constant could be estimated to 0.01 min-1 which is similar to the previously estimated 
spontaneous dissociation rate constant (Lovmar et al., 2004). 
In parallel to the measurements of tetrapeptide formation we also studied the drop-off 
products formed during translation of rpmRNAjosa (Fig. 1C) or control mRNA (Fig. 
1D). Interestingly, josamycin-containing ribosomes produced much less dipeptidyl-
tRNA when translating the rpmRNAjosa rather than the control peptide. The 
“production” of drop-off products occurs at 0.28 min-1 when josamycin containing 
ribosomes are translating rpmRNAjosa, compared to 2.1 min-1 when translating the 
control mRNA. The reason for this difference is that josamycin inhibits the peptidyl 
transfer to the phenylalanine acceptor much more efficiently than to the valine 
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acceptor (Lovmar et al., 2004). This causes the rpmRNAjosa to block josamycin 
containing ribosomes as stable initiation complexes, while peptidyl transfer and 




FIGURE 1. Biochemical characterization of peptide mediated josamycin resistance.  The amounts 
of produced resistance peptide (MFLV, panel A) and control peptide (MVSN, panel B) are plotted 
against time. Erythromycin (▲) allows formation of both tetra-peptides, while josamycin (●) does not 
allow any tetra-peptide formation. When josamycin dissociates in the chase experiment (■) it is 
replaced by erythromycin which enables tetra-peptide formation. In panels C and D the accumulation 
of dipeptidyl-tRNA drop-off products are plotted against time. The symbols in panels C and D is the 
same as the corresponding experiment in panels A and B. All experiments contain 1 pmol of active 
ribosomes. 
 
Erythromycin resistance is strictly dependent on the length of the encoded 
peptide while josamycin resistance is not 
The biochemical data propose that the mechanism of rpmRNAjosa is different to the 
previously described “bottle-brush” mechanism, and that it instead depends on the 
reduced rate of peptidyl tRNA-drop-off. The prediction is therefore that rpmRNAjosa, 
in contrast to rpmRNAeryt, is insensitive to the length of the encoded peptide. This 
prediction was tested by measuring the resistance activity in vivo of both rpmRNAjosa 
and rpmRNAeryt encoding peptides with varying lengths (Fig. 2). 
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The length of the open reading frames of both rpmRNAs where decreased to two 
codons and increased to seven or ten codons. Bacteria expressing the natural or the 
modified variants of rpmRNAeryt and rpmRNAjosa were grown in the presence and in 
the absence of the corresponding macrolide. The ratios of the optical densities with or 
without the respective macrolide are plotted for these strains in figure 2. The length of 
rpmRNAeryt is crucial for resistance against erythromycin (Fig. 2A), while josamycin 
resistance by rpmRNAjosa is solely dependent on the nature of the second codon and 
independent of the length in accordance with the prediction (Fig. 2B). 
 
 
FIGURE 2. The degree of erythromycin resistance is strictly dependent on resistance peptide 
length but not peptide-mediated josamycin resistance. Resistance is given as the ratio of bacterial 
growth as measured by optical density of resistance peptide expressing cells in the presence of (A) 
erythromycin (75 µg/ml) or (B) josamycin (200 µg/ml), respectively, and bacterial growth in the 
absence of the macrolide for the indicated peptide sequences. 
Expression of rpmRNAjosa “quarantines” ribosomes with josamycin and reduces 
peptidyl-tRNA drop-off  
The biochemical experiments described above in combination with previous studies 
provide kinetic constants that allow modeling of the direct effects of expression of 
rpmRNAjosa (Table 1 in Appendix). We adapted our previously developed model of 
peptide-mediated erythromycin resistance to josamycin as illustrated in Fig. 3A (see 
Appendix for details), but because expression of rpmRNAjosa does not promote 
dissociation of josamycin it can not increase protein synthesis directly. 
Instead, expression of rpmRNAjosa “quarantines” josamycin containing ribosomes in 
form of initiation complexes encoded with rpmRNAjosa. The direct effect of this 
“quarantine” is that the amount of peptidyl-tRNA drop-off is reduced (Fig. 3B), and 
thereby there is a reduced risk of peptidyl-tRNA hydrolase (Pth) saturation leading to 
depletion of tRNA pools. The selectivity of the “quarantine” mechanism allows a 
large fraction of the josamycin-free ribosomes to continue translating cellular 
mRNAs, despite the competition with high concentration of rpmRNAjosa. 
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FIGURE 3. Modeling the “quarantine” mechanism. Panel A show a schematic of the model. A 
josamycin-carrying ribosome stalls on a rpmRNAjosa (right) or on a protein mRNA (left) which results 
in drop-off of di-peptidyl-tRNA while josamycin stays bound on the ribosome. A drug-free ribosome 
completes both protein and resistance peptides synthesis (bottom). The uppermost part illustrates influx 
and efflux of josamycin in the cell (gram-negative bacterium). Panel B shows how the amount of 
peptidyl-tRNA drop-off is decreased by expression of rpmRNAjosa. 
 
mRNA limitation might account for the observed resistance peptide action in 
vivo 
In addition to the “quarantine” effects described above will expression of rpmRNAjosa 
lead to an increase in the total number of ribosome binding sites (RBS) because of the 
small size of rpmRNAjosa (assuming a fixed capacity of the RNA polymerases). This 
increase may be important because josamycin-containing ribosomes block RBS, 
eventually leading to mRNA depletion. Further, an increased concentration of RBS 
may lead to more rapid initiation and thus josamycin will have a smaller time window 
for binding the josamycin-free ribosomes. It is therefore possible that expression of 
rpmRNAjosa indirectly can decrease the fraction of ribosomes that contains josamycin. 
We modeled the quantitative effects of rpmRNAjosa expression by focusing on mRNA 
supply. Especially, the degradation of a protein mRNA with a stalled josamycin-
ribosome in the 5’ end was modeled in detail. As previously, the model also described 
both synthesis and degradation of both mRNA and rpmRNAjosa as well as dynamics 
of the antibiotic exchange over the inner and outer cell membranes. In addition, the 
model accounts for the dilution of all compounds due to cell growth. Using this model 
we predicted the growth at 8 hours after expression of rpmRNAjosa at different levels 
in the presence of different concentrations of josamycin (Fig. 4A). It should be 
pointed out that modeled resistance by mRNA limitation crucially depends on a much 
slower drop-off rate of the resistance di-peptidyl-tRNA than of other dipeptidyl-
tRNAs. 
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Peptide-mediated josamycin resistance demonstrated by cell population growth 
The expression of resistance peptide mRNA coding for peptide MFLV was under tac 
promoter control on a multi-copy plasmid and the expression level could therefore be 
varied by varying the concentration of IPTG. Cell growth at different IPTG and 
josamycin concentrations was detected by optical density at 600 nm after 8 hours 
following the addition of josamycin to the growth medium (Fig. 4B). The results 




FIGURE 4. Comparison between modeled and in vivo peptide-mediated josamycin resistance. A. 
Simulated growth (defined as how many times the cell volume has increased during the first 8 hours 
after the addition of josamycin) plotted against the rate of resistance peptide mRNA synthesis for 
different concentrations of josamycin. B. Optical density (600 nm) measured 8 hours after the addition 
of josamycin plotted against the concentration of IPTG. 
 
Peptides mediate macrolide resistance in wild-type E. coli cells but not in a pump 
mutant 
It has previously been predicted that the resistance peptide mechanism requires rapid 
equilibration between the intracellular macrolide concentration and the concentration 
in the surrounding media. It was further proposed that this could be accomplished by 
a naturally occurring drug-efflux system (Lovmar et al., 2006). Therefore, the 
resistance models for josamycin and erythromycin were used with the more detailed 
description of the flows of the antibiotic over the cell membranes described here to 
study resistance with and without antibiotic efflux pumps (see Appendix). As 
expected, removal of the antibiotic efflux pump system makes the cells hyper-
sensitive to both erythromycin and josamycin, but in addition the model predicts that 
the peptide mediated resistance disappears (Fig. 5). 
To validate these results we studied growth in bacterial populations of both wild-type 
E. coli cells and E. coli cells (TolC) with a mutated efflux pump system, containing a 
multi-copy vector expressing rpmRNA or containing a control vector. Expression of 
rpmRNA was under the control of a tac promoter induced by 100 µM of IPTG which 
corresponds to maximal resistance as observed in Fig. 4B for josamycin and as 
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previously reported for erythromycin (Fig. 3C in (Lovmar et al., 2006)). Bacterial 
mass was monitored as absorbance at 600 nm 4 hours after addition of varying 
concentrations of erythromycin or josamycin to the growth medium. Both the 




FIGURE 5. Modeled peptide-mediated resistance with but not without pumps. Cell growth is 
given as volume expansion (defined as how many times the cell volume has increased) 4 hours 
following the introduction of the indicated macrolide concentrations in the growth medium in the 
model, with resistance peptide mRNA (rpmRNA) expression (solid line), without rpmRNA expression 
(broken line). The wild-type (A and C) is modelled with pumps in the inner membrane but not the TolC 
mutant (B and D). The rate constant of rpmRNA synthesis was 2 nMs-1. 
 
DISCUSSION 
Although the clinical relevance of peptide mediated resistance is not clear, it is still an 
interesting phenomenon that reveals more information about the mechanisms by 
which macrolide antibiotics inhibit cell growth. It was previously shown that 
rpmRNAeryt works through a “bottle-brush” mechanism, i.e. expression of a resistance 
peptide “cleans” the nascent peptide exit tunnel from erythromycin (Lovmar et al., 
2006). Both the amino acid sequence and the length of the encoded peptide are 
essential parameters for the “bottle-brush” mechanism to work (Tenson et al., 1997) 
and, at least in the erythromycin case, the drug seems to be stoichiometrically 
expelled at the termination step (Lovmar et al., 2006). The “bottle-brush” mechanism 
has been proposed to be general for all classes of macrolides, albeit with modulated 
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sequence specificity (Vimberg et al., 2004). The 16-membered macrolide josamycin 
has been shown to in most cases only allow a single peptidyl transfer reaction to occur 
before the peptidyl-tRNA dissociates (Tenson et al., 2003) and it was therefore 
surprising that rpmRNAjosa expressing tetra- or pentameric peptides could be selected 
(Vimberg et al., 2004). The present study clearly shows that the “bottle-brush” 
mechanism is not responsible for the peptide-mediated resistance against josamycin; 
instead we propose a “quarantine” mechanism to be responsible for the observed 
resistance. 
 
FIGURE 6. Peptide-mediated resistance in vivo in the wild-type but not in a pump mutant. 
Absorbance (600 nm) of wild-type (A and C) and TolC (pump) mutant (B and D) Escherichia coli cells 
with a resistance peptide expressing vector (rpmRNA) or a control vector (no rpmRNA) after 4 hours 
of growth following addition of the indicated macrolide concentrations. 
 
Comparison between rpmRNAjosa and rpmRNAeryt 
Expression of rpmRNAeryt increase the erythromycin dissociation rate constant by an 
order of magnitude in concordance with the suggested “bottle-brush” mechanism 
(Lovmar et al., 2006). In contrast, expression of rpmRNAjosa did not change the 
dissociation rate constant of josamycin (Figs. 1A and 1B), but instead it slowed down 
the rate of peptidyl-tRNA drop-off by an order of magnitude (Fig. 1C) compared to 
the control mRNA (Fig. 1D). Peptidyl-tRNA drop-off is not an issue during 
rpmRNAeryt expression, because erythromycin leaves enough space in the tunnel to 
allow translation of the complete penta-peptide (Tenson et al., 2003). The present 
results on rpmRNAjosa suggest that it is never completely translated and thus the 
resistance mechanism for josamycin should be independent of the length of the 
encoded peptide. This is in contrast to the results on erythromycin resistance where 
 13
the peptide length was shown to be crucial for erythromycin resistance both in living 
cells (Tenson et al., 1997) and in a cell-free translation system (Lovmar et al., 2006). 
The prediction on the length dependence was tested by expressing peptides with 
lengths varying between 2 and 10 amino acids with sequences according to the 
consensus for rpmRNAeryt and rpmRNAjosa respectively (Vimberg et al., 2004). The 
resistance activity of rpmRNAeryt was shown to be strongly peptide length dependent 
in agreement with previous experiments (Fig. 2A). In contrast to rpmRNAeryt, but in 
agreement with the prediction, is the activity of rpmRNAjosa not sensitive to the length 
of the expressed peptides (Fig. 2B). The reason that most of the selected rpmRNAjosa 
encoded pentamers was simply that the mini-gene library encoded pentamers with 
randomized sequences (Vimberg et al., 2004). In conclusion, it seems that the only 
important feature of rpmRNAjosa appears to be that it encodes a phenylalanine or 
tyrosine in the second position (Vimberg et al., 2004). 
Josamycin resistance through “quarantining” josamycin containing ribosomes 
At first it might be hard to imagine how expression of an mRNA encoding 
phenylalanine or tyrosine in the second position can render resistance to josamycin. 
The key to understand the mechanism can be found in the slow peptidyl-tRNA drop-
off rate when expressing rpmRNAjosa compared to other mRNAs. Because 
rpmRNAjosa can not expel josamycin from the ribosomes, it instead works by 
minimizing the negative effects of josamycin bound ribosomes through 
“quarantining” them on rpmRNAjosa. The “quarantine” can be understood as follows; 
ribosomes containing josamycin will be stuck on the rpmRNAjosa ten times longer 
than on other mRNAs, while ribosomes without josamycin recycles much faster on 
the short rpmRNAjosa than on other mRNAs. These combined effects lead to an 
enrichment of josamycin containing ribosomes on rpmRNAjosa, while the ribosomes 
without josamycin are enriched on protein mRNAs where they continue synthesizing 
proteins with less interference from ribosomes containing josamycin. A requirement 
for the “quarantine” to work is a very slow exchange of josamycin between different 
ribosomes, so that most of the ribosomes keep their identity as “josamycin-
containing” or “josamycin-free” at least within the time range of ribosome recycling. 
The average recycling time for josamycin containing ribosomes on rpmRNAjosa is 4 
minutes, and josamycin stays bound to a ribosome for an average time of 1.5 hours 
(Lovmar et al., 2004) which clearly fulfils this requirement. It should further be noted 
that only very few natural mRNAs encodes phenylalanine or tyrosine in the second 
position, thus over-expression of rpmRNAjosa will have a strong impact on the fraction 
of mRNAs encoding these amino acids in the second position resulting in the 
“quarantine” effect. 
The apparent explanation to why “quarantining” josamycin containing ribosomes on 
rpmRNAjosa confer resistance is that it reduces the demand of a component necessary 
for translation or recycling of ribosomes, thus allowing the josamycin-free ribosomes 
to continue translation at a close to normal rate. For example, the josamycin induced 
peptidyl-tRNA drop-off may accumulate peptidyl-tRNA in the cells, thus the pools of 
free tRNA isoacceptors will be depleted when the capacity of peptidyl-tRNA 
hydrolase (Pth) is saturated (Heurgue-Hamard et al., 2000; Heurgue-Hamard et al., 
1996; Tenson et al., 1999). There are also some unpublished results indicating that 
depletion of tRNA pools contributes to the josamycin toxicity, i.e. suppression of Pth 
expression makes cells hyper-sensitive to josamycin, while a slight over-expression of 
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Pth leads to low-level resistance (Tenson T, unpublished results). However, a fraction 
of ribosomes containing josamycin might deplete other components of the translation 
machinery before the pools of tRNAs, and therefore the “quarantine” mechanism 
might render resistance also without saturated Pth. 
Resistance can occur through avoiding depletion of mRNA pools by 
“quarantining” the josamycin containing ribosomes 
A bacterial population containing a plasmid-borne rpmRNAjosa under control of the 
tac promoter was grown in media with varying IPTG concentrations to regulate the 
level of resistance peptide expression combined with varying josamycin 
concentrations. The increase in bacterial mass after 8 hours of growth after induction 
was monitored by absorbance as a function of the IPTG concentration in the medium. 
To test whether it is possible to reproduce the in vivo effects of rpmRNAjosa 
expression without considering the tRNA pools we adapted the model previously 
developed for peptide-mediated erythromycin resistance (Lovmar et al., 2006) to the 
parameter values for josamycin. The mathematical model was changed to account for 
josamycin resistance by modeling a delayed di-peptidyl-tRNA drop-off from a 
josamycin-carrying ribosome expressing the resistance peptide while the antibiotic 
stays bound to the ribosome. By assuming a low rate of degradation of mRNAs with a 
stalled ribosome in the 5’ end (Joyce and Dreyfus, 1998), we obtained growth curves 
mimicking the in vivo observed growth curves (Fig. 4). 
The importance of the modeled mRNA degradation can be understood as follows. The 
concentration of protein mRNAs in a cell is much lower than the concentration of 
ribosomes. Thus, only a small fraction of drug-inhibited ribosomes, stalled on mRNA 
can potentially severely slow down protein synthesis. When protein mRNAs with a 
stalled ribosome is slowly degraded, the free concentration of protein mRNAs on 
which a ribosome can initiate translation drastically declines (not shown). The delay 
at initiation increases the impact of josamycin since 50S subunits exist in a 
josamycin-susceptible state a longer period of time. The result is a larger fraction of 
non-translating and josamycin bound 50S subunits as well as a larger fraction of 
ribosomes stalled on mRNAs (not shown), which contributes to further lowering the 
concentration of free mRNAs. The feedback between the low concentration of free 
protein mRNAs and increased concentration of inactivated 50S subunits makes the 
growth rate severely reduced at a certain antibiotic concentration. When rpmRNAjosa 
is present in the cell, josamycin-infected ribosomes are “quarantined” on the 
rpmRNAjosa. The free concentration of protein mRNAs boosts and ribosomes can 
initiate translation at a higher rate and escapes josamycin to a larger extent. The 
concentration of josamycin-free translating ribosomes increases, thereby raising the 
cell growth rate. 
Peptide-mediated macrolide resistance requires a fast outflow rate of the 
antibiotic over the cell membrane 
Previous modeling of peptide-mediated erythromycin resistance predicted the 
requirement of a fast outflow rate of the drug over the cell membrane to confer 
resistance against a macrolide with the binding kinetics of erythromycin. In gram-
positive bacteria the cell wall does not offer much resistance to diffusion of small 
molecules and the rate of exchange of macrolides over the cell membrane is expected 
to be rapid, but previous in vivo experiments were done with gram-negative E. coli 
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cells (Lovmar et al., 2006; Tenson and Mankin, 2001). In gram-negatives the outer 
membrane confers an efficient barrier of permeation and the entrance rate of 
antibiotics are expected to be slow. Gram-negative bacteria also harbor broad-specific 
multidrug pumps in their inner membrane, which together with the outer membrane 
may explain the “intrinsic” resistance that gram-negatives exhibit (Li and Nikaido, 
2004). The AcrAB-TolC pump system is the major contributor of erythromycin 
resistance (Ma et al., 1995). The efflux pump, AcrB, resides in the inner membrane 
and seems to form a complex with a periplasmic protein, AcrA, which links or fuses 
the inner and outer membrane. Then, the channel, TolC, most likely provides the exit 
path back to the medium for drugs, solvents, detergents etc. (Zgurskaya and Nikaido, 
1999). Very little is known about the capacity of the AcrAB-TolC pump system in 
general and for erythromycin and josamycin in particular. 
To validate the model prediction we grew wild-type and TolC mutant E.coli cells 
containing either a resistance peptide expressing plasmid or a control plasmid in the 
presence of varying concentrations of erythromycin in the growth medium. 
Corresponding experiments were done with varying concentrations of josamycin in 
the growth medium. Growth was recorded by absorbance after 4 hours following 
induction and was registered as a function of the macrolide concentration and at an 
IPTG concentration corresponding to maximal resistance in the wild-type as seen in 
previous in vivo growth experiments. The in vivo experiments confirmed the model 
prediction for erythromycin. No resistance was observed in the TolC mutant (Fig. 
6B). The in vivo experiments also showed no josamycin resistance in the TolC mutant 
(Fig. 6D), which resistance mechanism clearly differs from that of erythromycin. 
The TolC mutant is as sensitive to macrolides as the AcrB mutant, why we do not 
expect the pump to function in the TolC mutant. The TolC mutant was therefore 
modeled without pumps. The models reproduced the in vivo growth curves. 
Resistance was substantially reduced in the TolC mutant for both erythromycin and 
josamycin (Fig. 5B and D). In the case of erythromycin, where expression of a 
resistance peptide actively removes a bound drug molecule from the ribosome 
(Lovmar et al., 2006) resistance is a consequence of an increased dissociation of 
erythromycin. Such a resistance mechanism is sensitive to the fate of the drug 
molecule after ejection. It can either leave the cell (by passive diffusion over the 
membrane or be actively transported by efflux pumps) or it re-associates to another 
ribosome. The value of the rate constant for leaving the cell in relation to the 
association rate constant of the antibiotic becomes very important. The requirement of 
a fast outflow rate for erythromycin resistance mechanism to work is then rather a 
requirement of a fast enough rate constant of leaving the cell once inside compared to 
the association rate constant to a ribosome of the antibiotic. We argue that the AcrAB-
TolC efflux pump system provide the required high efflux rate. Thus, a macrolide 
with a lower association rate constant but with the same or lower dissociation rate 
constant of erythromycin is predicted by the model to confer resistance also in the 
TolC mutant, if resistance is mediated by active removal of the drug by the same rate 
as of erythromycin. For instance, a macrolide with an association rate constant of 
josamycin but with a dissociation rate constant of erythromycin confer resistance in 
the simulated TolC mutant (not shown), while a macrolide with an 100 times higher 
association rate constant than erythromycin gives almost no resistance in the wild-
type (not shown).  
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In the case of josamycin, the absence of resistance in the modelled TolC mutant is 
also a consequence of a too high association rate constant compared to the rate 
constant of efflux of the drug. This creates a sharp boost of the intracellular 
concentration of josamycin within a very narrow interval of concentrations of the 
antibiotic in the medium accompanied by a dramatic reduction of the growth rate and 
leaves the resistance mechanism ineffective since it cannot remove josamycin once 
bound to the ribosomes. For example, if the association rate constant is increased 100 
times, resistance is greatly reduced even in the wild-type. 
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Model of peptide-mediated resistance against josamycin 
Below is a detailed description of the different states of ribosomes in the model. 
 
The model is described by the following system of differential equations, 
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A large ribosomal subunit can exist in eight different states. The 50S subunit may be 
free without ([50S]) or with ([50SM]) a bound macrolide. It may be a part of a 
ribosome ready to translate the first codons of a protein mRNA without ([R2]) or with 
([R2M]) a bound macrolide or it may have translated the first codons and become 
temporarily immune to the drug ([R´2]). If the mRNA starts to degrade before di-
peptidyl-tRNA drop-off or spontaneous dissociation of the macrolide it ends up in 
state ([R´2M]). State [R´2M] provides a more detailed description of the fate of 
ribosomes with a degrading mRNA but was not included in the erythromycin model 
(Lovmar et al., 2006), where q1>>kd3. However, the same approximations as in the 
erythromycin model are also valid in the josamycin model although they are less 
intuitive. The subunit may also be a part of a ribosome ready to translate a resistance 
peptide mRNA (rpmRNA) without ([R1]) or with ([R1M]) a bound antibiotic 
molecule. The rate constant of association and spontaneous dissociation of the 
antibiotic is q and q1, respectively. Association of the ribosomal subunits occurs with 
rate constant ka times the free concentration of protein mRNAs ([mRNAfree]) and free 
rpmRNA ([rpmRNAfree]). The first rounds of translation when the antibiotic can attack 
a ribosome (which is approximately the length of a resistance peptide) occur with rate 
k1. The rate for completing synthesis of a protein beyond translation of the first 
codons is k3, the drop-off rate of an antibiotic-carrying, stalled ribosome on a protein 
mRNA is k4 and the rate of drop-off of resistance di-peptidyl-tRNA is k2. The system 
of equations also contains differential equations describing the change of the total 
concentration of the macrolide in the cell ([mtot]) and of the total concentration of 
protein mRNAs ([mRNAtot]) and rpmRNA ([rpmRNAtot]), respectively. The macrolide 
passively diffuses over the outer membrane with rate constant cI and over the inner 
membrane with rate constant cII. The antibiotic is actively transported out of the cell 
by pumps (either from the cytoplasm or the periplasm) with rate constant cIII. The free 
intracellular (cytoplasmic) concentration of the macrolide is defined by 
'
1 2 2[ ] [ ] [50 ] [ ] [ ] [ ]free totm m SM R M R M R M= − − − − . The macrolide concentration in the 
periplasm is assumed to be quickly equilibrated. The synthesis rate of rpmRNA is ks1 
and active degradation of free rpmRNA occurs with rate constant kd1. The 
corresponding rates of synthesis and degradation of protein mRNAs are denoted ks2 
and kd2, respectively. It is also assumed that a stalled, macrolide-carrying ribosome on 
the 5´ end of an mRNA does not fully protect the mRNA from degradation, but it is 
degraded by a low rate constant, kd3. The free concentration of rpmRNA and protein 
mRNAs is defined by 1 1[ ] [ ] [ ] [ ]free totrpmRNA rpmRNA R R M= − −  and 
'
2 2 2[ ] [ ] [ ] [ ] [ ]free totmRNA mRNA R R M R M= − − − , respectively. The system expands by 





[ ] ,ev Rμ
ρ
⋅
=   [A2] 
where ve is the average elongation rate of an uninhibited ribosome and ρ0 is the 
concentration of amino acids incorporated in proteins. The total concentration of 50S 
subunits ([50Stot]) is kept constant and new 50S subunits are thus synthesised by rate 
μ·[50Stot] and the free concentration of 50S subunits varies according to 
' '
1 1 2 2 2 2[50 ] [50 ] [50 ] [ ] [ ] [ ] [ ] [ ] [ ]totS S SM R R M R R R M R M= − − − − − − − . 
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The system was solved numerically by Euler’s method (Heath, 1997). Cell growth 
was calculated for the first 4 (Fig. 5) or 8 (Fig. 3A) hours after introduction of a 
certain macrolide concentration in the growth medium, [mm] by 
 ,dtt t dtV V e
μ⋅
−= ⋅   [A3] 
where dt is a small time-step and Vt-dt and Vt is the volume prior and after time-step dt, 
respectively. Prior to macrolide exposure, the system resided at steady state for a 
certain synthesis rate of resistance peptide mRNA. The used program software was 
MATLAB 6.5 (The MathWorks, Inc., Natick, Massachusetts, U.S.A.). 
Peptide-mediated resistance against erythromycin 
The previously developed model for peptide-mediated erythromycin resistance was 
used for Fig. 5 (A and B) (see Supplementary material online of (Lovmar et al., 
2006)) but with the more detailed description of the flows over the inner membrane 
described in the differential equation for mtot in eq. [A1]. The extension of the model 
account for the difference in macrolide concentrations where cell growth are affected 
in the wild-type and in the TolC mutant.  
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Appendix table 1. Definitions and values of used parameters. 
 Description Value Reference 
ka 
association rate constant of ribosomal subunits at initiation 
of translation 2·10
6 M-1s-1 (1) 
k1 
rate constant for translation of the first codons when the 
ribosome is susceptible for the antibiotic or for translation 
of a resistance peptide by a drug-free ribosome 
1 s-1 (2) 
k2 
rate constant for translation of a resistance peptide by an 
erythromycin-infected ribosome 
0.008 s-1 (josa) 
0.1 s-1 (eryt) Present study and (3) 
k3 
rate constant for translation beyond the first codons of a 
protein mRNA and translation termination 0.03 s
-1 (2) 
k4 
drop-off rate constant of peptidyl-tRNA from a stalled 
ribosome on a protein mRNA 0.06 s
-1 Lovmar, unpublished results 
q association rate constant of erythromycin 3.3·10
4 M-1s-1 (josa) 
106 M-1s-1 (eryt) (4) 
q1 dissociation rate constant of erythromycin 
1.8·10-4 s-1 (josa) 
0.01 s-1 (eryt) (4) 
ks1 synthesis rate of resistance peptide mRNA (rpmRNA) 
0 - 10 nMs-1 in Fig. 3A
2 nMs-1 in Figs. 5-6  
kd1 degradation rate constant of free rpmRNA 8.3·10-3 s-1  
ks2max 
maximal synthesis rate of protein mRNAs (in the absence 
of rpmRNA) 8.3·10
-9 Ms-1 (5) 
ks2 synthesis rate of protein mRNAs ks2max-0.05·ks1 Ms-1  
kd2 degradation rate constant of free protein mRNAs 8.3·10-3 s-1 (6) 
kd3 
degradation rate constant of protein mRNAs with a drug-
inhibited, stalled ribosome 4.2·10
-4 s-1  
cI rate constant of passive diffusion over outer cell membrane 2·10-3 s-1  
cII rate constant of passive diffusion over inner cell membrane 0.1 s-1 (7) 
cIII rate constant of active transport by pump 0.9 s-1  
ve elongation rate of an uninhibited ribosome 20 s-1 (2) 
ρ0 concentration of amino acids in proteins 2 M (2) 
[50Stot] total concentration of 50S ribosomal subunits 4·10-5 M (2) 
[mm] concentration of macrolide in the growth medium 
10-7 – 1.5·10-3 M  
(see figures)  
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SUMMARY
We demonstrated with mathematical modelling that decreasing drug efflux pump 
efficiency eliminates differential effects of resistance mutations in strong drug targets. 
The predictions were tested with erythromycin, a clinically important macrolide 
antibiotic targeting the ribosome. We constructed the erythromycin resistant 
mutations L4(Lys63Glu), L4(Δ63-64) and L22(Δ82-84) in ribosomal proteins L4 and 
L22. In biochemical experiments we showed that all mutations decreased the 
erythromycin association rate constant 100-fold. We found in bacterial growth 
experiments that all target mutations similarly increased erythromycin resistance for 
E. coli cells growing in a tolC efflux pump proficient, but not in a tolC deficient 
background, which confirmed the theoretical predictions. Our findings suggest likely 
evolutionary pathways for the emergence of drug resistance and are therefore relevant 
to the choice of clinical strategies to slow down drug resistance evolution. The 
coupling between drug efflux and target binding is general, and cases other than 
antibiotic resistance are discussed. 
INTRODUCTION
The increasing antibiotic resistance among pathogens creates ever increasing 
problems in the clinical treatments of bacterial disease. Drug resistance may arise due 
to various combinations of three principally different mechanisms: modifications of 
drug target sites, chemical modifications of drugs and increased drug efflux from the 
bacterial cells. To study the combined effects of drug efflux efficiency and target 
mutations we first modeled in a general fashion their kinetic coupling in growing 
bacteria, and found that pump efflux deficiency may completely mask the differential
effects of target resistance mutations. For experimental testing of these predictions, 
we used Escherichia coli and focused on combinations of macrolide resistance due to 
ribosomal protein mutations and alterations in the AcrAB-TolC drug efflux pump 
system (Lomovskaya et al., 2007).
Macrolides constitute a growing set of clinically useful antibiotics (Omura, 
2002), with the first generation member erythromycin in extensive clinical use for 
more than fifty years. The structural mode of erythromycin binding to the entrance of 
the peptide exit tunnel of the large (50S) ribosomal subunit (Fig. 1A) has been 
characterized at atomic resolution with X-ray crystallography (Schlunzen et al., 2001; 
Tu et al., 2005). Although erythromycin and other macrolides bind in the vicinity of 
the peptidyl-transferase center, they do not inhibit peptide bond formation per se, but 
block entrance of the nascent chain to the peptide exit tunnel. This allows for the 
synthesis of short nascent peptides with a maximal length regulated by the space 
available for peptide growth between the macrolide and the peptidyl-transferase 
center (Tenson et al., 2003). In the case of erythromycin, ribosome stalling occurs for 
nascent peptide lengths between six and eight amino acids (Tenson et al., 2003), and 
the stalled ribosome complex may eventually be resolved by peptidyl-tRNA drop-off 
and recycling of the ribosome to a new round of initiation (Karimi et al., 1999). 
When, in contrast, erythromycin dissociation precedes drop-off, protein synthesis is 
rapidly resumed, now with the ribosome refractory to drug re-binding until 
termination and release of the full length protein (Lovmar et al., 2004; Tenson et al., 
2003), in correspondence with earlier E. coli cell growth data showing that 
erythromycin can only inhibit peptide elongation at or just after initiation of protein 
synthesis (Andersson and Kurland, 1987). These idiosyncratic features of 
erythromycin action require detailed modeling for prediction of the drug effects on 
bacterial growth. The present modeling work is based on previous results, where we 
successfully predicted the effects of cis-acting resistance peptides on bacterial growth 
in the presence of erythromycin (Lovmar et al., 2006).
Mutations in ribosomal RNA and ribosomal proteins conferring reduced 
macrolide susceptibility (Weisblum, 1995; Vester and Douthwaite, 2001) were first 
identified for proteins L4 and L22 in the 50S subunit of the E. coli ribosome (Apirion, 
1967; Wittmann et al., 1973). These mutations, eventually recognized as a lysine to 
glutamic acid substitution at position 63 of L4 and a deletion of methionine, lysine 
and arginine at positions 82-84 of L22 (Fig. 1B) (Chittum and Champney, 1994), will 
here be referred to as L4(Lys63Glu) and L22(Δ82-84), respectively. While the 
equilibrium binding affinity of erythromycin to the L4 protein seemed greatly reduced 
by the mutation, the erythromycin affinity to the L22 mutant appeared unaltered by 
the three amino acids deletion (Wittmann et al., 1973). These observations suggested 
that the drug resistance conferred by the L4 mutation is due to strongly reduced 
binding affinity, but left unexplained the resistance conferred by the L22 mutation. 
Since, however, these previous observations were qualitative, we have now quantified 
the kinetic effects of the classical mutations L4 and L22 mutations with the help of 
our cell free system for protein synthesis with in vivo like properties (Lovmar et al., 
2004; Pavlov and Ehrenberg, 1996), and used these observations as input data for 
detailed growth modeling.
The theoretical predictions were subsequently tested in experiments with 
growing E. coli cells containing combinations of ribosome and acrAB-tolC mutations. 
The message from the experiments was strikingly clear: the L4 and L22 mutations 
conferred reduced erythromycin susceptibility only in combination with acrAB-tolC
proficiency and not in combination with acrAB-tolC deficiency, perfectly in line with 
our hypothesis. In order to get quantitative correspondence between modeling and 
experiments not only for the L22, but also for the L4, mutated ribosomes, we 
uniformly decreased the rate constants for erythromycin dissociation from all 
ribosomal phenotypes.
The novel finding here that reduced affinity of antibiotic drugs to strong 
intracellular targets leads to decreased drug sensitivity only in the presence of 
efficient drug efflux pumps is important. It suggests that evolution of drug resistance 
by target mutations will be greatly slowed down when combined with pump efflux 
inhibition and greatly accelerated when combined with pump efflux activation. It
therefore provides a new angle to the evolution of drug resistance and further 
emphasizes the paramount importance of combining inhibition of intracellular target 
function with inhibition of drug efflux efficiency (Lomovskaya et al., 2007).
RESULTS
Mathematical modeling of the interplay between drug efflux pumps and target 
resistance mutations
To clarify the kinetic interactions between drug efflux pumps and target resistance 
mutations in pathogens, we formulated a general mathematical model for cases in 
which there is a well defined relation between bacterial growth-inhibition and the 
fraction of drug-bound targets, with the ribosome as a typical example
(Supplementary on line material). According to this model the relative extent –Δµ/µ0
of growth reduction by the drug at the onset of growth inhibition can be written as
(Supplementary on line material):
 
















Membrane transport in to and out from the cytoplasm can be approximated by first 
order rate constants kin and kout, respectively. The parameters µ and µ0 are the growth 
rates in the presence and absence of the drug, respectively and the total intracellular 
target concentration is [T0]. The external drug concentration is [Aext], and the 
intracellular rate constants for drug dissociation from and drug association to the 
target are kd and ka, respectively. Two special cases may serve to illustrate the 
meaning of Eq. 1. When the left term in the denominator is much larger than the right 
term, Eq. 1 is approximated by
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In this limit, the free concentration, [Af]=[Aext]∙kin/(µ0+kout), of drug inside the cell 
depends neither on target binding parameters (ka, kd) nor on target concentration [T0]. 
This limit is reached when the target is weak, i.e. with low affinity to the drug or 
present at a very low concentration. It is also reached for strong targets, provided that 
the drug efflux efficiency, kout/kin, is sufficiently large. In this limit, changes in the 
binding kinetics by target resistance mutations have maximal impact on growth 
inhibition by the drug (Fig. 2). From Eq. 2 it also follows that if kd<<µ0 it is only 
changes in the association rate constant ka that modifies growth rate (Fig. 2A), while 
if kd>>µ0 it is changes in the equilibrium dissociation constant Kd (=kd/ka) that alter 
the growth rate (Fig. 2B).
When, instead, the right term in the denominator of Eq. 1 is much larger than 
the left term, Eq. 1 is approximated by
 









In this remarkable limit, changes in the kinetic parameters ka and kd due to target 
mutations have no impact on growth inhibition by the drug. This limit is reached for 
strong targets, i.e. those with high affinity to the drug and high concentration, 
provided that the drug efflux efficiency, kout/kin, is not too high (Fig. 2). Here, 
virtually every drug molecule that enters the cell becomes target bound.
From this analysis follows that a drug efflux deficient pathogen with a strong 
antibiotic target will be subjected to growth inhibition according to the limit in Eq. 3, 
and thus be insensitive to target mutations. However, when the same pathogen is drug 
efflux proficient, it will be subjected to growth inhibition according to the limit in Eq. 
2, and thus be maximally sensitive to target mutations. This means, apart from the 
well known fact that efflux pump deficiency increases the drug sensitivity of 
pathogens, that low drug efflux efficiency may completely mask the effects of a large 
set of target resistance mutations that would give a clear fitness advantage at high 
drug efflux efficiency. This prediction by theory is relevant to the evolution of drug 
resistance among pathogens and may be important also in other contexts of interaction 
between efflux pumps and intracellular drug binding sites (see Discussion). To test 
this prediction, we studied the effects of drug efflux pump efficiency and target 
mutations on the growth inhibitory effect of erythromycin, a macrolide antibiotic with 
the ribosome as its strong target and previously characterized resistance mutations in 
ribosomal proteins.
Kinetics of erythromycin binding to wild type and mutant ribosomes
To study the mechanisms of erythromycin resistance conferred by the ribosomal 
protein mutations L22(Δ82-84) and L4(Lys63Glu) (Apirion, 1967; Chittum and 
Champney, 1994; Wittmann et al., 1973), these alterations were engineered into the E. 
coli MG1655 strain. By sequencing, we also identified L4(Δ63-64) as a previously 
unknown erythromycin resistant mutant. In the absence of erythromycin, in a rich LB 
medium at 37 °C, the L22(Δ82-84), L4(Lys63Glu) and L4(Δ63-64) strains had 
doubling times between 42 and 50 min, while the isogenic wild type MG1655 strain
had a doubling time of 29 min. We prepared ribosomes at high activity and purity
from these four strains to study the kinetics of their binding to 14C-labelled 
erythromycin with nitrocellulose filtration; all results are summarized in Table 1.
Rate constants for erythromycin dissociation from wild-type and mutant ribosomes
Dissociation rate constants for erythromycin in complex with wild-type and mutant 
ribosomes were obtained from chase experiments. Here, the different ribosome types
were initially equilibrated with 14C-labelled erythromycin, which was subsequently 
chased with an excess of unlabeled erythromycin. The remaining fractions of
ribosome bound 14C-labelled erythromycin were estimated by nitrocellulose filtration 
at varying incubation times, and the results are shown in Fig. 3. In the wild type case, 
the dissociation rate constant (kd) was estimated as 0.013 s-1, in line with a previous 
estimate obtained with a different method (Lovmar et al., 2004). In the L22 case, the 
dissociation rate constant was estimated as 0.0011 s-1, a value much smaller than the 
kd-value in the wild type case. In the L4 cases, the dissociation rate constants were 
slightly larger than in the wild type case, i.e. 0.018 s-1 for the L4(Lys63Glu) and 
0.029 s-1 for the L4(Δ63-64) mutant.
Rate constants for erythromycin association to wild-type and L22(Δ82-84) ribosomes
The association rate constants for complex formation between erythromycin and wild 
type or L22(Δ82-84) ribosomes were estimated as 1.0 µM-1s-1 (Fig. 4A) or 0.019
µM-1s-1 (Fig. 4B), respectively. In these experiments the ribosomes were mixed with 
14C-labelled erythromycin at time zero of the incubation and the fractions of 
erythromycin bound ribosomes were monitored by nitrocellulose filtering at varying 
incubation times (Figs. 4A and 4B). The estimate of the wild type association rate 
constant is similar to that obtained with a different method (Lovmar et al., 2004).
It has been suggested that erythromycin binding to the ribosome occurs via a 
pre-equilibrium step (Dinos and Kalpaxis, 2000), but we demonstrated in previous 
work that such a putative pre-equilibrium must have an (equilibrium) dissociation 
constant (KD) larger than ~1 µM (Lovmar et al., 2004). Here, we show that such a 
putative pre-equilibrium for the L22(Δ82-84) ribosome must have a KD–value larger 
than ~10 µM (Fig. 4B, insert).
Equilibrium dissociation constants for complexes between erythromycin and L4(Lys63Glu) 
or L4(Δ63-64) ribosomes
The low affinity of erythromycin binding to the L4 mutants made it technically
difficult to directly measure the association rate constants as in the previous section, 
but it was possible to estimate the dissociation (equilibrium) constants (KD).
Accordingly, KD-values for the L4(Lys63Glu) and L4(Δ63-64) mutants were 
estimated as 4.6 µM and 3 µM, respectively, from experiments in which the fractions 
of erythromycin bound ribosomes were monitored by nitrocellulose filtration at 
varying erythromycin concentrations (Fig. 4C).
Erythromycin-dependent growth inhibition of wild-type and mutant E. coli
populations
We studied the effects of erythromycin on the growth rate of the wild type, 
L4(Lys63Glu), L4(Δ63-64) and L22(Δ82-84) mutated variants of the MG1655 E. coli
strain in a wild type genetic background or in combination with ΔtolC or ΔacrB drug 
efflux pump deficient strains (Okusu et al., 1996). The growth rates were estimated as 
OD-values after four hours of growth, and the results are shown in Figs. 5A and 5B. 
In the pump proficient genetic background, the ribosomal wild type was most growth 
sensitive to erythromycin, and the level of resistance was similar for the three 
ribosomal mutants (Fig. 5A). The erythromycin sensitivity for the ribosomal wild type 
was greatly increased by the ΔacrB deletion, but the largest sensitivity was conferred 
by the ΔtolC deletion (Fig. 5A). We interpret this to mean that the erythromycin 
efflux pump activity was insignificant for the ΔtolC strain, and that the ΔacrB strain
retained a small but significant efflux pump activity. The erythromycin sensitivity of 
the L4 and L22 ribosome mutants was similar to that of the wild type ribosome in the
ΔtolC but smaller in the ΔacrB genetic background (Fig. 5B). This implies that 
elimination of the drug efflux activity by the ΔtolC alteration also eliminated the 
growth advantage of the L4 and L22 mutants in relation to the ribosomal wild type 
population. To investigate whether our kinetic data could quantitatively account for 
the growth inhibition by erythromycin (Figs. 5A and 5B), we used detailed
mathematical modeling based on these and previous (Lovmar et al., 2004) data on 
ribosome function to predict the growth rate inhibition curves for different E. coli
strains as displayed in Figs. 5C and 5D.
Detailed mathematical modeling of erythromycin-dependent growth inhibition 
for wild type and mutated E. coli strains
The erythromycin growth inhibition curves described in the previous section (Figs. 
5A and 5B) suggested that the drug resistance conferred by the L4 and L22 mutations
in relation to wild type was conditional on a fully active AcrAB-TolC efflux pump 
system. An essential part of the detailed mathematical model for growth inhibition by 
erythromycin (see Supplementary on-line material) is therefore drug transport over 
the two cell membranes of E. coli (Fig. 6A). E. coli is a gram-negative bacterium, and
we assumed passive diffusion over the outer and inner cell membranes with rate
coefficients CI and CII, respectively, with CI<<CII (Elf et al., 2006). We assumed, in
addition, active transport with a rate coefficient CIII from the periplasm to the 
medium. We set CIII to zero for ΔtolC, to an intermediate value for ΔacrB and to a
large value for wild-type cells. When CIII is smaller than CII, variation in CIII mainly 
affects the effective rate constant, kout, for drug efflux from the cytoplasm and when 
CIII is larger than CII, variation in CIII mainly affects the effective rate constant, kin, for
drug influx to the cytoplasm. In the former case, variation of CIII has profound effects 
on the propensity for bi-stable growth response to drug exposure (Elf et al., 2006)
and, as demonstrated here, on the relative growth advantage conferred by ribosomal 
drug resistance mutations. In the latter case, variation of CIII can trivially be mimicked 
by an inverse variation of the external drug concentration.
The protein synthesis part of the model (Fig. 6B) is a modified version of a 
previous model (Lovmar et al., 2006), successfully used to account for erythromycin 
resistance conferred by cis-acting peptides (Lovmar et al., 2006; Tenson et al., 1996; 
Vimberg et al., 2004). Kinetic data from the present (Table 1) and previous (Antoun 
et al., 2006; Bremer and Dennis, 1996) work have been integrated in the model, and 
the magnitude of the permeability parameters CI, CII and CIII have been adjusted to fit 
the in vivo data (Figs. 5A and 5B). All parameters used in the model are given in 
Table S1 of the Supplementary on-line material. This detailed model, in which the 
idiosyncrasies of erythromycin dependent inhibition of bacterial protein synthesis are 
explicitly taken into account, agrees well with the general scheme leading to Eqs 1-3 
above. Our numerical comparisons show, in particular, that the relations between drug 
efflux efficiency and target mutation sensitivity are model independent.
The model faithfully reproduces the erythromycin dependent growth inhibition 
for wild type and L22 mutated ribosomes in wild type as well as in ΔacrB or ΔtolC
genetic backgrounds, as can be seen by comparing Fig. 5C with Fig. 5A and Fig. 5D 
with Fig. 5B. Accordingly, the model accounts for the observation that the resistance 
conferred by the L22 alteration in relation to the wild type ribosome was largest in the 
presence of the wild type AcrAB-TolC system, smaller in the ΔacrB and insignificant 
in the ΔtolC background. It also accounts for the observation that the residual efflux 
pump activity in the ΔacrB strain led to larger erythromycin resistance than in the 
ΔtolC strain when the ribosome was L22 mutated, but not when the ribosome was of
wild type. These results confirm the prediction of a previously unknown link between 
the drug efflux system and the relative resistance increase by mutations in the 
ribosome and, by inference, in other drug targets in the cytoplasm. Although we 
successfully accounted for how the relative drug resistance conferred by the L22 
alteration depended on the efflux pump efficiency, there was a quantitative deviation 
between model and experiments concerning the two L4 mutants. Experimentally, we 
observed similar drug resistance for all three ribosomal mutants in all three efflux 
pump backgrounds (Figs. 5A and 5B), but the model predicted greater drug resistance 
for the two L4 mutants than for the L22 mutant (Figs. 5C and 5D). The deviation may 
be caused by a profound effect of molecular crowding (Berg, 1990; Ellis, 2001; 
Minton, 1981; Zimmerman and Trach, 1991) on intracellular rate constants, since a 
uniform re-scaling of all dissociation constants by a factor of a hundred resulted in a 
good fit between model and experimental growth inhibition curves for all 
combinations of  ribosomal and pump-efflux mutants. (Compare Fig. 5A with Fig. 5E
and Fig. 5B with Fig. 5F). After re-scaling, the kd values were smaller than the growth 
rate µ0, so that the resistance conferred by all three ribosomal mutations in the efflux 
proficient background was due to their similarly reduced association rate constant, ka. 
The remaining deviations between model and experiments are, we suggest, due to 
relatively large errors in our indirect estimates of the rate constants for drug
association to the L4 ribosome mutants (Figs. 3 and 4).
DISCUSSION
Increased drug resistance by intracellular target mutations conditional on 
efficient drug efflux pumping
Our in vivo observations demonstrate that the selective growth advantage in the 
presence of erythromycin, conferred by the L22 and L4 mutations in relation to the 
wild type, disappears in the ΔtolC genetic background (Fig. 5B). This appears to be a 
general phenomenon for high affinity drug targets and its origin can be traced to the 
efficiency by which drug efflux competes with drug-target binding, as illustrated by
Eq. 1 and Fig. 2 above. In the drug efflux deficient case, described by Eq. 3, growth 
inhibition by the drug is virtually insensitive to mutation driven variations in the 
association (ka) and dissociation (kd) rate constants for the ribosome-erythromycin 
interaction. This means that as long as Eq. 3 approximates Eq. 1, all drug molecules 
that enter the cell become ribosome bound in spite of variations in target affinity to 
the drug. In the drug efflux proficient case, described by Eq. 2, growth inhibition by 
the drug is maximally sensitive to variations in target affinity to the drug. Here, the 
pump efficiency is sufficiently high to establish a target-independent steady state 
relation between the external drug concentration in the medium and the free drug 
concentration in the cytoplasm.
Our detailed model for E. coli growth with our biochemical data as input 
accounts for the erythromycin dependent growth inhibition for wild type and L22 
mutated cell populations in wild type, ΔtolC and ΔacrB genetic backgrounds (Fig. 5).
There is a quantitative deviation between model predictions and the growth data from 
the L4 mutated strains (Compare Fig. 5A with 5C and Fig. 5B with 5D), primarily due 
to the large KD-values that characterize the binding of their ribosomes to erythromycin 
(Table 1). However, a uniform decrease of the rate constants for erythromycin 
dissociation from all ribosome types gives a good correspondence between model 
predictions and growth data for all combinations of ribosome and pump efflux 
mutants (Compare Fig. 5A with 5E and Fig. 5B with 5F). This suggests that re-scaling 
of kinetic in vitro data may in some cases be necessary to obtain the corresponding in 
vivo data. One reason for the need to rescale, could be that, in contrast to the situation 
in the test-tube, the interior of the bacterium is densely packed with RNA, protein, 
DNA and other molecules (Cayley et al., 1991). According to theory (Berg, 1990; 
Ellis, 2001; Minton, 1981; Zimmerman and Trach, 1991), this “molecular crowding” 
may have profound effects on the affinity of ligand binding to targets in the cell, but 
other explanations for the need of parameter re-scaling are conceivable. Direct 
measurements of specific dissociation rate constants in the living cell are hard to 
come by, but may soon be amenable to precise experimentation through novel 
techniques for single cell spectroscopy (Elf et al., 2007; Zlatanova and van Holde, 
2006).
The rate of emergence of target resistance mutations and drug efflux efficiency
The present theory (Eq. 1, supplementary on line material) and experimental 
results (Figs 5A and 5B) demonstrate how the “space” of target resistance 
mutations contracts with reduced and expands with enhanced drug efflux efficiency. 
That is, in a drug efflux proficient background there will be a multitude of target 
mutations that lead to increased fitness in the present of an antibiotic drug, which are 
masked in a efflux deficient background. Since the size of the space of possible 
resistance mutations will determine the rate of fixation of resistance mutations among 
pathogens, we infer that the evolution of target-conferred drug resistance will be 
much faster among pathogens with highly than among those with lowly efficient drug 
efflux systems. This is, in particular, the case for intracellular targets at high 
concentration and with high-affinity drug binding, as here exemplified experimentally 
by the strong erythromycin binding to the abundant E. coli ribosome. When, 
accordingly, antibiotics with intracellular targets are delivered together with drug 
efflux inhibiting molecules (Lomovskaya et al., 2007), our theory predicts that this 
will drastically slow down the rate of emergence of target resistance mutations.
How does erythromycin interact with the ribosome?
Our biochemical data show that L4(Lys63Glu) and L22(Δ82-84) ribosomes have 
equilibrium dissociation constants for erythromycin binding about three hundred
times and five times larger than wild type ribosomes, respectively (Figures 3 and 4
and Table 1). The association rate constants for all ribosomal mutants are about a 
factor of hundred smaller than for wild type ribosomes. While the dissociation rate 
constant for the L4(Lys63Glu) ribosome is much larger than for wild type, the 
dissociation rate constant for the L22(Δ82-84) ribosome is much smaller than for wild 
type. Accordingly, previous conclusions based on qualitative data that erythromycin 
has zero binding affinity to L4(Lys63Glu) ribosomes and wild type binding affinity to 
L22(Δ82-84) ribosomes (Wittmann et al., 1973) must be revised in light of the present 
results along with more recent conclusions based on these previous data in 
conjunction with structural data from cryo-EM (Gabashvili et al., 2001) and x-ray 
crystallography (Tu et al., 2005).
Using rolling sphere simulations on crystallographic atom coordinates, Moore 
and colleagues showed that the tunnel wall is impermeable to molecules with the size 
of erythromycin (Voss et al., 2006). Therefore, erythromycin either has to bind from 
the subunit interface through the peptidyl transferase center (PTC) or from the 
ribosome surface through the L4/L22 constriction in the peptide exit tunnel (Fig. 1A). 
The similar kinetics of erythromycin binding to initiation complexes (Lovmar et al., 
2004), empty ribosomes (Table 1) and 50S subunits (data not shown) makes binding 
via the interface less likely. In addition, it is reasonable to assume that the peptide exit 
tunnel of the wild type ribosome has been optimized for passage of the nascent 
peptide chain (Nissen et al., 2000), and that such an optimization may facilitate the 
passive transport of other ligands, like macrolides, through the tunnel. Accordingly, 
mutations in the L4 and L22 tunnel proteins are expected to move the tunnel away 
from its optimal design and thus to reduced rate of passive transport, as observed in 
our biochemical experiments.
We suggest, therefore, that the second order (microscopic) rate constant (Berg, 
1985), kpt, for passage through the peptide exit tunnel constriction, as defined by the 
L4 and L22 ribosomal proteins (Nissen et al., 2000), is maximal for wild type and 
greatly reduced for the L22 mutant and the two L4 mutants. Our data demonstrate, 
furthermore, that the dissociation constant, KD, for erythromycin binding to its 
specific site (Schlunzen et al., 2001; Tu et al., 2005) is increased about five fold for 
the L22 and about three hundred fold for the L4 mutations. Putting these two features 
together, suggests that the association rate constant (ka) is given by ka=kpt and the 
dissociation rate constant kd by kd=kpt·KD. Although our data do not prove 
erythromycin binding via the peptide exit tunnel, they are consistent with this
scenario, which furthermore offers a simple explanation to the decreased rate 
constants for erythromycin binding as caused by reduced rate of passage through the 
L4/L22 constriction due to a mutation in either one of L4 or L22.
Outlook: target binding affinities and compound efflux efficiencies in other 
contexts
Other examples of the general coupling between drug efflux efficiency and evolution 
of resistance discovered in the present work are provided by members of the 
fluoroquinolone family (inhibitors of DNA topoisomerases), where resistance often 
occurs as combinations of drug efflux and target site mutations (Ho et al., 2001; 
Kriengkauykiat et al., 2005).
Similarly, during chemotherapy against eukaryotic parasites, target site
resistance mutations are often combined with drug efflux pump activation 
(Nascimento et al., 2003; Wintermeyer and Zachau, 1979). In these cases it is not 
known whether the efflux activation or the target site mutation occurs first. Since, 
however, we predict the space of possible target site mutations to greatly increase
with increased drug efflux pump efficiency, we propose that pump activation precedes 
target site mutation.
Our theoretical results may also be relevant to the evolution of drug resistance 
among cancer cells. During cancer chemotherapy, resistance from target site 
mutations (Leontiou et al., 2004) and membrane efflux pump activation (Chen et al., 
1986; Cole et al., 1992; Gottesman and Ling, 2006) is often observed. The present 
findings suggest that there will be a large class of target site mutations that confer 
drug resistance only when combined with highly efficient membrane pumps. Since 
current mathematical models of P-glycoprotein efflux pump action (Michelson and 
Slate, 1992; Michelson and Slate, 1994; Zhou and Jin, 1998) do not consider target 
site binding parameters, they must be expanded to account for the expected coupling 
between drug efflux efficiency and target resistance mutations.
Finally, the present conclusions may be relevant to the increasing number of
studies, where the effects of genetic polymorphisms on drug and biomolecule binding 
sites are estimated. For example, the glucocorticoids have to reach their receptors 
inside the cell but are also substrates of the P-glycoprotein efflux pump (Mark and 
Waddell, 2006). Receptor polymorphisms that change hormone binding parameters 
have been described (Heeley et al., 2002), and we suggest that the effects of these 
polymorphisms may well be strongly dependent on the efflux parameters of the cells. 
Therefore, different choices of model cell lines or tissues (Rockett et al., 2004) may 
lead to apparently contradicting conclusions, if the interplay between drug efflux 
efficiency and receptor binding is neglected in the interpretation of experimental data.
EXPERIMENTAL PROCEDURES
Chemicals and buffers
GTP and ATP were from GE Healthcare. Putrescine, spermidine, 
phosphoenolpyruvate (PEP) and erythromycin were from Sigma-Aldrich. 
[14C]erythromycin was from Perkin-Elmer. Pyruvate kinase (PK) was from 
Boehringer-Mannheim. Nitrocellulose filters Protran BA85 were from VWR.
All cell-free experiments were performed at 37 °C in polymix buffer (Antoun et al., 
2004; Jelenc and Kurland, 1979) supplemented with 1 mM GTP, 1 mM ATP and 
10 mM PEP.
Procedures
Construction of mutations in ribosomal protein L4 and L22 in an isogenic background
E. coli MG1655 cells (Blattner et al., 1997), transformed with plasmid pKD46 
(Datsenko and Wanner, 2000) were grown in SOB medium containing ampicillin 
(100 µg/ml). 20ml of the culture was grown at 30 °C until OD(A600 nm) 0.6. The 
cells were collected by centrifugation (8 min, 5500g, 4 °C) and resuspended in ice 
cold sterile water. The washing procedure was repeated two more times and the cells 
were finally resuspended in 100 µl of water. 50 µl of the cells were electroporated 
with 10 ng (3 µl) of DNA oligonucleotide using Bio-Rad Gene Pulser at 1.8 kV, 
25 µF (2 mm cuvettes). The electroporated cells were diluted with 1 ml of LB 
medium, incubated for 2 h at 37 °C and plated on LB-agar containing erythromycin 
(300 µg/ml). The recombinase coding plasmid pKD46 was removed as described 









Construction of the double mutants
The acrB and tolC knockouts were made in both the wild-type and the erythromycin 
resistant strains (described above) by using the method of Datsenko and Wanner 
(Datsenko and Wanner, 2000). The PCR products for transforming the strains were 










Overnight cultures were diluted into 10 ml of LB medium to OD (600 nm) 0.1. The 
cultures were grown at 37 °C until OD 0.4-0.6 and again diluted to OD 0.1. 2 ml of 
the culture was used for one experimental point; erythromycin was added at 
concentrations indicated. OD was measured after 4 h of growth at 37 °C.
Ribosome purification
Mutant and wild-type ribosomes were purified by ultra-centrifugation as previously 
described (Tenson et al., 2003). Bacterial DNA from aliquots of the cultures used for 
purification was used for sequencing of the L4 and L22 coding genes to ensure the 
absence of revertants among the purified ribosomes.
Nitro cellulose filter assays
Ribosomes stick to nitrocellulose (NC) filters while erythromycin does not. Hence, 
the NC filter assay allows us to separate ribosome-bound [14C]erythromycin from the 
free [14C]erythromycin. The filters were pre-soaked in cold polymix buffer containing 
10 µM erythromycin. After each sample was applied, the filter was rapidly washed 
twice with 1 ml ice-cold polymix buffer before the radioactivity on the filter was 
measured in a scintillation counter.
Chase experiment
The ribosome mixture contained ~2 µM ribosomes (wild-type or mutant) and 
[14C]erythromycin (10 µM), and the chase mixture contained 225 µM erythromycin. 
After mixing 20 µl of the ribosome mixture with 20 µl of the chase mixture, reactions 
were quenched at different times by addition of 1 ml ice cold polymix and then 
rapidly applied to the nitrocellulose filter.
Least square fitting of these data points (i.e. bound fraction vs. time) to a single 
exponential function gives the erythromycin dissociation rate constants from wild-
type and mutant ribosomes as presented in Table 1.
Association rate experiment
The ribosome mixture contained ~0.32 µM wild-type ribosomes or ~0.2 µM L22-
mutant ribosomes, and the erythromycin mixture contained [14C]erythromycin (at 
different concentrations). After mixing 40 µl of the ribosome mixture with 40 µl of 
the erythromycin mixture, reactions were quenched at different times by addition of 
1 ml ice cold polymix containing 40 µM erythromycin and then rapidly applied to the 
nitrocellulose filter.
Least square fitting of the data points (i.e. bound fraction vs. time) to a hyperbolic 
function gives the erythromycin association rate constant to the wild-type ribosomes 
(Table 1) because the concentration of erythromycin is similar to the concentration of 
ribosomes in the experiment. In contrast, the data points for the L22-mutant were 
fitted to single exponential functions because the concentration of erythromycin in 
this setup was much higher than the ribosome concentration. Thus, the free 
erythromycin concentration can be regarded as a constant throughout the experiment. 
The linear relation between the estimated rates and the erythromycin concentration 
was used to estimate the erythromycin association rate constant for the L22-mutant
ribosome presented in Table 1.
Equilibrium binding experiment
The ribosome mixture contained ~0.7 µM L4-mutant ribosomes, and the 
erythromycin mixture contained [14C]erythromycin (at different concentrations). After 
mixing 40 µl of the ribosome mixture with 40 µl of the erythromycin mixture, 
reactions were incubated for ~15 minutes before quenched with 1 ml ice cold polymix 
buffer and then rapidly applied to the nitrocellulose filter.
Least square fitting of these data points (i.e. bound fraction vs. erythromycin 
concentration) to a hyperbolic function gives the erythromycin equilibrium binding 
constants for both L4 mutants as presented in Table 1.
Cell growth simulations
Based on our previously published model for peptide-mediated erythromycin 
resistance (Lovmar et al., 2006), we set up a system of differential equations of the 
large ribosomal subunit in different states in a growing system, i.e. each equation 
contains a term for dilution. The model accounts for changes in the total concentration 
of intracellular erythromycin by the passive inflow and outflow of the macrolide over 
the cell membranes and the active transport out from the cell by the AcrAB-TolC 
pump system. The system of equations was solved numerically by Euler’s method, 
after the introduction of a certain macrolide concentration in the growth medium. Cell 
growth was registered as volume expansion during the first 4 h after induction. Before 
macrolide exposure, the system resided at steady state. The used program software 
was MATLAB 6.5 (The MathWorks Inc., Natick, MA). A detailed description of the 
model and the parameter values used are presented in the on-line supplemental 
material.
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FIGURE LEGENDS
FIGURE 1. Localization of the erythromycin resistance mutations. Panel A is a cartoon showing a 
cross-section of the large ribosomal subunit along the nascent peptide exit tunnel, with the subunit 
interface to the right. The position of the ribosomal proteins L4 and L22 are shown in light brown and 
green respectively and the erythromycin binding site is indicated in blue. Panel B shows the positions 
of the mutated amino acids in L4 and L22 that leads to erythromycin resistance in relation to the 
erythromycin binding site. A dashed arrow indicates the flexibility of the β hairpin in the L22(Δ82-84) 
mutant (Tu et al., 2005). The figure is constructed using the ribosomal proteins from the crystal 
structure of 70S from E. coli (pdb: 2I2V) (Berk et al., 2006) combined with erythromycin from (pdb: 
1YI2) (Tu et al., 2005) by aligning the nucleotide A2058 (E. coli numbering) from both structures.
FIGURE 2. Drug sensitivity at different pump capacities as predicted by Eq 1. Three important 
features of Eq 1 are illustrated in these plots: (i) the elementary feature that drug sensitivity decreases 
with increasing efflux pump capacity; (ii) no or low efflux pump activities prevent differences in target 
site binding properties to be manifested in modified drug sensitivity; and (iii) if kd is much smaller than 
the growth rate the drug sensitivity only depends on ka (panel A), while the drug sensitivity depends on 
the equilibrium constant Kd (=kd/ka) if kd is larger than the growth rate (panel B). These plots are made 
with the following parameter values: [Aext]=10-5 M, kin=5∙10-4 s-1, [T0]=4∙10-5 M and µ0=10-4 s-1.
FIGURE 3. Determination of rate constants for dissociation of erythromycin from wild-type and 
mutant ribosomes. 14C-labeled erythromycin was pre-bound to wild-type and mutant ribosomes and a 
chase with a large excess of non-labeled erythromycin started at time zero. At the specified time points 
the reactions were quenched with ice-cold buffer and filtered through nitrocellulose filters. The amount 
of 14C-labeled erythromycin on the filters corresponds to the amount that remained bound to the
ribosomes. The lines are least square fits to single exponentials and were used to estimate the 
dissociation rate constants presented in Table 1. Insert. The same experimental points limited to a short 
time range between zero and 300 s.
FIGURE 4. Determination of erythromycin association rate constants for wild-type and L22 
mutant ribosomes and equilibrium dissociation constants for both L4 mutants. In panels A and B, 
the ribosomes were mixed with 14C-labeled erythromycin at time zero and at the specified time points 
quenched with ice-cold buffer containing a large excess of non-labeled erythromycin. The quenched 
reactions were rapidly filtered through nitrocellulose. The amount of filter-bound 14C-labeled 
erythromycin reflects the fraction of ribosomes at which the exchange of labeled versus unlabeled drug 
has not taken place. The line in panel A are a least square fit to a hyperbolic function and the lines in 
panel B are least square fits to single exponentials. These fits were used to estimate the association rate 
constants presented in Table 1. The insert in panel B show the rates of erythromycin association to the 
L22-mutant ribosomes as a function of erythromycin concentration. In panel C, the ribosomes were 
mixed with different concentrations of 14C-labeled erythromycin and incubated for 15 minutes before 
quenched with cold buffer and rapidly filtered through nitro-cellulose filters. The lines are least square 
fits to a hyperbolic function and were used to estimate the equilibrium dissociation constants presented 
in Table 1.
FIGURE 5. Erythromycin sensitivity measurements. The relative ODs after 4 hours are plotted as a 
function of the erythromycin concentration. The values are normalized to the ODs reached after 4 
hours in the absence of erythromycin. Panel A shows the results of an erythromycin titration in the 
concentration range required for inhibiting growth in E. coli with intact AcrAB-TolC efflux pumps. 
The level of resistance caused by the ribosomal protein mutants is best shown in this range. Panel B 
shows the results of an erythromycin titration in the lower concentration range required to study the 
efflux pump mutants. Panels C and D shows the corresponding simulation using the estimated binding 
constants, while Panels E and F shows the same simulation but with rescaled erythromycin dissociation 
rate constant kd.
FIGURE 6. Cartoon illustrating the model used for the mathematical simulations. Panel A shows 
how the erythromycin entry into the cells is modeled. Erythromycin diffuses over the outer membrane 
with a permeability constant CI and over the inner membrane with a permeability constant CII. In 
addition, erythromycin is actively pumped out over the outer membrane with a rate constant CIII by the 
AcrAB-TolC efflux pump system. Panel B shows the states used to model the inhibition of protein 
synthesis caused by erythromycin. A 50S subunit with (5) or without (1) erythromycin bound initiate 
with the rate k to form initiated 70S complexes (6) or (2) respectively. Elongation of the first few 
amino acids is made with rate k1 indepentenly of erythromycin. However, if no erythromycin is bound 
(3) the ribosome continue elongation and becomes refractory to the drug (4) with the rate k2, and finally 
a new protein is produced and the 50S is recycled (1) with a rate k3. In contrast, if the elongating 
ribosome contains erythromycin (7) it is stalled until either erythromycin dissociates with a rate kd or 
peptidyl-tRNA drops off and the erythromycin containing 50S is recycled with a rate k4. Erythromycin 
binds to state 1, 2 and 3 with a second order rate constant ka and dissociates from states 5, 6 and 7 with 
the rate constant kd.
Table 1. Erythromycin binding properties to wild-type and mutant ribosomes
Strain ka (µM-1s-1) kd (s-1) KD (µM)
wt 1.0 ±0.1 0.013 ±0.0006 0.012 ±0.001
L22 (Δ82-84) 0.019 ±0.0006 0.0011 ±0.00004 0.059 ±0.003
L4 (Lys63Glu) 0.0040 ±0.0006 0.018 ±0.001 4.6 ±0.7
L4 (Δ63-64) 0.0096 ±0.001 0.029 ±0.002 3.0 ±0.4









































































































































































1. Target inhibition in growing cells 
Here we will discuss target binding of growth inhibitors that enter and exit growing 
cells in all cases where there is a well defined relation between the fraction α, of 
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      [S1] 
Here, the total, inhibitor bound and free intracellular target concentrations are [T0], 
[Tb] and [Tf], respectively. The growth rate µ decreases monotonically from its highest 
value µ0 in the absence of inhibitor (α=0) to zero when all targets are inhibitor bound 
(α=1). 
When the intracellular inhibitor concentration is spatially uniform, changes in 
the concentration, [Tf], of free targets are determined by the differential equations  
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supplemented by the conservation conditions 
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Here, [A0], [Ab] and [Af] are the total, target bound and free intracellular 
concentrations of inhibitor, respectively, while [Aext] is the extracellular concentration 
of inhibitor in the medium. The rate constants for inhibitor binding to and dissociation 
from a target are given by ka and kd, respectively. The parameters kin and kout are the 
effective rate constants by which the inhibitor enters or exits the cell, respectively. 
The case when kin=kout, corresponds to passive diffusion through the cell wall. The 
case when kin<kout, corresponds to active pumping of inhibitors out from the cell. 
When there is a single cell membrane, like for gram-positive bacteria, these effective 
first order rate constants relate to membrane permeability through 
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A is the surface area of the cell, V is the cell volume, CI is the permeability due to 
passive inhibitor diffusion, while CIII accounts for active pumping of inhibitor out 
from the cell. In the case of gram-negative bacteria with two membranes and a 
periplasmic space, the same rate constant formalism with effective rate constants kin 
and kout approximates the in and out flux of inhibitors, provided that the periplasmic 
volume is much smaller than the internal cell volume V (see below). 
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2. Steady state relations for growth inhibition at low inhibitor 
concentration 
The steady state condition with all concentrations constant in time is described by 
equations [S2] and [S3] with their right side time derivatives set to zero. The resulting 
algebraic equations that relate the growth µ to the external inhibitor concentration, 
[Aext], are strongly non-linear with interesting properties. These have been described 
in the special case that drug binding to the target is equilibrated and on the assumption 
that f(α)=α in Eq. S1 (Elf et al., 2006). Here, we relax the equilibrium constraint and 
illustrate in what we hope is an intuitively accessible way the kinetic interplay 
between drug efflux pump efficiency and the antibiotic resistance conferred by target 
mutations affecting the rate constants ka and kd in Eq. S2. For this, we will inspect the 
first order approximation to the steady state version of Eqs. S2 and S3, when α, 
defined in Eq. S1, is much smaller than one. It follows from the definition of α in 
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Furthermore, from Eqs S3 and S6 it follows that 
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where the growth rate µ is given by Eq. S1. Eq. S7 is an exact expression, but for 
small values of α, the relative growth rate µ is to first order in α approximated by 
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Eq. 1 in the main text is derived on the assumption that f(α)=α and, hence, that C=1. 
3. Drug flows into and out from gram negative bacteria with 
two cell membranes  
The concentration, [AP], of the drug in the periplasm is governed by the equation (Fig. 
S1): 
[ ] [ ] ( ) [ ]( )/P I ext II f I II III P P
P
d A A C A C A C C C V A A
dt V
μ⎡ ⎤= ⋅ ⋅ + ⋅ − + + + ⋅ ⋅⎣ ⎦  [S10] 
VP is the volume of the periplasm and A is the area of each of the two cell walls that 
define the periplasm, which for simplicity are assumed to be the same. CI and CII are 
the drug permeability for the outer and inner membrane, respectively, while CIII is the 
active permeability due to pumping of the drug from the periplasm into the growth 
medium. 
 
Figure S1. A schematic of the flow of inhibitor over the cell membranes in a 
Gram-negative cell. 
 
The total concentration, [A0], of the drug in the cytoplasm is governed by the 
equation: 
[ ] [ ]( ) [0 0II P fd A C A A A Adt V μ
⋅ ⎡ ⎤= ⋅ − − ⋅⎣ ⎦ ] ,    [S11] 
where [Af] is the free drug concentration in the cytoplasm as before. Assuming that 
the concentration of drug in the cytoplasm is in the steady state with the external and 
the cytoplasmic drug concentration due to the small periplasmic volume and 
neglecting the term µ·VP/A in Eq. S10 give 
[ ] [ ]I ext II fP
I II III
C A C A
A
C C C
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+ +
        [S12] 
Introducing this expression into Eq. S11 leads to an expression equal for the total drug 
concentration, [A0], in the cell identical to that in Eq. S3, with the rate constants kin 
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4. Detailed model of inhibition of protein synthesis by 
erythromycin 
 
Figure S2. A schematic of the model for binding and translation inhibition by 
erythromycin.  
The model includes seven different states of the large ribosomal subunit (Figure S2), 
which are defined by the following system of differential equations 
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A 50S ribosomal subunit may be either bound [50SM] or not bound [50S] to 
erythromycin. It may also be in complex with a 30S subunit thus forming a ribosome 
ready to initiate translation, either bound [RM1] or not bound [R1] to erythromycin. 
The ribosome may be translating the first few codons either bound [RM2], or not 
bound, but still susceptible, to erythromycin, [R2]. Without erythromycin, the 
ribosome continues in elongation and become temporarily immune to erythromycin 
[Re]. 
The rate constant of association and spontaneous dissociation of the antibiotic 
is ka and kd, respectively. Association of the ribosomal subunits occurs with rate 
constant k and translation of the first few codons occurs with rate constant k1. The rate 
constant for translating the codon that makes the ribosome temporarily immune for 
erythromycin binding is k2. The rate constant for completing synthesis of the protein 
and recycling the ribosomal subunits is k3, and the rate constant of peptidyl-tRNA 
drop-off from erythromycin bound, stalled ribosome is k4. In addition, all 
concentrations are diluted by the cell growth rate μ. The total concentration of 50S 
subunits [50Stot] is kept constant and new 50S subunits are thus synthesized by rate 
μ·[50Stot] and the free concentration of 50S subunits varies according to 
[ ]1 2 1 2[50 ] [50 ] [50 ] [ ] [ ] [ ] [ ]tot eS S SM R R RM RM R= − − − − − − . 
The system expands by exponential growth with cell growth rate μ, defined by 
(Ehrenberg and Kurland, 1984) 
0
[ ] ,e ev Rμ
ρ
⋅
=         [S15] 
where ve is the average elongation rate of an uninhibited ribosome and ρ0 is the 
concentration of amino acids incorporated in proteins. The system was solved 
numerically by Euler’s method (Heath, 1997). Cell growth was calculated for the first 
4 hours after introduction of a certain erythromycin concentration in the growth 
medium, [Aext] by 
        [S16] ,dtt t dtV V e
μ⋅
−= ⋅
where dt is a small time-step and Vt-dt and Vt is the volume prior and after time-step dt, 
respectively. Prior to erythromycin exposure, the system resided at steady state. The 
used program software was MATLAB 6.5 (The MathWorks, Inc., Natick, 
Massachusetts, U.S.A.). 
References 
Antoun, A., Pavlov, M. Y., Lovmar, M., and Ehrenberg, M. (2006). How initiation 
factors tune the rate of initiation of protein synthesis in bacteria. Embo J 25, 2539-
2550. 
Bremer, H., and Dennis, P. P. (1996). Modulation of Chemical Composition and 
Other Parameters of the Cell by Growth Rate, In Escherichia coli and Salmonella : 
cellular and molecular biology, F. C. Neidhardt, ed. (Washington: ASM Press), pp. 
1553-1569. 
Ehrenberg, M., and Kurland, C. G. (1984). Costs of accuracy determined by a 
maximal growth rate constraint. Q Rev Biophys 17, 45-82. 
Elf, J., Nilsson, K., Tenson, T., and Ehrenberg, M. (2006). Bistable bacterial growth 
rate in response to antibiotics with low membrane permeability. Phys Rev Lett 97, 
258104. 




Table S1. Definitions and values of used parameters in the macrolide model. 
Model parameter Value Reference 
k  = association rate of ribosomal subunits at 
initiation of translation 
1 s-1 (Antoun et al., 2006) 
1k  = rate constant for translation of the first 
codons when the ribosome is susceptible for the 
antibiotic 
5 s-1 (Bremer and Dennis, 1996)  
2k  = rate constant for translation of the codon 
rendering the ribosome temporarily immune to 
erythromycin 
20 s-1 (Bremer and Dennis, 1996) 
3k  = rate constant for translation beyond the 
first codons and translation termination 
0.03 s-1 (Bremer and Dennis, 1996) 
4k  = drop-off rate constant of peptidyl-tRNA 
from a stalled ribosome 
0.1 s-1 (Lovmar, unpublished results) 
ak  = association rate constant of erythromycin Table 1 This paper 
dk  = dissociation rate constant of erythromycin Table 1* This paper 
/IC A V  = membrane permeability over the 
outer membrane 
 5·10-4 s-1 
/IIC A V  = membrane permeability over the 
inner membrane 
 0.1 s-1 
0 s-1 (tolC¯), /IIIC A V  = rate constant of erythromycin 
efflux over cell membrane by pumps (pump 
efficiency) 
 0.01 s-1 (acrB¯) 
1 s-1 (wt pumps) 
/P CV V = the volume of the periplasm divided 
by the volume of the cytoplasm (approximated 
to be constant) 
 0.1 
ev 20 s-1  = ribosome elongation rate (Bremer and Dennis, 1996) 
0ρ  = concentration of amino acids in proteins 2 M (Bremer and Dennis, 1996) 
[ ]50 totS  = total concentration of 50S 4·10-5 M (Bremer and Dennis, 1996) 
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